

arthritis and rheumatism

Official Journal of the American Rheumatism Association Section of the Arthritis Foundation

VOLUME 25

JANUARY

NO. 1

Presidential Address: The American Rheumatism Association, 1990: Presidential Address to the American Rheumatism Association, June 4, 1981	
<i>Giles G. Bole</i>	1
Defective Monocyte Cytotoxicity in Rheumatoid Arthritis: A Correlation with Disease Activity and Reversal by Levamisole	
<i>Franz A. Barada, William O'Brien, and David A. Horwitz</i>	10
Immunomodulating Effect of Human Placenta-Eluted Gamma Globulins in Rheumatoid Arthritis	
<i>J. Sany, J. Clot, M. Bonneau, and M. Andary</i>	17
Different Molecular Forms of Fibronectin in Rheumatoid Synovial Fluid	
<i>Inge Clemmensen and R. Bach Andersen</i>	25
Free Versus Bound Salicylate Concentration in Adults and Children with Chronic Inflammatory Joint Disease: Serum Albumin and Other Potential Factors Affecting the Levels	
<i>Patrick B. Costello, Floyd A. Green, and Chan Y. Jung</i>	32
Correction of a Suppressor Cell Deficiency and Amelioration of Familial Mediterranean Fever by Hemodialysis	
<i>David Ilfeld, Shulamit Weil, and Oded Kuperman</i>	38
Schönlein-Henoch Syndrome in Patients with Familial Mediterranean Fever	
<i>Edith Flatau, David Kohn, Dan Schiller, Miriam Lurie, and Emmanuel Levy</i>	42
A Serial Study of Splenic Reticuloendothelial System Fc Receptor Functional Activity in Systemic Lupus Erythematosus	
<i>Max I. Hamburger, Thomas J. Lawley, Robert P. Kimberly, Paul H. Plotz, and Michael M. Frank</i>	48
Clinical Features of Systemic Lupus Erythematosus: Differences Related to Race and Age of Onset	
<i>Stanley P. Ballou, Muhammad A. Khan, and Irving Kushner</i>	55
Electromyographic Findings in Various Forms of Progressive Systemic Sclerosis	
<i>Irena Hausmanowa-Petrusewicz, Stefania Jabłońska, Maria Blaszczyk, and Beżena Matz</i>	61
Pyrophosphate Arthropathy in Two Swedish Families	
<i>Anders Bjelle, Ulla Edvinsson, and Åsa Hagstam</i>	66
Immunohistochemical Findings in Cranial Arteritis	
<i>Patrick Gallagher and Karen Jones</i>	75
Articular Cartilage Atrophy in Lower Limb Amputees	
<i>C. Benichou and J. M. Wirotius</i>	80
Predictive Value of Radionuclide Joint Scintigrams	
<i>John Shearman, John Esdaile, David Hawkins, and Leonard Rosenthal</i>	83
T Cell Leukemia Presenting as Chronic Polyarthritis	
<i>Renée M. van Soesbergen, Thea M. Feltkamp-Vroom, Constance A. Feltkamp, Reinier Somers, and Wim P. van Beek</i>	87
An Evaluation Strategy for Rheumatology Education	
<i>Robert P. Meenan, Don L. Goldenberg, Marita K. Murrman, and Alan S. Cohen</i>	92
Brief Reports	
Diagnostic Potential of Rapid Electron Microscopic Analysis of Joint Effusions	
<i>P. Varghese Cherian and H. Ralph Schumacher</i>	98
Subaxial Cervical Subluxation and Cord Compression in Psoriatic Spondylitis	
<i>Adel G. Fam and Bruce Cruickshank</i>	101
Tropical Pyomyositis	
<i>Phillip Kallen, Kenneth M. Nies, James S. Louie, Margaret Keller, Nancy Worthen, and Arnold S. Bayer</i>	107
Pharmacokinetics of Reduced D-Penicillamine in Patients with Rheumatoid Arthritis	
<i>Michael Butler, George Carruthers, Manfred Harth, David Freeman, John Percy, and Dallas Rabenstein</i>	111

Letters

Thrombosis in the Lupus Kidney <i>K. D. Grant, K. S. Kant, V. E. Pollak, M. A. Weiss, and E. V. Hess</i>	117
Polyarteritis Nodosa with Inappropriate ADH Secretion <i>Sayid Fighali, Ibrahim Jawad, and Rida A. Frayha</i>	118
Hypocupremia-Related Hypochromic Anemia During D-Penicillamine Treatment <i>Maurizio Cutolo, Silvano Accardo, Marco A. Cimmino, Guido Rovetta, Gerolamo Bianchi, and Vittorio Bianchi</i>	119
Treatment of Polymyalgia Rheumatica <i>Harry Spiera and Selvan Davison</i>	120
ARA Announcements.....	A11

VOLUME 25

FEBRUARY

NO. 2

Current Comment: The Autologous Mixed Lymphocyte Reaction: A Precautionary Note <i>David Hellmann and John Stobo</i>	121
Clinical and Pathogenetic Implications of Histopathology in Childhood Polydermatomyositis <i>William E. Crowe, Kevin E. Bove, Joseph E. Levinson, and Pamela K. Hilton</i>	126
Ankylosing Spondylitis and Motherhood <i>Monika Østensen, Øistein Romberg, and Gunnar Husby</i>	140
IgA Nephropathy Associated with Seronegative Spondylarthropathies <i>J. Charles Jennette, Alfred L. Ferguson, Michael A. Moore, and Douglas G. Freeman</i>	144
Differential Patterns of In Vitro IgM Rheumatoid Factor Synthesis in Seronegative and Seropositive Rheumatoid Arthritis <i>Graciela S. Alarcón, William J. Koopman, and Ralph E. Schrohenloher</i>	150
The Incidence of Sjögren's Sicca Complex in a Population of Patients with Keratoconjunctivitis Sicca <i>Joseph Z. Forstot, S. Lance Forstot, Robert O. Greer, and Eng M. Tan</i>	156
Activation of the Classical Pathway of Complement by Rheumatoid Factors: Assessment by Radioimmunoassay for C4 <i>Umesh K. Sabharwal, John H. Vaughan, Sherman Fong, Peter H. Bennett, Dennis A. Carson, and John G. Curd</i>	161
Association Between Endogenously Activated T Cells and Immunoglobulin-Secreting B Cells in Patients with Active Systemic Lupus Erythematosus <i>Philip L. Cohen, David A. Litvin, and John B. Winfield</i>	168
Superoxide Anion Generation by Human Neutrophils Exposed to Monosodium Urate: Effect of Protein Adsorption and Complement Activation <i>Steven Abramson, Sylvia T. Hoffstein, and Gerald Weissmann</i>	174
Stimulation of the Respiratory Burst in Human Neutrophils by Crystal Phagocytosis <i>Louis Simchowicz, John P. Atkinson, and Isaias Spilberg</i>	181
Fibroblast Selection in Scleroderma: An Alternative Model of Fibrosis <i>Gary R. Botstein, Glenn K. Sherer, and E. Carwile LeRoy</i>	189
In Vitro Conditions Affecting the Synthesis of Sulfated Proteoglycans by Normal and Rheumatoid Synovial Cells in Culture <i>Joanne M. Marsh, David W. Roback, and Garry T. Ross</i>	196
The Association of Amyloid Deposits and Osteoarthritis <i>Michael S. Egan, Don L. Goldenberg, Alan S. Cohen, and David Segal</i>	204
Aspiration of the Asymptomatic Metatarsophalangeal Joint in Gout Patients and Hyperuricemic Controls <i>Tracey Rouault, David S. Caldwell, and Edward W. Holmes</i>	209
Fibrositis and Psychologic Disturbance <i>Timothy C. Payne, Frank Leavitt, David C. Garron, Robert S. Katz, Harvey E. Golden, Paul B. Glickman, and Cal Vanderplate</i>	213
Brief Reports	
Spinal Cord Block with a Destructive Lesion of the Dorsal Spine in Ankylosing Spondylitis <i>Armin E. Good, Ted S. Keller, Lee Weatherbee, and Ethan M. Braunstein</i>	218
Arthritis Caused by Metastatic Melanoma <i>Fetze Speerstra, Agnes M. Th. Boerbooms, Levinus B. A. van de Putte, Henricus J. A. Kruls, Urbain J. G. M. van Haelst, and Gijsbert P. Vooijs</i>	223

Plasma Colchicine Concentration in Patients with Recurrent Polyserositis (Familial Mediterranean Fever) on Long-Term Prophylaxis <i>E. Zylber Katz, M. Ehrenfeld, M. Levy, and M. Eliakim</i>	227
Severe Giant Cell Valvulitis in a Patient with Reiter's Syndrome <i>Terry E. Podell, Daniel J. Wallace, Michael C. Fishbein, Kent Bransford, James R. Klinenberg, and Seymour Levine</i>	232
Letters	
Arthropathy of Behcet's Disease with Marked Synovial Pleocytosis Responsive to Colchicine <i>Rida A. Frayha</i>	235
High Risk of Sacroiliitis in HLA-B27-Positive Pima Indian Men <i>J. R. Lisse, T. T. Kuberski, P. H. Bennett, W. C. Knowler, J. P. Gofton, A. Calin, and D. L. Mann</i> ..	236
Antigen-Specific Suppressor Cell Activity in Procainamide Therapy <i>Charles J. Shames, Stuart Klein, and Edward C. Keystone</i>	238
LE Cells in Reiter's Syndrome <i>I. W. Tomlinson and M. I. V. Jayson</i>	239
ARA Announcements	A17

VOLUME 25

MARCH

NO. 3

Variable Response to Oral Angiotensin-Converting-Enzyme Blockade in Hypertensive Scleroderma Patients <i>Hendricks H. Whitman III, David B. Case, John H. Laragh, Charles L. Christian, Gary Botstein, Hildegard Maricq, and E. Carwile LeRoy</i>	241
Followup Study on Patients with Reiter's Disease and Reactive Arthritis, with Special Reference to HLA-B27 <i>Marjatta Leirisalo, Grethe Skyly, Merja Kousa, Liisa-Maria Voipio-Pulkki, Hannu Suoranta, Martti Nissilä, Lone Hvidman, Erik Damm Nielsen, Arne Svejgaard, Anja Tiilikainen, and Ossi Laitinen</i>	249
Antibody to Cytomegalovirus in Patients with Sjögren's Syndrome: As Determined by an Enzyme-Linked Immunosorbent Assay <i>Edward J. Shillito, Troy E. Daniels, John P. Whitcher, C. Vibeke Strand, Norman Talal, and John S. Greenspan</i>	260
Type II Collagen-Induced Auricular Chondritis <i>W. Joseph McCune, Alan L. Schiller, Roselynn A. Dynesius-Trentham, and David E. Trentham</i>	266
Immunity to Homologous Type III Collagen after Partial Meniscectomy and Sham Surgery in Rabbits <i>Brian R. Champion and A. Robin Poole</i>	274
Gold Inhibition of the Production of the Second Complement Component by Lymphokine-Stimulated Human Monocytes <i>Bruce H. Littman and Pamela Schwartz</i>	288
Rheumatoid Factor Inhibition of In Vitro Binding of IgG Complexes in the Human Glomerulus <i>W. Kline Bolton, Jon H. Schrock, and John S. Davis IV</i>	297
Abnormalities in the Content of Nucleic Acids of Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus: Relationship to DNA Antibodies <i>Donato Alarcón-Segovia, Luis Llorente, Eugenia Fishbein, and Efraín Díaz-Jouanen</i>	304
Stimulation of DNA Synthesis by Ascorbate in Cultures of Articular Chondrocytes <i>Geoffrey Krystal, Gregory M. Morris, and Leon Sokoloff</i>	318
Quantitation of Rat Liver Xanthine Oxidase by Radioimmunoassay: A Mechanism for Sex-Specific Differences <i>Douglas E. Decker and Dennis J. Levinson</i>	326
Radiologic Vignette: Vascular Influence on Patterns of Deossification <i>Anne C. Brower and Robert M. Allman</i>	333
Brief Reports	
Weekly Intravenous Methotrexate in the Treatment of Rheumatoid Arthritis <i>Robert M. Michaels, David J. Nashel, Andrea Leonard, Anthony J. Sliwinski, and Stephen J. Derbes</i>	339
Granulomatous Angiitis of the Nervous System: Case Report and Review of the Literature <i>Umesh K. Sabharwal, Louise H. Keogh, Michael H. Weisman, and Nathan J. Zvaifler</i>	342
Osteomyelitis of Cervical Spine from <i>Propionibacterium acnes</i> <i>Majid Serushan, David L. Spencer, William L. S. Yeh, Mary Kaminski, and John L. Skosey</i>	346

Cauda Equina Syndrome in a Patient with High Titer Anti-RNP Antibodies <i>Joji Kappes and Robert M. Bennett</i>	349
Acute Temporomandibular Arthritis in a Patient with Bruxism and Calcium Pyrophosphate Deposition Disease <i>Armin E. Good and L. George Upton</i>	353
Letters	
Memorable Knee Effusions <i>Nathan J. Zvaifler</i>	356
Australian Knee Effusion <i>Jeffrey R. Eisman</i>	356
New Zealand Knee Effusion <i>David G. Palmer</i>	356
The Record Synovial Effusion <i>James C. Leisen</i>	357
Increase in Con A-induced Suppressor Cell Activity after Indomethacin Treatment <i>Lars Skoldstam, David Zoschke, and Ronald Messner</i>	357
Severe, Reversible Thrombocytopenia Associated with Meclofenamate <i>Gregory F. Schimizzi, Phillip M. Graehl, and Joseph P. Michalski</i>	359
Book Review	360

VOLUME 25

APRIL

NO. 4

Palindromic Onset of Rheumatoid Arthritis: Clinical, Synovial Fluid, and Biopsy Studies <i>H. Ralph Schumacher</i>	361
Genetic Predictors of Patient Response and Side Effects in the Treatment of Rheumatoid Arthritis with a High Dose Nonsteroidal Antiinflammatory Drug Regimen <i>Elliott Semble, Douglas Metcalf, Robert Turner, Carlos Agudelo, Edward Pisko, A. Myron Johnson, and Eugene Heise</i>	370
Antibodies to and Elevations of Beta 2 Microglobulin in the Serum of Ankylosing Spondylitis Patients <i>Russell Curry, Jorn Thoen, Charles Shelborne, Gustav Gaudernack, and Ronald Messner</i>	375
Suppression of the Normal Autologous Mixed Leukocyte Reaction by Sera from Patients with Systemic Lupus Erythematosus <i>Bevra H. Hahn, L. Susan Pletscher, Miguel Muniain, and Richard P. MacDermott</i>	381
Autologous and Allogeneic Mixed Lymphocyte Reactions in Progressive Systemic Sclerosis <i>Jane H. Morse and Betsy S. Bodi</i>	390
Multiple Interferons in the Circulation of Patients with Systemic Lupus Erythematosus and Vasculitis <i>John J. Hooks, George W. Jordan, Thomas Cupps, Haralampos M. Moutsopoulos, Anthony S. Fauci, and Abner Louis Notkins</i>	396
Serum Interferon Levels in Patients with Systemic Lupus Erythematosus <i>Steven R. Ytterberg and Thomas J. Schnitzer</i>	401
Histone Antibodies in Systemic Lupus Erythematosus: A Possible Diagnostic Tool <i>M. Gioud, M. Ait Kaci, and J. C. Monier</i>	407
High Rate of Death Caused by Systemic Lupus Erythematosus Among U. S. Residents of Asian Descent <i>Richard A. Kaslow</i>	414
Use of Monoclonal Antibodies to Analyze Peripheral Blood and Salivary Gland Lymphocyte Subsets in Sjögren's Syndrome <i>Robert I. Fox, Scott A. Carstens, Sherman Fong, Charles A. Robinson, Frank Howell, and John H. Vaughan</i>	419
Oropharyngeal Epstein-Barr Virus Excretion in Rheumatoid Arthritis <i>Joel M. Depper, Nathan J. Zvaifler, and Harry G. Bluestein</i>	427
Stimulation of the Plasminogen Activator Activity of Human Synovial Fibroblasts by Retinoids <i>John A. Hamilton</i>	432
In Vitro Cartilage Degradation by <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> <i>R. Lane Smith, Thomas C. Merchant, and David J. Schurman</i>	441
Improving Patient Cooperation with Arthritis Treatment Regimens <i>Alan M. Jette</i>	447

Brief Reports

Low Plasma Androgens in Women with Active or Quiescent Systemic Lupus Erythematosus <i>Paul Jungers, Khalil Nahoul, Clara Pelissier, Maxime Dougados, François Tron, and Jean-François Bach</i>	454
A Connective Tissue Disease Complicated by Insulin Resistance Due to Receptor Antibodies: Report of a Case with High Titer Nuclear Ribonucleoprotein Antibodies <i>Joe G. Hardin, Jr. and Alan M. Siegal</i>	458
Comparable Serum Salicylate Concentrations from Choline Magnesium Trisalicylate, Aspirin, and Buffered Aspirin in Rheumatoid Arthritis <i>Mark H. Binus, James A. Lyon, and John L. Nicholas</i>	464
Septic Sternoclavicular Arthritis with <i>Pasteurella multocida</i> and <i>Streptococcus sanguis</i> <i>John F. Nitsche, John H. Vaughan, Gary Williams, and John G. Curd</i>	467

Letters

Levamisole Treatment of Systemic Lupus Erythematosus <i>Jozef Rovenský, Ladislav Cebecauer, Dušan Žitňan, Jozef Lukáč, and Miroslav Ferenčík</i>	470
Correction of Nonsuppressible Responder Cells by Colchicine in Familial Mediterranean Fever <i>David Ilfeld, Shulamit Weil, and Oded Kuperman</i>	471
Plasterer's Tophi <i>Jeffrey L. Kraines and Michael H. Ellman</i>	472
Diagnosis of Myocarditis <i>Thomas W. Bunch and Robert G. Tancredi</i>	473
Anti-SS-B Antibodies in Immune Hemolytic Anemia <i>B. Clotet, J. Pujol Borrell, J. Vilaseca Momplet, and J. Guardia Masso</i>	473
Allopurinol-like Action of Diflunisal <i>U. Ambanelli and G. F. Ferraccioli</i>	474
Neoplasm and Systemic Vasculitis: A Case Report <i>Thomas R. Cupps and Anthony S. Fauci</i>	475
Pseudothrombophlebitis and Behcet's Syndrome <i>Lawrence M. Mulhern and Burton H. Pollock</i>	477
Bowler's Finger Syndrome <i>Lourdes Romano-Jana</i>	478
Use of Ultrasound in Identifying Tophaceous Versus Rheumatoid Nodules <i>Nicholas Tiliakos, A. Rafael Morales, and C. H. Wilson, Jr.</i>	478
Book Reviews	479

VOLUME 25

APRIL SUPPLEMENT

NO. 4

VIII Pan-American Congress of Rheumatology Abstracts	S1-S155
--	---------

VOLUME 25

MAY

NO. 5

An Analysis of the American Rheumatism Association Criteria for Rheumatoid Arthritis <i>Donald M. Mitchell and James F. Fries</i>	481
Immune Functions of Human Synovial Cells: Phenotypic and T Cell Regulatory Properties of Macrophage-like Cells That Express HLA-DR <i>Lars Klareskog, Urban Forsum, Dieter Kabelitz, Leif Plöen, Christer Sundström, Kenneth Nilsson, Anders Wigren, and Hans Wigzell</i>	488
Seronegative Rheumatoid Arthritis: A Distinct Immunogenetic Disease? <i>Graciela S. Alarcón, William J. Koopman, Ronald T. Acton, and Bruce O. Barger</i>	502
The Role of Cell Surface Proteins in Platelet Stimulation by Monosodium Urate Crystals <i>Bryon C. Jaques and Mark H. Ginsberg</i>	508
Antibodies to Collagen in Scleroderma <i>Anne M. Mackel, Frank DeLustro, Frank E. Harper, and E. Carwile LeRoy</i>	522

Immunosuppression by Fractionated Total Lymphoid Irradiation in Collagen Arthritis <i>W. Joseph McCune, Judith A. Buckley, James A. Belli, and David E. Trentham</i>	532
Clinical Responses During Gold Therapy for Rheumatoid Arthritis: Changes in Synovitis, Radiologically Detectable Erosive Lesions, Serum Proteins, and Serologic Abnormalities <i>John T. Sharp, Martin D. Lidsky, and Joseph Duffy</i>	540
Aspirin Survival in Human Blood Modulated by the Concentration of Erythrocytes <i>Patrick B. Costello and Floyd A. Green</i>	550
The Association of Antinuclear Antibodies, Antilymphocyte Antibodies, and C4 Activation Among the Relatives of Children with Systemic Lupus Erythematosus: Preferential Activation of Complement in Sisters <i>Thomas J. A. Lehman, John G. Curd, Nathan J. Zvaifler, and Virgil Hanson</i>	556
Natural Killer Augmentation in Systemic Lupus Erythematosus Via a Soluble Mediator Derived from Human Lymphocytes <i>Donald B. Kaufman</i>	562
Estrogen and Glucocorticoid Receptors in Adult Canine Articular Cartilage <i>Peter C. M. Young and Michael T. Stack</i>	568
Gonococcal Arthritis-Dermatitis Syndrome: Study of Serum and Synovial Fluid Immune Complex Levels <i>Daniel H. Manicourt and Serge Orloff</i>	574
Brief Reports	
Chronic Liver Disease and Still's Disease <i>John R. P. Tesser, Edward J. Pisko, John W. Hartz, and Michael E. Weinblatt</i>	579
Central Nervous System Systemic Lupus Erythematosus Versus Central Nervous System Infection: Low Cerebral Spinal Fluid Glucose and Pleocytosis in a Patient with a Prolonged Course <i>Elizabeth Reinitz, David Hubbard, and Arthur I. Grayzel</i>	583
Thyroid Acropachy Complicated by Lymphatic Obstruction <i>Bruce M. Rothschild and Bong H. Yoon</i>	588
A Possible Role of Prolactin in Adjuvant Arthritis <i>I. Berczi and E. Nagy</i>	591
Government Affairs: FDA Arthritis Advisory Committee Meeting <i>Harold E. Paulus</i>	595
Letters	
Temporomandibular Joint Erosions in Systemic Lupus Erythematosus <i>David Gerbracht and Lee Shapiro</i>	597
Naïfold Capillary Microscopy as a Diagnostic Tool and in Followup Examination <i>Michel Vayssairat, Pascal Priollet, James Goldberg, and Edouard Housset</i>	597
Clinical Bleeding Due to Diclofenac (Voltaren) <i>Rita Michalevich and Uri Seligsohn</i>	599
Delayed Fracture Union Associated with Dexamethasone Nasal Spray <i>Joel Kovarsky and John O. Bishop</i>	599
Vertebral Osteomyelitis and Bacterial Endocarditis <i>Marcel F. Kahn</i>	600
ARA Announcements	A33

VOLUME 25

JUNE

NO. 6

A Multicenter Study of Outcome in Systemic Lupus Erythematosus. I. Entry Variables as Predictors of Prognosis

<i>Ellen M. Ginzler, Herbert S. Diamond, Max Weiner, Michael Schlesinger, James F. Fries, Cody Wasner, Thomas A. Medsger, Jr., Gayle Ziegler, John H. Klippel, Nortin M. Hadler, Daniel A. Albert, Evelyn V. Hess, George Spencer-Green, Arthur Grayzel, David Worth, Bevra H. Hahn, and Eugene V. Barnett</i>	601
A Multicenter Study of Outcome in Systemic Lupus Erythematosus. II. Causes of Death <i>Steven Rosner, Ellen M. Ginzler, Herbert S. Diamond, Max Weiner, Michael Schlesinger, James F. Fries, Cody Wasner, Thomas A. Medsger, Jr., Gayle Ziegler, John H. Klippel, Nortin M. Hadler, Daniel A. Albert, Evelyn V. Hess, George Spencer-Green, Arthur Grayzel, David Worth, Bevra H. Hahn, and Eugene V. Barnett</i>	612

Influence of Oral Contraceptive Therapy on the Activity of Systemic Lupus Erythematosus <i>Paul Jungers, Maxime Dougados, Clara Pélissier, Frédérique Kuttenn, François Tron, Philippe Lesavre, and Jean-François Bach</i>	618
Studies of Repeat Skin Biopsies of Nonlesional Skin in Patients with Systemic Lupus Erythematosus <i>Naomi Rothfield and Cathy Marino</i>	624
Specificity in Systemic Lupus Erythematosus of Antibodies to Double-Stranded DNA Measured with the Polyethylene Glycol Precipitation Assay <i>Ruud Smeenk, Gonnée van der Lelij, Tom Swaak, Janny Groenwold, and Lucien Aarden</i>	631
Antibodies to Single-Stranded DNA in Patients with Discoid Lupus Erythematosus <i>Kevin B. Kulick, Thomas T. Provost, and Morris Reichlin</i>	639
Adult-Onset Still's Disease: Twenty-Year Followup and Further Studies of Patients with Active Disease <i>K. B. Elkon, G. R. V. Hughes, E. G. L. Bywaters, P. F. J. Ryan, R. D. Inman, N. B. Bowley, M. P. James, and R. A. J. Eady</i>	647
Chemotaxis in Yersinia Arthritis: In Vitro Stimulation of Neutrophil Migration by HLA-B27 Positive and Negative Sera <i>Heikki Repo, Marjatta Leirisalo, Anja Tiilikainen, and Ossi Laitinen</i>	655
Antibodies to SS-B in Chronic Inflammatory Connective Tissue Diseases: Relationship with HLA-Dw2 and HLA-Dw3 Antigens in Primary Sjögren's Syndrome <i>Rolf Manthorpe, Anna-Maija Teppo, Gunnar Bendixen, and Otto Wegelius</i>	662
Modulation of Chondrocyte Synthesis by Lymphokine-Rich Conditioned Media <i>Jerome H. Herman, Ramesh C. Khosla, Clifford S. Mowery, and Alan M. Appel</i>	668
Vascular Changes in Psoriatic Synovium: A Light and Electron Microscopic Study <i>Luis R. Espinoza, Frank B. Vasey, Carmen G. Espinoza, Tomas S. Bocanegra, and Bernard F. Germain</i>	677
Immunoelectron Microscopic Demonstration of Prostaglandin E in Rheumatoid Synovium <i>Shunichi Shiozawa, Ralph C. Williams, Jr., and Morris Ziff</i>	685
Post-Mammoplasty Connective Tissue Disease <i>Sheryl A. van Nunen, Paul A. Gatenby, and Antony Basten</i>	694
Tiopronin (N-[2-Mercaptopropionyl] Glycin) in Rheumatoid Arthritis <i>Bernard Amor, Christian Mery, and Annie de Gery</i>	698
Special Article: AHPA: Past, Present, Future <i>Gail E. Riggs</i>	704
Brief Reports	
Interphalangeal Joint Involvement in Gaucher's Disease, Type I, Resembling Juvenile Rheumatoid Arthritis <i>Zvi Weizman, Alexander Tennenbaum, and Shaul Yatziv</i>	706
Eosinophilic Synovial Effusions Complicating Chronic Urticaria and Angioedema <i>R. W. Kloforn and Thomas J. A. Lehman</i>	708
Amyloid Deposition in Intervertebral Discs of Senescence-Accelerated Mouse <i>Katsuji Shimizu, Masaharu Ishii, Takao Yamamuro, Shuji Takeshita, Masanori Hosokawa, and Toshio Takeda</i>	710
Letters	
Depression of Lymphocyte Blastogenesis in Steroid-Treated Rheumatoid Arthritis <i>Yoshinori Chinen, Kengo Nagaoka, Takehiko Sakurami, and Hiroo Imura</i>	713
Coexistent Gout and Systemic Lupus Erythematosus <i>Edward P. Rose and Larry E. Alves</i>	713
Treatment of Behcet's Disease with Levamisole <i>M'hamed Hamza, Khaled Ayed, and Hassouna Ben Ayed</i>	714
In Vitro Ig Synthesis and Antilymphocyte Antibody in Monozygotic Twins Discordant for Systemic Lupus Erythematosus <i>Kiyooki Tanimoto and Kunio Okudaira</i>	715
HLA-B27 and Ankylosing Spondylitis in African Blacks <i>Patrick Klemp, Orlando L. Meyers, and Ernette D. Du Toit</i>	716
Giant Cell Arteritis Associated with Progressive Systemic Sclerosis <i>Francisco Perez-Jimenez, Fernando Lopez-Rubio, Francisco Cañadillas, Juan Jimenez-Alonso, and Jose Jimenez-Perez</i>	717
First Year of a Rheumatologist in Private Practice <i>Daniel J. Mazanec</i>	718
Book Reviews	719

CURRENT PERSPECTIVES ON THE IMMUNOLOGY OF SYSTEMIC LUPUS ERYTHEMATOSUS

Proceedings of the Conference Sponsored by
The Hahnemann Medical College and Hospital
June 7-9, 1981, Philadelphia, Pennsylvania

Introduction to Current Perspectives on the Immunology of Systemic Lupus Erythematosus <i>David Koffler</i>	vi
Murine Lupus—An Overview <i>Frank J. Dixon</i>	721
Role of the Thymus in Murine Lupus and Cellular Transfer of the Disease <i>Argyrios N. Theofilopoulos</i>	726
Genetic, Environmental, and Cellular Factors in the Pathogenesis of Systemic Lupus Erythematosus <i>Alfred D. Steinberg, Elizabeth S. Raveche, Carl A. Laskin, Michael L. Miller, and Robert T. Steinberg</i>	734
Monoclonal Lupus Autoantibodies <i>Joyce Rauch, Eileen Lafer, Chester Andrzejewski, B. David Stollar, and Robert S. Schwartz</i>	744
Characteristics of Pathogenic Subpopulations of Antibodies to DNA <i>Bevra H. Hahn</i>	747
Special Antibodies for the Study of Systemic Lupus Erythematosus: An Analysis <i>Eng M. Tan</i>	753
Anti-nRNP and Anti-Sm Antibodies <i>Gordon C. Sharp</i>	757
Deciphering the Mysteries of RNA-Containing Lupus Antigens <i>Ethan A. Lerner, Michael R. Lerner, John A. Hardin, Charles A. Janeway, Jr., and Joan A. Steitz</i>	761
Clinical and Immunological Significance of Antibodies to Ro and La in Systemic Lupus Erythematosus <i>Morris Reichlin</i>	767
Antineuronal Antibodies in Systemic Lupus Erythematosus <i>Harry G. Bluestein and Virgil L. Woods, Jr.</i>	773
Specificity of Anti-Histone Antibodies in Systemic Lupus Erythematosus <i>Robert L. Rubin, Fenneke G. Joslin, and Eng M. Tan</i>	779
Pathophysiology of Circulating Immune Complexes <i>Mart Mannik</i>	783
Evidence for Detection of Low Molecular Weight DNA–Anti-DNA Complexes in Systemic Lupus Erythematosus <i>Vincent Agnello and Tadayuki Mitamura</i>	788
Complement and Lupus Erythematosus <i>Peter H. Schur</i>	793
Staphylococcal Protein A Fluoroimmunoassay for Immune Complexes <i>Isidore Faiferman and David Koffler</i>	799
Interferon Production in Patients with Systemic Lupus Erythematosus <i>Robert M. Friedman, Olivia Preble, Roberta Black, and Sharon Harrell</i>	802
Prostaglandins, Immune Responses, and Murine Lupus <i>Robert B. Zurier</i>	804
Cellular Mechanism of Tissue Injury and Immune Derangement in Systemic Lupus Erythematosus <i>Ralph C. Williams, Jr.</i>	810
Antibodies to Activated T Cells and Their Soluble Products in Systemic Lupus Erythematosus <i>John B. Winfield, Philip L. Cohen, and David A. Litvin</i>	814
The Autologous Mixed Lymphocyte Reaction in Systemic Lupus Erythematosus <i>Patrick J. Riccardi, Perrie B. Hausman, Howard V. Raff, and John D. Stobo</i>	820
Immune Responses to Hapten-Modified Self and Their Regulation in Normal Individuals and Patients with Systemic Lupus Erythematosus <i>Ira Green, Shunichi Kumagai, and Alfred D. Steinberg</i>	824

Lymphocyte Subsets in Patients with Systemic Lupus Erythematosus <i>Raphael J. DeHoratius</i>	828
Some Genetic Aspects of Systemic Lupus Erythematosus <i>R. J. Winchester and A. Nunez-Roldan</i>	833
Interleukin-2 Deficiency, Genes, and Systemic Lupus Erythematosus <i>Norman Talal, Michael J. Dauphinee, and David Wofsy</i>	838
Estrogen Metabolism in Systemic Lupus Erythematosus: Patients and Family Members <i>Robert G. Lahita, Leon Bradlow, Jack Fishman, and Henry G. Kunkel</i>	843
Studies Regarding a Possible Function for Viruses in the Pathogenesis of Systemic Lupus Erythematosus <i>Theodore Pincus</i>	847
Drug-Related Lupus <i>Evelyn V. Hess</i>	857
Immunopathogenesis of Systemic Lupus Erythematosus <i>David Koffler, Gregory Biesecker, and Sheila Moriber Katz</i>	858
The Pathogenesis of Central Nervous System Manifestations of Systemic Lupus Erythematosus <i>Nathan J. Zvaifler and Harry G. Bluestein</i>	862
The Value of the Renal Biopsy in Lupus Nephritis <i>Robert T. McCluskey</i>	867
Immunopathology of the Membrane Attack Complex in Systemic Lupus Erythematosus Nephritis <i>Gregory Biesecker and David Koffler</i>	876
The Pathogenesis of Extrarenal Lesions in Systemic Lupus Erythematosus <i>Jan R. Brentjens and Giuseppe A. Andres</i>	880
Systemic Lupus Erythematosus: Clinical Manifestations and Prognosis <i>Charles L. Christian</i>	887
Overlap Features of Connective Tissue Disease <i>E. Carwile LeRoy</i>	889
The Management of Systemic Lupus Erythematosus <i>John L. Decker</i>	891
Philadelphia, the Founding Fathers, and Systemic Lupus Erythematosus <i>Richard M. Krause</i>	895
Author Index	898
Subject Index	899

VOLUME 25

AUGUST

NO. 8

Current Comment: Collagen Arthritis as a Relevant Model for Rheumatoid Arthritis: Evidence Pro and Con <i>David E. Trentham</i>	911
Prior Gold Therapy Does Not Influence the Adverse Effects of D-Penicillamine in Rheumatoid Arthritis <i>Walter F. Kean, Colin J. L. Lock, Helen E. Howard-Lock, and W. Watson Buchanan</i>	917
Controlled Multicenter Trial of Tiopronin and D-Penicillamine for Rheumatoid Arthritis <i>Gianpiero Pasero, Pietro Pellegrini, Umberto Ambanelli, Maria Laura Ciompi, Vincenzo Colamussi, Gianfranco Ferraccioli, Paola Barbieri, Maria Rosa Mazzoni, Germano Menegale, and Donatella Trippi</i>	923
Ultrastructure of Arthritis Induced by a Caprine Retrovirus <i>Alberta L. Brassfield, D. Scott Adams, Timothy B. Crawford, and Travis C. McGuire</i>	930
Chronic Arthritis of Rabbits Induced by Mycoplasmas. III. Induction with Nonviable <i>Mycoplasma arthritidis</i> Antigens <i>Leigh Rice Washburn, Barry C. Cole, and John R. Ward</i>	937
Gas-Liquid Chromatographic Analysis of Synovial Fluid: Succinic Acid and Lactic Acid as Markers for Septic Arthritis <i>David G. Borenstein, Christina A. Gibbs, and Robert P. Jacobs</i>	947
Nailfold Capillary Abnormalities and Clinical Outcome in Childhood Dermatomyositis <i>George Spencer-Green, William E. Crowe, and Joseph E. Levinson</i>	954
Frequencies of Epstein-Barr Virus-Inducible IgM Anti-IgG B Lymphocytes in Normal Children and Children with Juvenile Rheumatoid Arthritis <i>Sherman Fong, John J. Miller III, Terry L. Moore, Constantine D. Tsoukas, John H. Vaughan, and Dennis A. Carson</i>	959

Mechanisms of Abnormal Platelet Aggregation in Systemic Lupus Erythematosus <i>Carole A. Dorsch and John Meyerhoff</i>	966
Factors Influencing Articular Cartilage Wear In Vitro <i>Eric L. Radin, David A. Swann, Igor L. Paul, and Paul J. McGrath</i>	974
Further Characterization of a Neutral Metalloprotease Isolated from Human Articular Cartilage <i>Asher I. Sapolsky and David S. Howell</i>	981
Olecranon Bursitis Related to Calcium Pyrophosphate Dihydrate Crystal Deposition Disease: Clinical and Pathologic Study <i>Jean-C. Gerster, René Lagier, and Georges Boivin</i>	989
Reproducibility Studies for Anti-DNA Antibody Detection in Systemic Lupus Erythematosus and Related Diseases: FIAx Fluorometric Immunoassay and Farr Radioimmunoassay <i>Bernard H. Berne, Kathryn T. DeBlock, and Oliver J. Lawless</i>	997
Reference Sera for Antinuclear Antibodies. I. Antibodies to Native DNA, Sm, Nuclear RNP, and SS-B/La <i>Eng M. Tan, Marvin J. Fritzler, J. Steven McDougal, Frederic C. McDuffie, Robert M. Nakamura, Morris Reichlin, Charles B. Reimer, Gordon C. Sharp, Peter H. Schur, Merlin R. Wilson, and Robert J. Winchester</i>	1003
Brief Reports	
Pancreatitis in Systemic Lupus Erythematosus <i>Murray Baron and Marie-Laure Brisson</i>	1006
A Study of the Relationship of Alpha ₁ -Antitrypsin Phenotype to the Occurrence and Severity of Juvenile Rheumatoid Arthritis <i>William E. Crowe, George Hug, Gail Chuck, David S. Knapp, and Joseph E. Levinson</i>	1010
Cognitive Dysfunction Associated with Naproxen and Ibuprofen in the Elderly <i>James S. Goodwin and Martha Regan</i>	1013
Concurrent Naproxen- and Penicillamine-Induced Renal Disease in Rheumatoid Arthritis <i>Matthew R. Quigley, Michael Richfield, Frank A. Krumlovsky, Yashpal S. Kanwar, Frank A. Carone, and Mark P. Jarrett</i>	1016
Special Article: Rheumatoid Arthritis and Mortality <i>John L. Abruzzo</i>	1020
Letters	
Placental Products in the Treatment of Rheumatoid Arthritis <i>William H. Kammerer and Abraham S. Jacobson</i>	1024
Collagen-Induced Arthritis in a Human <i>Mark P. Jarrett and Jadwiga Roguska-Kyts</i>	1024
Myositis in Behçet's Disease <i>Vincenzo Di Giacomo, Giuseppe Carmenini, Fortunato Meloni, and Guido Valesini</i>	1025
The Arthropathy of Progressive Systemic Sclerosis <i>Luis J. Catoggio and Peter J. Maddison</i>	1026
Joint Changes with Progressive Systemic Sclerosis <i>Silvia Rouzaud and Arnold L. Katz</i>	1026
"Rugger Jersey" and Osteopetrosis <i>Bruce M. Rothschild</i>	1028
In Memoriam	1029
Book Review	1030
ARA Announcements	A15

VOLUME 25

SEPTEMBER

NO. 9

Interrelationships of HLA-DR, MB, and MT Phenotypes, Autoantibody Expression, and Clinical Features in Systemic Lupus Erythematosus <i>Joseph M. Ahearn, Thomas T. Provost, Carole A. Dorsch, Mary Betty Stevens, Wilma B. Bias, and Frank C. Arnett</i>	1031
A Syndrome of Seronegative Enthesopathy and Arthropathy in Children <i>Alan M. Rosenberg and Ross E. Petty</i>	1041

The Arthritis Impact Measurement Scales: Further Investigations of a Health Status Measure <i>Robert F. Meenan, Paul M. Gertman, John H. Mason, and Richard Dunaif</i>	1048
Immunopathology of Rheumatic Pericarditis <i>Scott T. Persellin, German Ramirez, and Farhad Moatamed</i>	1054
Serum Pepsinogen I in Rheumatic Diseases: Reduced Levels in Sjögren's Syndrome <i>C. Peter J. Maury, Vesa Räsänen, Anna-Maija Teppo, Tapani Helve, and Otto Wegelius</i>	1059
Strain and Sex Variation in the Susceptibility to Streptococcal Cell Wall-Induced Polyarthritis in the Rat <i>Ronald L. Wilder, Gary B. Calandra, A. Julian Garvin, Karen D. Wright, and Carl T. Hansen</i>	1064
Radiologic Vignette: Fish Vertebrae <i>Donald L. Resnick</i>	1073
Noncollagenous Proteins in Cartilage of Normal Subjects and Patients with Degenerative Joint Disease: A Gel Electrophoretic Study <i>F. Chaminade, V. Stanesco, R. Stanesco, P. Maroteaux, and J. G. Peyron</i>	1078
Partial Reversal by Beta-D-Xyloside of Salicylate-Induced Inhibition of Glycosaminoglycan Synthesis in Articular Cartilage <i>Marshall J. Palmoski and Kenneth D. Brandt</i>	1084
Gamma-Carboxyglutamate Excretion and Calcinosis in Juvenile Dermatomyositis <i>Jane B. Lian, Lauren M. Pachman, Caren M. Gundberg, Raymond E. H. Partridge, and Mona C. Maryjowski</i>	1094
Human Complement Activation by Self-Associated IgG Rheumatoid Factors <i>Paul B. Brown, Francis A. Nardella, and Mart Mannik</i>	1101
Induction of Human Rheumatoid Factor Producing Cells by Aggregated IgG <i>Edward J. Pisko, Robert A. Turner, and Susan L. Foster</i>	1108
Ultrastructure of the Esophagus in Scleroderma <i>M. Lynn Russell, Dianne Friesen, R. D. Henderson, and Wedad M. Hanna</i>	1117
Government Affairs: FDA Arthritis Advisory Committee Meeting <i>Harold E. Paulus</i>	1124
Brief Reports	
Lupus Patients Who Lack Detectable Anti-DNA: Clinical Features and Survival <i>Stanley P. Ballou and Irving Kushner</i>	1126
Cancer in Connective Tissue Disease <i>K. A. Black, P. J. Zilko, R. L. Dawkins, B. K. Armstrong, and G. L. Mastaglia</i>	1130
Systemic Lupus Erythematosus and Acute Intermittent Porphyrin: Coincidence or Association? <i>Jack I. Rosemarin, Emil J. Nigro, Richard D. Levere, and Bento R. Mascarenhas</i>	1134
Cold Activation of Complement <i>Shuhei Takemura, Tadahiho Hotta, Naoyuki Matsumura, Toshikazu Yoshikawa, and Motoharu Kondo</i>	1138
Scleroderma, Amyloidosis, and Extensor Tendon Rupture <i>Harold M. Horwitz, Joseph D. DiBeneditto, Jr., Salvatore R. Allegra, and Harvey M. Baumann</i>	1141
Letters	
Preliminary Criteria for Remission in Rheumatoid Arthritis <i>John T. Sharp</i>	1144
Tolmetin-Induced Thrombocytopenia <i>Jack M. Lockhart</i>	1144
Unconventional Arthritis Therapies <i>Andrea Dlesk, Mark P. Ettinger, Selden Longley, Gerald H. Stein, James L. Templeton, and Richard S. Panush</i>	1145
Abuse of Computed Tomography <i>Andrei Calin</i>	1147
Intraarticular Gold Salts in Rheumatoid Arthritis <i>Perry R. Sloop, Jr.</i>	1148
Charcot-Leyden or Corticosteroid Crystals? <i>Charles B. Kahn</i>	1148
Azathioprine-Induced Pancreatitis <i>A. L. Poznaniak and M. Ahern</i>	1149
Rheumatology Education in Medical Schools <i>Ida Gregoire</i>	1149
Book Reviews	1149

Current Comment: Studies of Immune Complexes	
<i>Paul H. Plotz</i>	1151
Comparison of Five Assays for Immune Complexes in the Rheumatic Diseases: An Assessment of Their Validity for Rheumatoid Arthritis	
<i>J. Steven McDougal, Marjorie Hubbard, Frederic C. McDuffie, Phyllis L. Strobel, S. Jay Smith, Noah Bass, John A. Goldman, Sanford Hartman, Gary Myerson, Stephen Miller, Rafael Morales, and C. H. Wilson, Jr.</i>	1156
Immune Complexes in Progressive Systemic Sclerosis (Scleroderma)	
<i>James R. Seibold, Thomas A. Medsger, Jr., Alan Winkelstein, Robert H. Kelly, and Gerald P. Rodnan</i>	1167
Circulating Immune Complexes in Patients with Progressive Systemic Sclerosis	
<i>K. Siminovitch, M. Klein, W. Pruzanski, S. Wilkinson, P. Lee, Sung-Ja Yoon, and E. Keystone</i>	1174
Circulating Immune Complexes in Eosinophilic Fasciitis	
<i>James R. Seibold, Gerald P. Rodnan, Thomas A. Medsger, Jr., and Alan Winkelstein</i>	1180
Hypertrophic Osteoarthropathy in Cyanotic Congenital Heart Disease: Its Prevalence and Relationship to Bypass of the Lung	
<i>Manuel Martínez-Lavín, María Bobadilla, José Casanova, Fause Attié, and Marco Martínez</i>	1186
Susceptibility to Adjuvant Arthritis in DA and F ₃₄₄ Rats: A Dominant Trait Controlled by an Autosomal Gene Locus Linked to the Major Histocompatibility Complex	
<i>Jack R. Battisto, R. N. Smith, Karla Beckman, Mona Sternlicht, and Wanda L. Welles</i>	1194
Immobilization of the Knee Prevents Osteoarthritis after Anterior Cruciate Ligament Transection	
<i>Marshall J. Palmoski and Kenneth D. Brandt</i>	1201
Abnormal Softening in Articular Cartilage: Its Relationship to the Collagen Framework	
<i>Neil D. Broom</i>	1209
Effect of Purified Growth Factors on Rabbit Articular Chondrocytes in Monolayer Culture. I. DNA Synthesis	
<i>A. Pieter A. Prins, Jack M. Lipman, and Leon Sokoloff</i>	1217
Effect of Purified Growth Factors on Rabbit Articular Chondrocytes in Monolayer Culture. II. Sulfated Proteoglycan Synthesis	
<i>A. Pieter A. Prins, Jack M. Lipman, Cahir A. McDevitt, and Leon Sokoloff</i>	1228
Experimental Hydroxyapatite Synovial and Articular Cartilage Calcification: Light and Electron Microscopic Studies	
<i>Antonio J. Reginato, H. Ralph Schumacher, and Carl T. Brighton</i>	1239
Brief Reports	
Primary Biliary Cirrhosis Associated with Sjögren's Syndrome: Evidence for Circulating and Tissue-Deposited Ro/Anti-Ro Immune Complexes	
<i>E. Penner and Morris Reichlin</i>	1250
Tarsal Arthritis with Ankylosis in Late Onset Still's Disease	
<i>L. A. Healey and Robert F. Willkens</i>	1254
Vertebral Ankylosis in a Patient with Hereditary Chondrocalcinosis: A Chance Association?	
<i>Jerome B. Brem</i>	1257
Juvenile Metabolic Gout Caused by Chronic Compensated Hemolytic Syndrome	
<i>Uri A. Liberman, Ruth Samuel, Aaron Halabe, Henry Joshua, Ernesto Lubin, Esther Zoref-Shani, and Oded Sperling</i>	1264
Letters	
The Absence of Reactive Arthritis after <i>Shigella sonnei</i> Infection	
<i>Robert B. Lewis</i>	1267
Nifedipine in Digital Ulceration in Scleroderma	
<i>Israeli A. Jaffe</i>	1267
Treatment of Hip Damage in Children with Juvenile Rheumatoid Arthritis	
<i>Jerry C. Jacobs</i>	1269
Use of Azathioprine for Rheumatoid Arthritis	
<i>Duncan A. Gordon and Murray B. Urowitz</i>	1269
Book Review	1270
ARA Announcements	A42

Special Article: The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus <i>Eng M. Tan, Alan S. Cohen, James F. Fries, Alfonse T. Masi, Dennis J. McShane, Naomi F. Rothfield, Jane Green Schaller, Norman Talal, and Robert J. Winchester</i>	1271
Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies: A Diagnostic Evaluation <i>L. Matter, K. Schopfer, J. A. Wilhelm, T. Nyffenegger, R. F. Parisot, and E. M. De Robertis</i>	1278
Skin Response to Intradermal DNA and RNA in Systemic Lupus Erythematosus <i>Yrjö T. Konttinen, Erkki Tolvanen, Eija Johansson, Sakari Reitamo, and Otto Wegelius</i>	1284
Prolonged Lifespans in Female NZB/NZW Mice Treated with the Experimental Immunoregulatory Drug Frentizole <i>Sara Ellen Walker, Marilyn Solsky, and Bertram Schnitzer</i>	1291
IgM and IgG Anti-F(ab') ₂ Antibodies in Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>Ralph Heimer, Lawrence D. Wolfe, and John L. Abruzzo</i>	1298
Evidence for the Local Production and Utilization of Immune Reactants in Rheumatoid Arthritis <i>F. Cecere, J. Lessard, S. McDuffy, and R. M. Pope</i>	1307
Nonreducible Rotational Head Tilt and Lateral Mass Collapse: A Prospective Study of Frequency, Radiographic Findings, and Clinical Features in Patients with Rheumatoid Arthritis <i>James T. Halla, Sohrab Fallahi, and Joe G. Hardin</i>	1316
Adjuvant Polyarthritis. VII. The Role of Type II Collagen in Pathogenesis <i>Yoshio Iizuka and Yi-Han Chang</i>	1325
Aspirin Aggravates the Degeneration of Canine Joint Cartilage Caused by Immobilization <i>Marshall J. Palmoski and Kenneth D. Brandt</i>	1333
Functional Aberration of T Cell Subsets in Patients with Behçet's Disease <i>Tsuyoshi Sakane, Hiroyuki Kotani, Shinsuke Takada, and Tokugoro Tsunematsu</i>	1343
Serum Eosinophilic Activity in Eosinophilic Fasciitis <i>Stephen I. Wasserman, James R. Seibold, Thomas A. Medsger, Jr., and Gerald P. Rodnan</i>	1352
Digital Sclerosis in Children with Insulin-Dependent Diabetes Mellitus <i>James R. Seibold</i>	1357
Brief Reports	
Joint Contractures Preceding Insulin-Dependent Diabetes Mellitus <i>David D. Sherry, Ralph R. L. Rothstein, and Ross E. Petty</i>	1362
Polyarthritis with Birefringent Lipid Within Synovial Fluid Macrophages: Case Report and Ultrastructural Study <i>Peter A. Schlesinger, M. Thomas Stillman, and LoAnn Peterson</i>	1365
Hemorrhagic Bursitis and Bone Crises in Chronic Adult Gaucher's Disease: A Case Report <i>Gilbert Gelfand and Harry Bienenstock</i>	1369
Localized Myositis Presenting as Pseudothrombophlebitis <i>Krishna Kalyanaraman and Uma P. Kalyanaraman</i>	1374
Superior, Posterior, and Lateral Displacement of C1 in Rheumatoid Arthritis <i>Steven Weiner, Lawrence Bassett, and Timothy Spiegel</i>	1378
Rheumatoid Synovial Cyst of the Hip <i>Roger N. Levy, George Hermann, Moshe Haimov, Herbert S. Sherry, John S. Train, and Selvan Davison</i>	1382
Paganini's Hand <i>Richard Dean Smith</i>	1385
Letters	
Spontaneous Hemarthrosis in a Patient Treated with Hemodialysis for Chronic Renal Failure <i>Catherine Marino and Hal Kazdin</i>	1387
Systemic Lupus Erythematosus Triggered by Diphenylhydantoin <i>Helga Gleichmann</i>	1387
Azathioprine-induced Hypotension with Oliguria <i>Francesco Trotta, Germano Menegale, and Orazio Fiocchi</i>	1388
HLA Specificities and Psoriatic Arthritis <i>Claudio Cervini and Walter Grassi</i>	1389
Methodology Errors in Fibrositis Study <i>Daniel Hamaty</i>	1389

Selection Bias in Fibrositis Study	
<i>Frederick Wolfe</i>	1390
Book Review	1390

VOLUME 25

DECEMBER

NO. 12

Cytotoxic Activity of Sera from Scleroderma and Other Connective Tissue Diseases: Lack of Cellular and Disease Specificity	
<i>William R. Shanahan, Jr. and Joseph H. Korn</i>	1391
Histoplasmosis Presenting with Joint Pain and Hilar Adenopathy: "Pseudosarcoidosis"	
<i>Denise K. Thornberry, L. Joseph Wheat, Kenneth D. Brandt, and Jerome Rosenthal</i>	1396
Evidence for <i>Pseudomonas</i> Antigen in Immune Complexes in <i>Pseudomonas</i> Osteomyelitis	
<i>Daniel W. Rahn, Allen C. Steere, Robert L. Grodzicki, Joseph H. Levine, and John A. Hardin</i>	1403
Increased Endothelial Cell Adherence, Aggregation, and Superoxide Generation by Neutrophils Incubated in Systemic Lupus Erythematosus and Felty's Syndrome Sera	
<i>Yoshimi Hashimoto, Morris Ziff, and Eric R. Hurd</i>	1409
Circadian Variations of Serum Myoglobin Levels in Normal Subjects and Patients with Polymyositis	
<i>Stefano Bombardieri, Aldo Clerico, Lucrezia Riente, Maria Grazia Del Chicca, and Claudio Vitali</i>	1419
Circulating DNA in Polyarteritis Nodosa and Related Syndromes	
<i>Charles R. Steinman</i>	1425
Immunogenetic Factors in Inflammatory Eye Disease: Influence of HLA-B27 and Alpha ₁ -Antitrypsin Phenotypes on Disease Expression	
<i>Denis Wakefield, Samuel N. Breit, Peggy Clark, and Ronald Penny</i>	1431
HLA Antigens in Yakima Indians with Rheumatoid Arthritis: Lack of Association with HLA-Dw4 and HLA-DR4	
<i>Robert F. Willkens, John A. Hansen, Judith A. Malmgren, Brenda Nisperos, Eric M. Mickelson, and Margaret A. Watson</i>	1435
Natural Killer Cell Activity of Mononuclear Cells from Rheumatoid Patients Measured by a Conjugate-Binding Cytotoxicity Assay	
<i>Elizabeth Reinitz, P. Andrew Neighbour, and Arthur I. Grayzel</i>	1440
Quantitation of Cells Secreting Rheumatoid Factor of IgG, IgA, and IgM Class after Elution from Rheumatoid Synovial Tissue	
<i>Torstein Egeland, Tor Lea, George Saari, Ove J. Mellbye, and Jacob B. Natvig</i>	1445
Relationship Between Reduced B Cell Susceptibility to IgM Antibodies and Reduced IgD-Bearing B Cells in Patients with Systemic Lupus Erythematosus	
<i>Hiroshi Suzuki, Takehiko Sakurami, and Hiroo Imura</i>	1451
Articular Cartilage in the Degenerative Arthropathy of Hemochromatosis	
<i>H. Ralph Schumacher</i>	1460
Effect of Metal Chelators and Antiinflammatory Drugs on the Degradation of Hyaluronic Acid	
<i>W. Henry Betts and Leslie G. Cleland</i>	1469
Brief Reports	
Toxic Synovitis from Denatured Rapeseed Oil	
<i>Manuel Rodriguez, Enrique Noguera, Rafael S. Del Villar, S. Vegazo, Juan Mulero, Juan Cruz, and Antonio Larrea</i>	1477
Polyarthritis in Immunoblastic Lymphadenopathy	
<i>Richard J. Raskin, Joseph T. Tesar, and Oliver J. Lawless</i>	1481
Selective Immobilization of Human Mononuclear Phagocytes by Benoxaprofen	
<i>Edward J. Goetzl and Frank H. Valone</i>	1486
Seronegative Peripheral Arthritis in B27 Positive Monozygotic Twin Sisters	
<i>Edward V. Lally, Daniel G. Baker, and Harold M. Horwitz</i>	1490
Arthritis and Carpal Tunnel Syndrome Associated with Disulfiram (Antabuse) Therapy	
<i>John F. Howard</i>	1494
Bony Ankylosis of the Hips in Progressive Systemic Sclerosis	
<i>Christopher J. Huyck and Gary S. Hoffman</i>	1497
Subclavian Artery Thrombosis Mimicking the Aortic Arch Syndrome in Systemic Lupus Erythematosus	
<i>F. Michael Ferrante, Gary E. Myerson, and John A. Goldman</i>	1501

Letters

Local Injections of Tiopronin in Dupuytren's Contracture <i>Marco A. Cimmino, Maurizio Cutolo, and Francesco Beltrame</i>	1505
Coexistence of Systemic Lupus Erythematosus and Gout <i>L. Kalmar, E. Ablonczy, G. Y. Müzes, P. Gergely, and T. Neumark</i>	1505
The Definition of Fibrositis <i>Michael D. Reynolds</i>	1506
T Cell Subsets in the Blood of Rheumatoid Arthritis Patients in Clinical Remission <i>G. Faure, M. F. Kahn, M. A. Bach, and J. F. Bach</i>	1507
Colchicine and Arthropathy of Behçet's Disease <i>Venceslao Fossaluzza</i>	1509
Colchicine and Pseudogout <i>Tomás González and Marian Gantes</i>	1509
Thrombocytopenia in Sjögren's Syndrome <i>Alain Berrebi, Motti Shtalrid, Monica Talmor, and Eljakim Vorst</i>	1510
Rarity of Nephropathy in Ankylosing Spondylitis <i>Andrei Calin</i>	1510
Reviewers	1511
Contents Volume 25, 1982	1513
Indexes	1528

AUTHOR INDEX

A
Aarden L, 631
Ablonczy E, 1505
Abramson S, 174
Abruzzo JL, 1020, 1298
Accardo S, 119
Acton RT, 502
Adams DS, 930
Agudelo C, 370
Ahearn JM, 1031
Ahern M, 1149
Ait Kaci M, 407
Alarcon GS, 150, 302
Alarcon-Segovia D, 304
Albert DA, 601 612
Allegra SR, 1141
Allman RM, 333
Alves LE, 713
Ambanelli U, 474, 923
Amor B, 698
Andary M, 17
Andersen RB, 25
Andres GA, 880
Andrzejewski C, 744
Agnello V, 788
Appel AM, 668
Armstrong BK, 1130
Arnett FC, 1031
Atkinson JP, 181
Attie F, 1186
Ayed HB, 714
Ayed K, 714

B
Bach JF, 454, 618, 1507
Bach MA, 1507
Baker DG, 1490
Ballou SP, 55, 1126
Barada FA, 10
Barbieri P, 923
Barger BO, 502
Barnett EV, 601, 612
Baron M, 1006
Bass N, 1156
Bassett L, 1378
Basten A, 694
Battisto JR, 1194
Baumann HM, 1141
Bayer AS, 107
Beckman K, 1194
Bell JA, 532
Beltrame F, 1505
Bendixen G, 662
Benichou C, 80
Bennett PH, 161, 236
Bennett RM, 349
Berczi I, 591
Berne BH, 997

Berrebi A, 1510
Betts WH, 1469
Bianchi G, 119
Bianchi V, 119
Bias WB, 1031
Bienenstock H, 1369
Biesecker G, 858, 876
Binus MH, 464
Bishop JO, 599
Bjelle A, 66
Black KA, 1130
Black R, 802
Blaszczuk M, 61
Blodgett RC Jr, 1390
Bluestein HG, 427, 773, 862
Bobadilla M, 1186
Bocanegra TS, 677
Bodi BS, 390
Boerbooms AMTh, 223
Boivin G, 989
Bole GG, 1
Bolton WK, 297
Bombardieri S, 1419
Bonneau M, 17
Borenstein DG, 947
Borrell JP, 473
Botstein GR, 189, 241
Bove KE, 126
Bowley NB, 647
Bradlow L, 843
Brandt KD, 1084, 1201, 1333, 1396
Bransford K, 232
Brassfield AL, 930
Braunstein EM, 218
Breit SN, 1431
Brem JB, 1257
Brentjens JR, 880
Brighton CT, 1239
Brisson ML, 1006
Broom ND, 1209
Brower AC, 333
Brown PB, 1101
Buchanan WW, 917
Buckley JA, 532
Bunch TW, 473
Butler M, 111
Bywaters EGL, 647

C
Calandra GB, 1064
Caldwell DS, 209
Calin A, 236, 1147, 1510
Canadillas F, 717
Carmenini G, 1025
Carone FA, 1016
Carruthers G, 111
Carson DA, 161, 360, 959

Carstens SA, 419
Casanova J, 1186
Case DB, 241
Catoggio LJ, 1026
Cebecauer L, 470
Cecere F, 1307
Cervini C, 1389
Chaminade F, 1078
Champion BR, 274
Chang YH, 1325
Cherian PV, 98
Chinen Y, 713
Christian CL, 241, 887
Chuck G, 1010
Cimmino MA, 119, 1505
Ciompi ML, 923
Clark P, 1431
Cleland LG, 1469
Clemmensen I, 25
Clerico A, 1419
Clot J, 17
Clotet B, 473
Cohen AS, 92, 204, 1271
Cohen PL, 168, 814
Colamussi V, 923
Cole BC, 937
Convery FR, 720
Costello PB, 32, 550
Crawford TB, 930
Crowe WE, 126, 954, 1010
Cruickshank B, 101
Cruz J, 1477
Cupps TR, 396, 475
Curd JG, 161, 467, 556
Curry R, 375
Cutolo M, 119, 1505

D
Daniels TE, 260
Dauphinee MJ, 838
Davis JS IV, 297
Davison S, 120, 1382
Dawkins RL, 1130
DeBlock KT, 997
Decker DE, 326
Decker JL, 891
deGery A, 698
DeHoratius RJ, 828
Del Chicca MG, 1419
DeLustro F, 522
Del Villar RS, 1477
Depper JM, 427
Derbes SJ, 339
DeRoberts EM, 1278
Diamond HS, 601, 612
Diaz-Jouanen E, 304
DiBeneditto JD Jr, 1141
Di Giacomo V, 1025

Dixon FJ, 721
Dlesk A, 1145
Dorsch CA, 966, 1031
Dougados M, 454, 618
Duffy J, 540
Dunaif R, 1048
Du Toit ED, 716
Dynesius-Trentham RA, 266

E
Eady RAJ, 647
Edvinsson U, 66
Egan MS, 204
Egeland T, 1445
Ehrenfeld M, 227
Ehrlich GE, 719
Eisman JR, 356
Eliakim M, 227
Elkon KB, 647
Ellman MH, 472
Esdaile J, 83
Espinoza CG, 677
Espinoza LR, 677
Ettinger MP, 1145

F
Faerman I, 799
Fallahi S, 1316
Fam AG, 101
Fauci AS, 396, 475
Faure G, 1507
Feltkamp CA, 87
Feltkamp-Vroom TM, 87
Ferencik M, 470
Ferguson AL, 144
Ferraccioli GF, 474, 923
Ferrante FM, 1501
Fighali S, 118
Fiocchi O, 1388
Fishbein E, 304
Fishbein MC, 232
Fishman J, 843
Flatau E, 42
Fong S, 161, 419, 959
Forrester DM, 480
Forstot JZ, 156
Forstot SL, 156
Forsum U, 488
Fossaluzza V, 1509
Foster SL, 1108
Fox RI, 419
Frank MM, 48
Frayha RA, 118, 235
Freeman D, 111
Freeman DG, 144
Friedman RM, 802
Fries JF, 481, 601, 612, 1271

Friesen D, 117
Fritzler MJ, 1003

G

Gallagher P, 75
Gantes M, 1509
Garron DC, 213
Garvin AJ, 1064
Gatenby PA, 694
Gaudernack G, 375
Gelfand G, 1369
Gerbracht D, 597
Gergely P, 1505
Germain BF, 677
Gerster JC, 989
Gertman PM, 1048
Gibbs CA, 947
Ginsberg MH, 508
Ginzler EM, 601, 612
Gioud M, 407
Gleichmann H, 1387
Glickman PB, 213
Goetzl EJ, 1486
Gofton JP, 236
Goldberg J, 597
Golden HE, 213
Goldenberg DL, 92, 204
Goldman JA, 1156, 1501
Gonzalez T, 1509
Good AE, 218, 353
Goodwin JS, 1013
Gordon DA, 1269
Graehl PM, 359
Grant KD, 117
Grassi W, 1389
Grayzel AI, 583, 601, 612, 1440
Green FA, 32, 550
Green I, 824
Greenspan JS, 260
Greer RO, 156
Gregoire I, 1149
Grodzicki RL, 1403
Groenwold J, 631
Gundberg CM, 1094

H

Hadler D, 612
Hadler NM, 601, 612, 1150
Hafeli DM, 1149
Hagstam A, 66
Hahn BH, 381, 601, 612, 747
Haimov M, 1382
Halabe A, 1264
Halla JT, 1316
Hamaty D, 1389
Hamburger MI, 48
Hamilton JA, 432
Hamza M, 714
Hanna WM, 1117

Hansen CT, 1064
Hansen JA, 1435
Hanson V, 556
Hardin JA, 761, 1403
Hardin JG Jr, 458, 1316
Harper FE, 522
Harrell S, 802
Harth M, 111
Hartman S, 1156
Hartz JW, 579
Hashimoto Y, 1409
Hausman PB, 820
Hausmanowa-Petrusewicz I, 61
Hawkins D, 83
Healey LA, 1254
Heimer R, 1298
Heise E, 370
Hellmann D, 121
Helve T, 1059
Henderson RD, 1117
Herman JH, 668
Hermann G, 1382
Hess EV, 117, 601, 612, 857
Hilton PK, 126
Hoffman GS, 1497
Hoffstein ST, 174
Holmes EW, 209
Hooks JJ, 396
Horwitz DA, 10
Horwitz HM, 1141, 1490
Hosokawa M, 710
Hotta T, 1138
Housset E, 597
Howard JF, 1494
Howard-Lock HE, 917
Howell DS, 981
Howell F, 419
Hubbard D, 583
Hubbard M, 1156
Hug G, 1010
Hughes GRV, 647
Hunder GG, 479
Hurd ER, 1409
Husby G, 140
Huyck CJ, 1497
Hvidman L, 249

I

Iizuka Y, 1325
Ilfeld D, 38, 471
Imura H, 713, 1451
Inman RD, 647
Ishii M, 710

J

Jablonska S, 61
Jacobs JC, 1269
Jacobs RP, 947
Jacobson AS, 1024

Jaffe IA, 1267
James MP, 647
Janeway CA Jr, 761
Jarrett MP, 1016, 1024
Jaques BC, 508
Jawad I, 118
Jayson MIV, 239
Jennette JC, 144
Jette AM, 447
Jimenez-Alonson J, 717
Jimenez-Pereperez J, 717
Johansson E, 1284
Johnson AM, 370
Jones K, 75
Jordan GW, 396
Joshua H, 1264
Joslin FG, 779
Jung CY, 32
Jungers P, 454, 618

K

Kabelitz D, 488
Kahn CB, 1148
Kahn MF, 600, 1507
Kallen P, 107
Kalmar L, 1505
Kalyanaraman K, 1374
Kalyanaraman UP, 1374
Kaminski M, 346
Kammerer WH, 1024
Kant KS, 117
Kanwar YS, 1016
Kappes J, 349
Kaslow RA, 414
Katz AL, 1026
Katz EZ, 227
Katz RS, 213
Katz SM, 858
Kaufman DB, 562
Kazdin H, 1387
Kean WF, 917
Keller M, 107
Keller TS, 218
Kelly RH, 1167
Keogh LH, 342
Keystone EC, 238, 1174
Khan MA, 55
Khosla RC, 668
Kimberly RP, 48
Klarskog L, 488
Klein M, 1174
Klein S, 238
Klemp P, 716
Klinenberg JR, 232
Klippel JH, 601, 612
Kloforn RW, 708
Knapp DS, 1010
Knowler WC, 236
Koffler D, vi, 799, 858, 876
Kohn D, 42

L

Kondo M, 1138
Kontinen YT, 1284
Koopman WJ, 150, 502
Korn JH, 1391
Kotani H, 1343
Kousa M, 249
Kovarsky J, 599
Kraines JL, 472
Krause RM, 895
Kruis HJA, 223
Krumlovsky FA, 1016
Krystal G, 318
Kuberski TT, 236
Kulick KB, 639
Kumagai S, 824
Kunkel HG, 843
Kuperman O, 38, 471
Kushner I, 55, 1126
Kutten F, 618
Lafer E, 744
Lagier R, 989
Lahita RG, 843
Laitinen O, 249, 655
Lally EV, 1490
Laragh JH, 241
Larrea A, 1477
Laskin CA, 734
Lawless OJ, 997, 1481
Lawley TJ, 48
Lea T, 1445
Leavitt F, 213
Lee P, 1174
Lehman TJA, 556, 708
Leirisalo M, 249, 655
Leisen JC, 357
Leonard A, 339
Lerner EA, 761
Lerner MR, 761
LeRoy EC, 189, 241, 522, 889
Lesavre P, 618
Lessard J, 1307
Levere RD, 1134
Levine JH, 1403
Levine S, 232
Levinson DJ, 326
Levinson JE, 126, 954, 1010
Levy E, 42
Levy M, 227
Levy RN, 1382
Lewis RB, 1267
Lian JB, 1094
Lieberman UA, 1264
Lick CJL, 917
Lidsky MD, 540
Lipman JM, 1217, 1228
Lisse JR, 236
Littman BH, 288

Litvin DA, 168, 814
 Llorente L, 304
 Lockhart JM, 1144
 Longley S, 1145
 Lopez-Rubio F, 717
 Louie JS, 107
 Lubin E, 1264
 Lukac J, 470
 Lurie M, 42
 Lyon JA, 444

M

Macco JG, 473
 MacDermott RP, 381
 Mackel AM, 522
 Maddison PJ, 1026
 Malmgren JA, 1435
 Manicourt DH, 574
 Mann DL, 236
 Mannik M, 783, 1101
 Manthorpe R, 662
 Maricq H, 241
 Marino C, 624, 1387
 Maroteaux P, 1078
 Marsh JM, 196
 Martinez M, 1186
 Martinez-Lavin M, 1186
 Maryjowski MC, 1094
 Mascarenhas BR, 1134
 Masi AT, 1271
 Mason JH, 1048
 Mastaglia GL, 1130
 Matsumura N, 1138
 Matter L, 1278
 Matz B, 61
 Maury CPJ, 1059
 Mazanec DJ, 718
 Mazzoni MR, 923
 McCluskey RT, 867
 McCune WJ, 266, 532
 McDevitt CA, 1228
 McDougal JS, 1003, 1156
 McDuffie FC, 1003, 1156
 McDuffy S, 1307
 McGrath PJ, 974
 McGuire TC, 930
 McShane DJ, 1271
 Medsger TA, 601, 612, 1167, 1180, 1352
 Meenan RF, 92, 1048
 Mellbye OJ, 1445
 Meloni F, 1025
 Menegale G, 923, 1388
 Merchant TC, 441
 Mery C, 698
 Messner R, 357, 375
 Metcalf D, 370
 Meyerhoff J, 966
 Meyers OL, 716
 Michaels RM, 339

Michalevicz R, 599
 Michalski JP, 359
 Mickelson EM, 1435
 Miller JJ III, 959
 Miller ML, 734
 Miller S, 1156
 Mitamura T, 788
 Mitchell DM, 481
 Moatamed F, 1054
 Momplet JV, 473
 Monier JC, 407
 Moore MA, 144
 Moore TL, 959
 Morales AR, 478, 1156
 Morris GM, 318
 Morse JH, 390
 Moutsopoulos HM, 396
 Mowery CS, 668
 Mulero J, 1477
 Mulhern LM, 477
 Munian M, 381
 Murrman MK, 92
 Muzes GY, 1505
 Myerson GE, 1156, 1501

N

Nagaoka K, 713
 Nagy E, 591
 Nahoul K, 454
 Naides SJ, 1030
 Nakamura RM, 1003
 Nardella FA, 1101
 Nashel DJ, 339
 Natvig JB, 1445
 Neighbour PA, 1440
 Neumark T, 1505
 Nicholas JL, 464
 Nielsen ED, 249
 Nies KM, 107
 Nigro EJ, 1134
 Nilsson K, 488
 Nisperos B, 1435
 Nissila M, 249
 Nitsche JF, 467
 Noguera E, 1477
 Notkins AL, 396
 Nunez-Roldan A, 833
 Nyffenegger T, 1278

O

O'Brien W, 10
 Okudaira K, 715
 Orloff S, 574
 Østensen M, 140

P-Q

Pachman LM, 1094
 Palmer DG, 356

Palmoski MJ, 1084, 1201, 1333
 Panush RS, 1145
 Parisot RF, 1278
 Partridge REH, 1094
 Pasero G, 923
 Paul IL, 974
 Paulus HE, 595, 1124
 Payne TC, 213
 Pelissier C, 454, 618
 Pellegrini P, 923
 Penner E, 1250
 Penny R, 1431
 Percy J, 111
 Perez-Jimenez F, 717
 Persellin ST, 1054
 Peterson L, 1365
 Petty RE, 1041, 1362
 Peyron JG, 1078
 Pincus T, 847
 Pisko EJ, 370, 579, 1108
 Pletscher LS, 381
 Ploen L, 488
 Plotz PH, 48, 1151
 Podell TE, 232
 Pollak VE, 117
 Pollock BH, 477
 Poole AR, 274
 Pope RM, 1307
 Pozniak AL, 1149
 Preble O, 802
 Prins APA, 1217, 1228
 Priollet P, 597
 Provost TT, 639, 1031
 Pruzanski W, 1174
 Quigley MR, 1016

R

Rabenstein D, 111
 Radin EL, 974, 1270
 Raff HV, 820
 Rahn DW, 1403
 Rakic MT, 1030
 Ramirez G, 1054
 Rasanen V, 1059
 Raskin RJ, 1481
 Rauch J, 744
 Raveche ES, 734
 Regan M, 1013
 Reginato AJ, 1239
 Reichlin M, 639, 767, 1003, 1250
 Reimann HA, 1150
 Reimer CB, 1003
 Reinitz E, 583, 1440
 Reitano S, 1284
 Repo H, 655
 Resnick DL, 1073
 Reynolds MD, 1506
 Riccardi PJ, 820

Richfield M, 1016
 Riente L, 1419
 Riggs GE, 704
 Roback DW, 196
 Robinson CA, 419
 Rodnan GP, 1167, 1180, 1352
 Rodriguez M, 1477
 Roguska-Kyts J, 1024
 Romano-Jana L, 478
 Romberg Ø, 140
 Rose EP, 713
 Rosemarin JI, 1134
 Rosenberg AM, 1041
 Rosenthal J, 1396
 Rosenthal L, 83
 Rosner S, 612
 Ross GT, 196
 Rothfield NF, 624, 1271
 Rothschild BM, 588, 1028
 Rothstein RRL, 1362
 Rouault T, 209
 Rouzard S, 1026
 Rovinsky J, 470
 Rovetta G, 119
 Rubin RL, 779
 Russell ML, 1117
 Ryan PFJ, 647

S

Saari G, 1445
 Sabharwal UK, 161, 342
 Sakane T, 1343
 Sakurami T, 713, 1451
 Samuel R, 1264
 Sany J, 17
 Sapolsky AI, 981
 Schaller JG, 1271
 Schiller AL, 266
 Schiller D, 42
 Schimizzi GF, 359
 Schlesinger M, 601, 612
 Schlesinger PA, 1365
 Schnitzer B, 1291
 Schnitzer TJ, 401
 Schopfner K, 1278
 Schrock JH, 297
 Schrohenloher RE, 150
 Schumacher HR, 98, 361, 1239, 1460
 Schur PH, 793, 1003
 Schurman DJ, 441
 Schwartz P, 288
 Schwartz RS, 744
 Segal D, 204
 Seibold JR, 1167, 1180, 1352, 1357
 Seligsohn U, 599
 Semble E, 370
 Serushan M, 346
 Shames CJ, 238

Shanahan WR Jr, 1391
 Shapiro L, 597
 Sharp GC, 757, 1003
 Sharp JT, 540, 1144
 Shearman J, 83
 Shelborne C, 375
 Sherer GK, 189
 Sherry DD, 1362
 Sherry HS, 1382
 Shillitoe EJ, 260
 Shimuzu K, 710
 Shiozawa S, 685
 Shtalrid M, 1510
 Siegal AM, 458
 Simchowitz L, 181
 Siminovitch K, 1174
 Skoldstam L, 357
 Skosey JJ, 346
 Skyly G, 249
 Sliwinski AJ, 339
 Sloop PR, 1148
 Smeenk R, 631
 Smith RD, 1385
 Smith RL, 441
 Smith RN, 1194
 Smith SJ, 1156
 Sokoloff L, 318, 1217, 1228
 Solsky M, 1291
 Somers R, 87
 Speerstra F, 223
 Spencer DL, 346
 Spencer-Green G, 601, 612, 954
 Sperling O, 1264
 Spiegel T, 1378
 Spiera H, 120
 Spilberg I, 181
 Stack MT, 568
 Stanescu R, 1078
 Stanescu V, 1078
 Steere AC, 1403
 Stein GH, 1145
 Steinberg AD, 734, 824
 Steinberg RT, 734
 Steinman CR, 1425
 Steitz JA, 761

Sternlicht M, 1194
 Stevens MB, 1031
 Stillman MT, 1365
 Stobo JD, 121, 820
 Stollar BD, 744
 Strand CV, 260
 Strobel PL, 1156
 Sundstrom C, 488
 Suoranta H, 249
 Suzuki H, 1451
 Svejgaard A, 249
 Swaak T, 631
 Swann DA, 974

T

Takada S, 1343
 Takada T, 710
 Takemura S, 1138
 Takeshita S, 710
 Talal N, 260, 838, 1271
 Talmor M, 1510
 Tan EM, 156, 753, 779, 1003, 1271
 Tancredi RG, 473
 Tanimoto K, 715
 Templeton JL, 1145
 Tennenbaum A, 706
 Teppo AM, 662, 1059
 Tesar JT, 1481
 Tesser JRP, 579
 Theofilopoulos AN, 726
 Thoen J, 375
 Thornberry DK, 1396
 Tiilikainen A, 249, 655
 Tiliakos N, 478
 Tolvanen E, 1284
 Tomlinson IW, 239
 Train JS, 1382
 Trentham DE, 266, 532, 911
 Trippi D, 923
 Tron F, 454, 618
 Trotta F, 1388
 Tsoukas CD, 959
 Tsunematsu T, 1343
 Turner RA, 370, 1108

U-V

Upton LG, 353
 Urowitz MB, 1269
 Valesini G, 1025
 Valone FH, 1486
 van Beek WP, 87
 van de Putte LBA, 223
 van der Lelij G, 631
 Vanderplate C, 213
 van Haelst UJGM, 223
 van Nunen SA, 694
 van Soesbergen RM, 87
 Vasey FB, 677
 Vaughan JH, 161, 419, 467, 959
 Vayssairat M, 597
 Vegazo S, 1477
 Vitali C, 1419
 Voipio-Pulkki L-M, 249
 Vooijs GP, 223
 Vorst E, 1510

W

Wakefield D, 1431
 Walker SE, 1291
 Wallace DJ, 232
 Ward JR, 937
 Washburn LR, 937
 Wasner C, 601, 612
 Wasserman SI, 1352
 Watson MA, 1435
 Weatherbee L, 218
 Wegelius O, 662, 1059, 1284
 Weil S, 38, 471
 Weinblatt ME, 579
 Weiner M, 601, 612
 Weiner S, 1378
 Weisman MH, 342
 Weiss MA, 117
 Weissmann G, 174, 1029
 Weizman Z, 706
 Welles WL, 1194

Wheat LJ, 1396
 Whitcher JP, 260
 Whitman HH III, 241
 Wigren A, 488
 Wigzell H, 488
 Wilder RL, 1064
 Wilhelm JA, 1278
 Wilkinson S, 1174
 Williams G, 467
 Williams RC Jr, 685, 810
 Willkens RF, 1254, 1435
 Wilson CH Jr, 478, 1156
 Wilson MR, 1003
 Winchester RJ, 833, 1003, 1271
 Winfield JB, 168, 814
 Winkelstein A, 1167, 1180
 Wirotius JM, 80
 Wofsy D, 838
 Wolfe F, 1390
 Wolfe LD, 1298
 Woods VL Jr, 773
 Worth D, 601, 612
 Worthen N, 107
 Wright KD, 1064

Y-Z

Yanamuro T, 710
 Yatziv S, 706
 Yeh WLS, 346
 Yoon BH, 588
 Yoon SJ, 1174
 Yoshikawa T, 1138
 Young PCM, 568
 Ytterberg SR, 401
 Ziegler G, 601, 612
 Ziff M, 685, 1409
 Zilko PJ, 1130
 Zitnan D, 470
 Zoref-Shani E, 1264
 Zoschke D, 357
 Zurier RB, 804
 Zvaifler NJ, 342, 356, 427, 556, 862

SUBJECT INDEX

Arthritis and Rheumatism, Volume 25, Numbers 1 through 12, 1982

A

- Abscesses, muscle, 107
- Accessory cell function, gold salts and, 288
- Acetylator phenotypes, drug-induced lupus and, 857
- Acetylcholinesterase, aspirin hydrolysis and, 550
- Acetylsalicylic acid. *See* Aspirin
- Achalasia, esophagus in, 1120
- Acne
 - collagen injections for and collagen-induced arthritis, 1024
 - in Reiter's syndrome, 346
- Acquired serum complement abnormalities, 795
- Acropachy, thyroid, complicated by lymphatic obstruction, 588
- Active nephritis, as a cause of death in SLE, 612
- Acute intermittent porphyria, SLE and, 1134
- Acute rheumatic fever, pericarditis in, 1054
- Acute temporomandibular arthritis, bruxism, CPPD and, 353
- Acute vascular injury, immune complex induced, 864
- Addison's disease, DNA binding in, 634
- Adenopathy, hilar, in "pseudosarcoidosis," 1396
- Adenosine diphosphate, in SLE, 968
- Adipose tissue, in ankylosing spondylitis, 218
- Adjuvant arthritis
 - in DA and F₃₄₄ rats, 1194
 - major histocompatibility complex in, 1194
 - Mycobacterium in, 1325
 - prolactin in, 591
 - type II collagen in, 1325
- Adjuvant CP-20961 induced polyarthritis, in Sprague-Dawley rats, 270
- Adjuvant disease, human, mammoplasty and, 694
- Adjuvants
 - B cell hyperactivity and, 741
 - nucleic acids as, 739
- Adrenal corticosteroids, in SLE, 892
- Adult canine articular cartilage, estrogen and glucocorticoid receptors in, 568
- Adult Gaucher's disease (type I). *See* Gaucher's disease, adult
- Adult human articular cartilage, ascorbate stimulation of DNA
 - nuclear labeling of, 323
 - synthesis and, 318, 531
- Adult onset Still's disease, 647. *See also* Late onset Still's disease; Rheumatic fever; Still's disease
- Agarose gel electrophoresis
 - in eosinophilic fasciitis, 1180
 - in progressive systemic sclerosis, 1167
- Ageusia. *See also* Taste
 - in RA, 700, 702
- Aggregated IgG, induction of human rheumatoid factor by, 1108
- Aggregated proteins, 785
- AHPA. *See* Arthritis Health Professions Association
- AKR mice
 - type C retroviruses and, 850
 - viruses and, 852
- Akv genes, viruses and, 850, 852
- Albumin
 - human serum, aspirin hydrolysis and, 550
 - in CSF in SLE, 864
 - in RA, gold therapy and, 544
 - serum, salicylates and, in chronic inflammatory joint disease, 32
- Alcoholism, septic arthritis in, 948
- Aldosterone, plasminogen activator activity and, 438
- Alkaline phosphatase, in chronic liver disease and Still's disease, 580
- Alloantigens, in SLE, 1031
- Allogeneic mixed lymphocyte culture, Ia antigens and, 835
- Allogeneic mixed lymphocyte reaction. *See also* Autologous mixed lymphocyte reaction; Mixed lymphocyte reaction
 - in progressive systemic sclerosis, 390
 - SLE and, 386
- Allopurinol-like actions, diflunisal and, 474
- All-trans retinoic acid, plasminogen activator activity and, 432
- Alopecia, in SLE, 1036
- Alpha interferon, 802
 - antibodies to in SLE and vasculitis, 396
 - in SLE, 401
- Alpha₁-antitrypsin
 - in JRA, 1010
 - phenotypes, and inflammatory eye disease, 1431
 - in RA, 372
- α -globulin, in RA, gold therapy and, 545
- α_2 macroglobulin levels in RA, 1309
- Alphamercaptopropionylglycine. *See* Tiopronin
- Alveolar capillary wall permeability, immune deposits in SLE and, 882
- American Indian populations, survival in SLE in, 608
- American Rheumatism Association, 704
 - Arthritis Advisory Committee, 595
 - committee structure of, 7
 - criteria for RA, 481
 - criteria for SLE, survival in SLE and, 601
 - functional classification of RA and, 486

- American Rheumatism Association (*cont'd*)
 governance, 7
 membership of, 1
 preliminary criteria for systemic lupus erythematosus, 631
 Presidential Address (1981), 1
 purpose of, 7
 relationship with Arthritis Foundation, 5
 1982 revised criteria for classification of SLE, 1271
- American Rheumatism Association Medical Information System (ARAMIS), 482
 data analysis of SLE criteria, 1272
 in scleroderma, 1167
- Amino acids
 in cartilage protease, 981
 gamma carboxyglutamic acid in childhood dermatomyositis, 1094
- Aminotriazole, in synovial tissue, 691
- Amphotropic viruses, 850
- Amputations, articular cartilage atrophy and osteoporosis in, 80
- Amyloid
 in cartilage, 206
 progressive systemic sclerosis, extensor tendon rupture and, 1141
- Amyloid deposits
 in intervertebral disc of senescent mouse, 710
 osteoarthritis and, 204
- Amyloidosis
 dialysis in, 38
 keratoconjunctivitis sicca in, 156
 renal, in adult onset Still's disease, 647
 scleroderma, extensor tendon rupture and, 1141
- Androgens
 autoimmune disease and, 840
 in B/W mice, 840
 canine articular cartilage and, 568
 interleukin-2 and, 840
 murine lupus and, 838
 plasma, in women with SLE, 454
- Androstenedione, in SLE, in women, 454
- Anemia. *See also* Hemocytopenia; Hemolytic anemia; Hypocupremia-related hypochromic anemia; Thrombocytopenia
 immune hemolytic, anti-SS-B antibodies in, 473
 in RA, 486
- Angiitis, granulomatous, of nervous system, 342
- Angioedema, eosinophilic synovial effusions in, 708
- Animal models of immune complex disease, extrarenal lesions in, 880
- Animal studies. *See* Baboon studies; Canine articular cartilage; Canine studies; Goat studies; Mouse studies; Rabbit studies; Rat liver xanthine oxidase; Rat studies
- Ankle
 in hypertrophic osteoarthropathy, 1188, 1190
 in RA, 486
- Ankle (*cont'd*)
 tarsal arthritis with ankylosis in late onset Still's disease, 1254
- Ankylosing chondrocalcinosis, hereditary chondrocalcinosis with vertebral ankylosis and, 1257
- Ankylosing spondylitis
 antibodies to beta 2 microglobulin in, 375
 in children, 1041
 dorsal spine in, 218
 HLA-B27 in African blacks, 716
 IgA nephropathy and, 144
 nephropathy in, 1510
 pregnancy and, 140
 sacroiliac joints in, 221
 spinal block in, 218
 unproven remedies in, 1145
 vertebral ankylosis in hereditary chondrocalcinosis and, 1257
- Ankylosis
 bony, in PSS, 1497
 carpal, in adult onset Still's disease, 647
 tarsal arthritis with late onset Still's disease, 1254
 vertebral, in hereditary chondrocalcinosis, 1257
- Antabuse. *See* Disulfiram
- Anterior uveitis
 alpha₁-antitrypsin and, 1011
 immunogenetic factors in, 1431
- Antiantigen, immune regulation and, 740
- Antibodies
 to alpha interferon in SLE and vasculitis, 396
 anti-DNA, 748, 750, 1271
 anti-dsDNA, 729
 antigial, 775
 anti-idiotypic, 745
 anti-La, 771
 antilymphocyte, 383, 556, 715, 811, 824
 antineuronal, 773, 864
 anti-nRNP, 757
 antinuclear, 159, 383, 421, 460, 556, 694, 753, 961, 1011
 anti-RNP, 349, 460, 761
 anti-Ro, 460, 768, 771, 1250
 anti-Sm, 460, 757
 anti-SS-B, 473
 anti-ssDNA, 729
 anti-T cell, 826
 in autoimmune disease, 765
 to beta interferon in SLE and vasculitis, 396
 to beta 2 microglobulin in ankylosing spondylitis and RA, 375
 brain reactive, 863
 cell suppression and, 826
 circulating, 865
 to collagen, 532
 in scleroderma, 522
 complement and, 797

Antibodies (*cont'd*)

- complement abnormalities and in SLE, 795
 - to cytomegalovirus in Sjögren's syndrome, 260
 - DNA, 695, 747
 - in SLE, 304, 383, 564
 - to DNA, 747
 - in lupus, 1126
 - in proliferative lupus nephritis, 873
 - in 1982 revised criteria for classification of SLE, 1271
 - in SLE, 55, 304, 381
 - DNA-anti-DNA, 747
 - dsDNA, 407, 410
 - to dsDNA, in SLE, 631
 - Epstein-Barr virus, 427
 - in glomeruli, 750
 - histone, in SLE, 407
 - horseradish peroxidase-conjugated, 685
 - IgM, 639, 1451
 - in immune complexes, 783
 - immune regulation and, 740
 - insulin receptor, 458
 - to La, 769
 - lymphocytotoxic, 381, 773, 817, 828
 - monoclonal, 419, 745, 750, 764, 820, 822
 - anti-DNA, 749
 - murine, 749
 - native DNA, 639, 753
 - to native DNA, 1003
 - PGE1 and in murine lupus, 806
 - neurocytotoxic, 773
 - to neuronal cell membranes in SLE, 774
 - nRNP, 758
 - to nRNP, 458, 754, 1003
 - to platelet membrane proteins, 517
 - platelet responses to urate and, 508
 - in primary biliary cirrhosis and Sjögren's syndrome, 1251
 - Pseudomonas aeruginosa*, 1403
 - receptor, 458
 - ribonucleoprotein, 695
 - RNP antigens and, 765
 - to Ro, 768
 - in septic arthritis, 947
 - in SLE, 375, 631, 753, 817, 864
 - Sm, 759
 - to Sm, 754, 1003, 1271
 - Sm antigens and, 765
 - SS-A, 159
 - to SS-A, 754
 - SS-A/Ro, 755
 - SS-B, 159
 - in connective tissue disease, 662
 - to SS-B/La antigen, 1003
 - to ssDNA, in DLE, 639
 - viruses and, 847
- Antibody-dependent cellular cytotoxicity, in RA, 10
- Antibody measurement, in SLE, 631
- Antibody production, by peripheral blood lymphocytes in Sjögren's syndrome, 424
- Antibody responses, in mycoplasma-induced arthritis, 942
- Antibody synthesis, T cells and in SLE, 830
- Anticoagulant, circulating, in SLE, 383
- Anti-concanavalin A supernatant, 814, 816
- Anti-cryoglobulin sera, antineuronal antibodies in, 775
- Antidiuretic hormone, in polyarteritis nodosa, 118
- Anti-DNA. *See also* Anti-dsDNA; Antinative DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
- lack of, in lupus, 1126
 - in rheumatic disease, 999
 - in SLE, 310, 624, 1031
 - oral contraceptives and, 619
- Anti-DNA antibodies, 748
- in CNS SLE, 586
 - detection in SLE, 997
 - DR4 alloantigen and, 836
 - monoclonal, 749
 - PGE1 and in NZB/W mice, 806
 - in SLE, 50, 454, 812, 997
- Anti-DNA binding, in SLE, interferon and, 401
- Anti-DNA IgG, T cells and, 313
- Anti-DNA production, T cells in, 739
- Anti-dsDNA. *See also* Anti-DNA; Antinative DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
- in SLE, 171, 631, 970
- Anti-dsDNA antibodies
- in murine lupus, 729
 - in SLE, 796
- Anti-F(ab')₂ antibodies
- in RA, 1298
 - radioimmunoassay for, 1299
 - in SLE, 1298
- Anti-Fc antibodies. *See* Rheumatoid Factor
- Antigen-antibody avidity, in immune complexes in glomeruli, 785
- Antigen-antibody complexes, 783
- Antigen-specific suppressor cell activity, procainamide and, 238
- Antigenic determinants on RNP particles, 763
- Antigenic specificity
- antibodies to DNA and, 748
 - of monoclonal anti-DNA antibodies, 749
 - SLE and, 168
- Antigens. *See also* Ga; HLA; La; RNP; Sm
- autologous mixed lymphocyte reaction and, 121, 124
 - blastogenic responses after joint surgery and, 278
 - circulating DNA, 753
 - complement and, 797
 - environmental, 124
 - gold salts and, 288

Antigens (*cont'd*)

- gonococcal, 575
 - haptten-modified self, 824
 - Ia, 121, 124
 - in IgA nephropathy associated with spondylarthropathies, 144
 - in immune complexes, 783
 - immune regulation and, 740
 - in membranous lupus nephritis, 873
 - in mixed lymphocyte reactions, 390
 - mycoplasmal, chronic arthritis and, 937
 - neuronal, 776, 865
 - in primary biliary cirrhosis and Sjögren's syndrome, 1250
 - nRNP, 759
 - nuclear, 882
 - nucleic acids as, 739
 - Pseudomonas aeruginosa*, 1403
 - ribonucleoprotein, 765
 - RNA-containing lupus, 761
 - Ro, 770
 - self, 824
 - in Sjögren's syndrome, 263, 421
 - in SLE, 811
 - soluble, immune function of synovial cells and, 388
- Antiglial antibodies, in SLE sera, 775
- Antihistone antibodies, in SLE, 779
- Anti-H2A-H2B activity, in SLE, 779
- Anti-human IgG, antibodies to beta 2 microglobulin and, 375
- Anti-human IgM, antibodies to beta 2 microglobulin and, 375
- Antihypertensive therapy, in scleroderma, 241
- Anti-idiotypic antibodies, in rabbits produced against anti-DNA hybridoma antibodies, 745
- Anti-IgG. *See also* IgG; Immunoglobulin
- DNA binding and, 639
- Anti-IgG plaque-forming cell response, rheumatoid factor and, 1113
- Anti-IgM. *See also* IgM; Immunoglobulin
- DNA binding and, 639
- Antiinflammatory drugs. *See also* Aspirin; Drugs; Nonsteroidal antiinflammatory drugs
- effect on degradation of hyaluronic acid, 1469
- thrombocytopenia and, 359
- Antiinflammatory glucocorticoids, plasminogen activator activity and, 432
- Anti-insulin receptor autoantibodies, in diabetes mellitus and MCTD, 458
- Anti-La, 770, 1034
- Antilymphocyte antibodies
- in monozygotic twins discordant for SLE, 715
- in relatives of SLE children, 556
- in SLE, 383, 810, 824
- Antimalarial drugs, in RA, 427, 699
- Antinative DNA. *See also* Anti-DNA; Anti-dsDNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-

Antinative DNA (*cont'd*)

- DNA complexes; Native DNA; Single-stranded DNA
 - in connective tissue disease, 461
 - in SLE, 1034, 1127
- Anti-nDNA. *See* Anti-native DNA
- Antineuronal activity, in CSF in SLE, 776, 864
- Antineuronal antibodies, in SLE, 773
- Anti-nRNP. *See* Antinuclear ribonucleoprotein
- Antinuclear antibodies, 754
- connective tissue diseases, insulin receptor antibodies and, 461
 - in diabetes mellitus and MCTD, 458
 - fluorescent, in connective tissue diseases, 460
 - immunofluorescence patterns of, 1278
 - immunologic specificities of, 754
 - in JRA, 961
 - alpha₁-antitrypsin phenotypes and, 1011
 - lack of in SLE, 768
 - in post-mammoplasty connective tissue disease, 695
 - in RA, 914
 - reference sera for, 1003
 - in relatives of SLE children, 556
 - in rheumatic diseases, 756
 - RNP antigens bound by, 1278
 - RNP specificities and, 761
 - in scleroderma, diffuse, 1167
 - serum, mononuclear cells and in SLE, 310
 - in Sjögren's-sicca syndrome, 159
 - in Sjögren's syndrome, 421
 - in SLE, 383, 753
 - beta 2 microglobulin and, 375
- Antinuclear antibody reactions, phospholipids and, 745
- Antinuclear ribonucleoprotein (nRNP) antibodies, 757
- in MRL/1 spleen cells, 761
 - nuclear proteins and, 762
 - in SLE, 1034
 - snRNA and, 761
- Antiprostaglandin E, in immunoelectron microscopy of rheumatoid synovium, 686
- Anti-ribonucleoprotein (RNP) antibodies
- in autoimmune disease, 765
 - in cauda equina syndrome, 349
 - in connective tissue diseases, 460
- Anti-RNP. *See* Anti-ribonucleoprotein
- Anti-RNP autoantibodies, in diabetes mellitus and MCTD, 458
- Anti-Ro, 770
- genetics and, 769, 771
 - in primary biliary cirrhosis with Sjögren's syndrome, 1250
 - in SLE, 769
 - sicca complex and, 1031
 - in vasculitis, 768
- Anti-Ro antibodies
- in connective tissue diseases, 460
 - in neonatal lupus, 768

- Anti-Ro antibodies (*cont'd*)
 in primary biliary cirrhosis with Sjögren's syndrome, 1250
 in SLE, 768
- Antisera, SLE and, 811
- Anti-SLE cryoglobulin immunoprecipitated neuronal membrane antigens, 777
- Anti-Sm, in SLE, 1034
- Anti-Sm activity, detected by radioimmunoassay, 764
- Anti-Sm antibodies, 757
 in autoimmune disease, 765
 connective tissue disease and, 460
 in MRL/1 spleen cells, 761
 nuclear proteins and, 762
 snRNA and, 761
- Anti-SS-B antibodies, in immune hemolytic anemia, 473
- Anti-ssDNA. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA antibodies and, 748
 in SLE, 970
- Anti-ssDNA antibodies. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
 in murine lupus, 729
- Anti-T cell antibodies, in SLE, 826
- Antitragus, inflammation of, 268
- Antiviral activity, interferons and in SLE and vasculitis, 396
- Aortic arch syndrome, symptoms mimicking, in SLE, 1501
- Aortic valve, giant cell valvulitis in, 232
- Apatite crystal deposition disease. *See also* Calcium pyrophosphate dihydrate crystal deposition disease; Chondrocalcinosis; Hereditary chondrocalcinosis; Hereditary pyrophosphate arthropathy; Pseudogout
 joint effusions in, 98
- Apatite crystals, 1239
 in hemochromatosis, 1460
- Aphthae
 in Behcet's disease, 714
 in RA, 702
- Ar gene locus, major histocompatibility complex and, in adjuvant arthritis, 1194
- ARA. *See* American Rheumatism Association
- Arachidonic acid, 804
- ARAMIS. *See* American Rheumatism Association Medical Information System
- Arch, aortic syndrome, 1501
- ARFT. *See* Autologous rosette forming T lymphocytes
- Arterial oxygen, in hypertrophic osteoarthropathy, 1186
- Arteries, in childhood dermatomyositis, 126
- Arterioles, endothelial cell swelling in psoriatic arthritis, 681
- Arterioli, in proliferative lupus nephritis, 872
- Arteritis. *See also* Familial Mediterranean fever
 giant cell, 120
 progressive systemic sclerosis and, 717
- Arteritis (*cont'd*)
 granulomatous angiitis of nervous system, 342
 necrotizing, in proliferative lupus nephritis, 872
 responder cells in familial Mediterranean fever, 471
 temporal, 75
- Arthralgia
 gelling, in RA, 485
 seropositive, in RA, 485
 in Sjögren's-sicca syndrome, 159
 in Sjögren's syndrome, 421
- Arthritis. *See also* Monarthritis; Palindromic rheumatism; Polyarthritis
 adjuvant, 1194
 in adult onset Still's disease, 647
 in Behcet's disease, 714
 CAEV, 930
 caprine retrovirus-induced, 930
 caused by metastatic melanoma, 223
 chronic, 1066
 mycoplasma-induced, 937
 in chronic liver disease and Still's disease, 580
 collagen, 532, 911
 collagen-induced
 human, 1024
 type II, 268
 CP-20961-induced, 268
 cranial, 75
 and disulfiram therapy, 1494
 gonococcal, 574, 950
 by Gram stain, 950
 in hypertrophic osteoarthropathy, 1189
 inflammatory, 357
 juvenile. *See* Juvenile rheumatoid arthritis
 "pencil pointing" in radiologic diagnosis of, 333
 peripheral, 375
 psoriatic, 335, 337, 356, 677, 948, 950
 psychologic disturbance and, 213
 pyrophosphate arthropathy and, 66
 reactive, 249, 574, 1041, 1267
 retrovirus-induced, 930
 rheumatoid. *See* Rheumatoid arthritis
 rheumatoid factor and in MRL/1 mice, 723
 salmonella, 249
 in scleroderma, 525
 septic, 467, 947
 seronegative, in B27+ monozygotic twins, 1490
 seronegative enthesopathy and arthropathy in children and, 1041
 in SLE, 410
 sternoclavicular, septic, 467
 stress-related, 478
 tarsal, 1254
 temporomandibular, 353
 traumatic, 950
 urate crystals in, 209

Arthritis (*cont'd*)

- yersinia, 249, 655
- Arthritis-dermatitis syndrome, gonococcal, 574
- Arthritis Foundation, 702
 - AHPA Fellowship Awards 1977-1981 and Research Grant, 705
 - bylaws of, 7
 - goals and strategies, 1980-1985, 7
 - governance mechanisms of, 6
 - organization of, 5
 - paramedical section, 704
 - potential lay-professional interaction in, 8
 - purposes of, 7
 - relationship with American Rheumatism Association, 5
 - rheumatology manpower and, 1
- Arthritis Foundation-Centers for Disease Control Committee on Antinuclear Antibody Serology, 1003
- Arthritis Health Professions Association, 6, 704
- Arthritis Impact Measurement Scales, 1048
- Arthritis Regional Medical Programs, 704
- Arthritis treatment, improving patient cooperation in, 447
- Arthrocentesis, in septic arthritis, 947
- Arthropathy. *See also* Hereditary pyrophosphate arthropathy of Behcet's disease, 235, 1509
 - degenerative, of hemochromatosis, 1460
 - erosive, in CREST syndrome, 1026
 - of progressive systemic sclerosis, 1026
 - seronegative enthesopathy and in children, 1041
- Articular cartilage. *See* Cartilage, articular
- Articular chondrocytes
 - ascorbate stimulation of DNA in, 318, 531
 - rabbit, effect of purified growth factors on, 1217, 1228
- Articular disease, beta 2 microglobulin and in RA, 375
- Ascorbate
 - DNA synthesis by rabbit articular chondrocytes and, 1217
 - human cartilage and, 321
 - in sulfated proteoglycan synthesis on rabbit articular chondrocytes and, 1228
- Ascorbate stimulation of DNA synthesis in articular chondrocytes, 318, 531
- Asian populations, mortality from SLE in, 414
- Aspirin. *See also* Antiinflammatory drugs; Buffered aspirin; Drugs; Nonsteroidal antiinflammatory drugs; Salicylates
 - benoxaprofen and, 595
 - in childhood dermatomyositis and scleroderma, 1098
 - in chronic inflammatory joint disease, 32
 - in degeneration of canine cartilage, 1333
 - hematocrit and, 552
 - liver toxicity and, 1124
 - in RA, 370, 464
- Aspirin acetylation, human serum albumin and, 35
- Aspirin hydrolysis, erythrocytes and, 550
- Assay

Assay (*cont'd*)

- conjugate-binding cytotoxicity for natural killer cell activity, 1440
- counterimmunoelectrophoresis for dsDNA, 1425
- Atlantoaxial involvement in RA, 1316, 1378
- Atypical SLE flares, infection in, 583
- Auranofin, 595. *See also* Chrysotherapy; Gold; Gold salts; Gold sodium thiomalate; Gold therapy; Injectable gold preparations; Oral gold
- Auricular chondritis, type II collagen-induced, 266
- Aurothiomalate. *See also* Chrysotherapy; Gold salts; Gold therapy; Gold sodium thiomalate; Injectable gold preparations; Oral gold
 - auranofin and, 596
- Autoantibodies, 763
 - B cells and, 828
 - beta 2 microglobulin, ankylosing spondylitis and, 375
 - in cauda equina syndrome, 349
 - circulating, Sjögren's syndrome and, 419
 - collagen in scleroderma and, 522
 - in diabetes mellitus and MCTD, 458
 - erythrocyte, in NZB/*xid/xid* and DBA/2/*xid/xid* mice, 737
 - glomerular thrombosis and, 117
 - hybridoma, 744
 - in lupus, 754
 - in membranous lupus nephritis, 873
 - monoclonal, 744
 - in progressive systemic sclerosis, 1174
 - in Sjögren's syndrome, 419
 - in SLE, 773, 817, 819, 858, 1031
 - T cell defects and, 828
- Autoimmune abnormalities, in SLE-like disease, 741
- Autoimmune connective tissue disease, post-mammoplasty, 694
- Autoimmune disease. *See also* Rheumatic disease
 - androgens and interleukin-2 in B/W mice, 840
 - anti-RNP antibody in, 765
 - anti-Sm antibody in, 765
 - autologous mixed lymphocyte reaction in, 121, 390
 - in BXSB mice, 731
 - experimental, in collagen arthritis, 532
 - immunologic regulation and, 841
 - interferon and, 401
 - PEG assay in, 631
 - retroviruses and, 852
 - sex hormones and, 838
 - transplantability of, 731
- Autoimmune gastritis, DNA binding in, 634
- Autoimmune liver disease
 - DNA binding in, 634
 - PEG assay in, 631
- Autoimmune markers, in NZB/*xid* mice, 737
- Autoimmune response, in SLE mice, 724, 725
- Autoimmune syndrome, of SLE, 744

Autoimmune thyroid disease, DNA binding in, 634
 Autoimmune traits of NZB mice, 738
 Autoimmunity
 genetics in, 741
 immunizing stimulus in, 745
 in NZB mice, 727
 pathogenesis of, 734
 Autologous mixed lymphocyte culture, Ia antigens and, 835
 Autologous mixed lymphocyte reaction, 121. *See also* Allogeneic mixed lymphocyte reaction; Mixed lymphocyte reaction
 autoimmune disease and, 390
 B cells and, 820
 murine, 124
 in progressive systemic sclerosis, 390
 in SLE, 381, 820
 T cells and, 820, 829
 Autologous non-T cells
 proliferation responses in, 825
 in SLE, 824
 Autologous rosette forming T lymphocytes (ARFT), 826
 Auto-MLR. *See also* Nonmodified autologous non-T cells
 ARFT and, 826
 Azathioprine
 hypotension and oliguria caused by, 1388
 in RA, 97, 1269
 in SLE, 893
 Azathioprine-induced pancreatitis, 1149

B

B cell activators, in NZB/*xid/xid* mice and DBA/2/*xid/xid* mice, 737
 B cell alloantigens, 830
 B cell hyperactivity
 in murine lupus, 721, 724, 729
 in NZB mice, 727
 in SLE-like disease, 741
 viruses and in SLE, 847
 B cells, 830
 in autoimmune mice, 727
 autologous mixed lymphocyte reaction and, 381, 820
 bearing IgD, in SLE, 1451
 blastogenic responses to cyanogen bromide peptides and, 285
 complement and, 797
 immune regulation and, 740
 in JRA, 959
 PGE1 and in NZB/W mice, 806
 in post-mammoplasty connective tissue disease, 695
 reduced susceptibility to IgM antibodies in SLE, 1451
 in SLE, 168, 816, 820
 in mice, 722, 726, 734
 nucleic acids and, 304

B plus null cells in SLE, 381
 Babinski sign, in CNS SLE, 586
 Baboon studies, link proteins in cartilage, 1078
 Back pain
 chronic, 249
 prevalence in rheumatic disease, 718
 pyrophosphate arthropathy and, 66
 Bacteria
 cartilage degradation and, 441
 chondrocytes and, 441
 in sternoclavicular arthritis, 467
 Bacterial endocarditis, vertebral osteomyelitis and, 600
 Bacterial inoculation, effect of on chondrocytes, 444
 Balanitis, in Reiter's disease, 251
 Basement membrane (type IV) collagen, antibodies to in scleroderma, 522
 Behçet's syndrome
 arthropathy in, 235
 colchicine for, 1509
 levamisole in, 714
 myositis in, 1025
 pseudothrombophlebitis in, 477
 synovial pleocytosis in, 235
 T cell subsets in, 1343
 Benoxaprofen, 595
 selective immobilization of human mononuclear phagocytes by, 1486
 Beta-D-xylopyranoside
 GAG synthesis in cartilage and, 1087
 proteoglycans and, 1089
 β -glucosidase, interphalangeal joints in Gaucher's disease, type I and, 706
 Beta interferon, antibodies to in SLE and vasculitis, 396
 β_2 -microglobulin
 antibodies to in RA, 375
 pepsinogen I in Sjögren's syndrome and, 1059
 Biliary cirrhosis, interferon in, 396
 Bilirubin, in chronic liver disease and Still's disease, 580
 Black populations
 deaths from SLE in, 414
 survival in SLE in, 608
 Blastogenic responses, homologous type III collagen and, 274
 Bleeding, diclofenac and, 599
 Blood brain barrier, in SLE, 863, 865
 Blood CSF interface, blood brain barrier and, 863
 Blood flow, in hypertrophic osteoarthropathy, 1186
 Blood groups, in calculation of relative risk, 835
 Blood mononuclear cells
 abnormal nucleic acids in SLE, 304
 blastogenic responses of
 to cartilage proteoglycan, 284
 to collagen, 279, 281, 283
 Blood pressure, in scleroderma, 241

Blood typing, NSAID and in RA, 370

Blood vessels

- in adult onset Still's disease, 651
- in connective tissue diseases, 890
- deossification and, 333

Bone, 277

- carpal, in adult onset Still's disease, 647
- crises, in adult Gaucher's disease, 1369
- in "fish vertebrae," 1073
- metastatic melanoma in, 223
- pannus invasion of, 277
- in RA, 913
- spinal cord block in ankylosing spondylitis and, 218
- subchondral, cartilage loss in, 974
- vascular influences on deossification of, 333

Bone marrow

- and auranofin, suppression of, 596
- in murine lupus, 723
- T cell leukemia and, 87
- transfer in murine lupus, 731

Bone resorption, vascular influences on, 333

Bony ankylosis of hips in PSS, 1497

Book Reviews

Children with Chronic Arthritis: A Primer for Patients and Parents. Gordon F. Williams, 1149

Diagnosis of Bone and Joint Disorders. Donald Resnick and Gen Niwayama, 480

Epidemiology of Osteoarthritis: Symposium. Paris, June 1980. Edited by J.G. Peyron, 1150

Joints and Synovial Fluid, Volume II. Edited by Leon Sokoloff, 1270

Manual of Rheumatology and Outpatient Disorders: Diagnosis and Therapy. Edited by John F. Beary III, Charles L. Christian, and Thomas P. Sculco, 1030

Patient Compliance. Edited by J. J. De Blécourt, 1390

Progress in Clinical Immunology, Volume 4. Edited by Robert S. Schwartz, 360

Recurrent Polyserositis (Familial Mediterranean Fever, Periodic Disease). M. Eliakim, M. Levy, M. Ehrenfeld, 1150

Surgery in Rheumatoid Arthritis: An Up-to-Date Account. I. F. Goldie, 719

Surgical Treatment of Rheumatoid Arthritis. Norbet Gschwend, 719

Tutorials in Clinical Rheumatology. Douglas N. Golding, 719

Vasculitides. Thomas R. Cupps and Anthony S. Fauci, 479

Bovine articular cartilage, abnormal softening in, collagen and, 1209

Bovine conglutinin assay, for immune complexes in RA, 1156

Bovine gamma globulin, in murine SLE, 736

Bovine serum albumin

- in binding of IgG in human glomerulus, 297
- DNA synthesis by rabbit articular chondrocytes and, 1219

Bowler's finger syndrome, 478

Brain, in SLE, 862, 865

Brain reactive antibodies, in SLE, 863

Brain reactive lymphocytotoxic antibodies, 773

Bruxism, in acute temporomandibular arthritis, 353

Buffered aspirin, in RA, 464. *See also* Antiinflammatory drugs; Aspirin; Drugs; Nonsteroidal antiinflammatory drugs; Salicylates

Bursitis

- hemorrhagic, in adult Gaucher's disease, 1369
- olecranon, CPPD and, 989

B/W mice. *See* NZB/NZW F₁ mice

BXSB mice, 721

autoimmune disease in, 731

DNA antibodies and, 749

interleukin-2 and, 727, 840

murine monoclonal antibody in, 750

SLE-like disease in, 729, 738

BSXB/Mp mice, SLE in, 734

C

C1q. *See* Complement C1q

C1qBA. *See* Complement C1q fluid phase binding assay

C1qSP. *See* C1q solid phase assay

C2. *See* Complement C2

C3. *See* Complement C3

C3H/BI mice, viruses in, 850

C4. *See* Complement C4

C57BL/6 mice, interleukin-2 and, 838

C57BL/6-lpr mice, interleukin-2 and, 839

C57BL/6-+/+ mice, interleukin-2 and, 839

C57BR mice, viruses and, 850

CAEV. *See* Caprine arthritis-encephalitis virus

Calcification

in bursitis, 989

experimental hydroxyapatite, 1239

experimental intraarticular, 1240

soft tissue, in childhood dermatomyositis, 1094

subcutaneous, gamma carboxyglutamic acid, in childhood dermatomyositis, 1094

Calcinosis

in childhood dermatomyositis, 1094

in scleroderma esophageal disease, 1118

Calciophylaxis, intraarticular, with cartilage and synovial calcification, 1239

Calcium, in RA, 465

Calcium deposits, 1239

Calcium phosphate metabolism, pyrophosphate arthropathy and, 66

- Calcium pyrophosphate crystals, joint effusions and, 99
- Calcium pyrophosphate dihydrate crystal (CPPD) deposition disease. *See also* Apatite crystal deposition disease; Chondrocalcinosis; Hereditary chondrocalcinosis; Hereditary pyrophosphate arthropathy; Pseudogout
- olecranon bursitis and, 989
- Calcium pyrophosphate dihydrate crystals (CPPD)
- in acute temporomandibular arthritis, 353
 - amyloid and in osteoarthritis, 204
 - in cartilage, 206
 - in hemochromatosis, 1460
 - nitroblue tetrazoleum reduction and, 183
- Cancer
- arthritis in, caused by metastatic melanoma, 223
 - in connective tissue disease, 1130
- Canine articular cartilage, estrogen and glucocorticoid
- effect of aspirin on, 1333
 - receptors in, 568
- Canine studies, GAG synthesis in articular cartilage by xyloside, 1084
- Capillaries
- in childhood dermatomyositis, 126
 - in esophagus in systemic sclerosis, 1119
- Capillary basement membrane changes, in esophagus in scleroderma, 1117
- Caprine arthritis-encephalitis virus, in goat arthritis, 930
- Captopril, in hypertension in scleroderma, 241
- Cardiac involvement
- in scleroderma, 525
 - in scleroderma esophageal disease, 1118
 - in SLE, 564
- Cardiopulmonary hemodynamics, in hypertrophic osteoarthropathy, 1186
- Carpal ankylosis, in adult onset Still's disease, 647
- Carpal joints, in late onset Still's disease, 1254
- Carpal tunnel syndrome, and disulfiram therapy, 1494
- Cartilage, 125
- amyloid
 - and CPPD in, 206
 - in osteoarthritis, 204
 - articular, 277, 318, 531
 - abnormal softening in, 1209
 - amino acids in, 981
 - amyloid in osteoarthritis, 204
 - canine, estrogen and glucocorticoid receptors in, 568
 - collagen and, 1209
 - experimental hydroxyapatite, calcification of, 1239
 - in familial pyrophosphate arthropathy, 69
 - in hemochromatosis, 1460
 - human, neutral metalloprotease in, 981
 - in lower limb amputees, 80
 - molecular weight of, 981
 - noncollagenous, 1078
 - protein in, 983
- Cartilage (*cont'd*)
- scarification of, 974
 - wear in vitro, 974
 - xyloside in GAG synthesis in, 1084
 - ascorbate stimulation of DNA synthesis and, 318, 531
 - chondrocyte synthesis and, 668
 - ear, collagen-induced inflammation in, 266
 - effect of *Escherichia coli* on, 443
 - effect of *Staphylococcus aureus* on, 443
 - human
 - effect of ascorbate and collagenase on, 322
 - nuclear labeling of, 323
 - in mycoplasma-induced arthritis, 940
 - noncollagenous protein in, 1078
 - osteoarthritic, proteoglycans in, 125
 - rabbit, ascorbate stimulation of DNA in, 320
 - Cartilage atrophy, in lower limb amputees, 80
 - Cartilage calcification, intraarticular calciphylaxis with, 1239
 - Cartilage degeneration, immunity to cartilage proteoglycans and, 274
 - Cartilage degradation by *Escherichia coli* and *Staphylococcus aureus*, 441
 - Cartilage glycosaminoglycan, effect of bacteria on, 441
 - Cartilage protease, 981
 - Cartilage proteoglycans
 - blastogenic responses to, 283
 - immunity to in rabbits after meniscectomy, 274
 - Cartilage thickness, in lower limb amputees, 80
 - Cartilaginous (Schmorl's) nodes, fish vertebrae and, 1073
 - Caucasian populations
 - deaths from SLE in, 414
 - survival in SLE in, 608
 - Cauda equina syndrome, with high titer anti-RNP antibodies, 349
 - CBA/N mice, *xid* gene in, 734
 - Cell growth, purified growth factors and, 1228
 - Cell mediated immunity, in SLE, 810
 - Cell mediated mechanisms, of tissue injury in SLE, 810
 - Cell membrane, in esophagus in systemic sclerosis, 1120
 - Cell proliferation, Ia antigens and, 835
 - Cell surface antigens, monoclonal antibodies and in Sjögren's syndrome, 419
 - Cell surface charges, PGE and, 807
 - Cell surface protein, in platelet stimulation by MSU crystals, 508
 - Cell vacuoles, synovial membrane apatite deposits in, 1239
 - Cell viability, effect of bacteria on, 441
 - Cells, mononuclear, natural killer cell activity of, 1440
 - Cellular factors, in SLE, 734
 - Cellular immune functions, in SLE, 810
 - Cellular immunity
 - to collagen after total lymphoid irradiation, 532
 - to homologous type III collagen in rabbits after meniscectomy, 274

- Cellular infiltration, 878
- Cellular mechanisms, in SLE, 810
- Cellular transfer of murine lupus, 726
- Centers for Disease Control, Arthritis Foundation and, Committee on Antinuclear Antibody Serology, 1003
- Central nervous system
- cauda equina syndrome and, 349
 - granulomatous angiitis of, 342
 - in scleroderma, 243
 - in SLE, 55, 410, 463, 564, 773, 862, 884, 891, 970, 1127
 - survival and, 606, 609
- Central nervous system disease
- lymphocytotoxic antibodies in, 773
 - in SLE, 776
 - survival in and, 612
- Central nervous system infection, central nervous system SLE and, 583
- Central nervous system pleocytosis, in SLE, 583
- Central nervous system SLE, 583. *See also* Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Iatrogenic SLE; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- Cerebritis, in SLE, 1035
- Cerebrospinal fluid
- antineuronal activity in SLE, 776
 - antineuronal antibodies, 774
 - complement in, 797
 - glucose in, 583
 - in SLE, 863
- Cerebrovascular accident, as cause of death in SLE, 613
- Ceruloplasmin levels in RA, 1309
- Cervical ankylosis, in hereditary chondrocalcinosis, 1257
- Cervical spine
- in hereditary chondrocalcinosis with vertebral ankylosis, 1261
 - osteomyelitis of, 346
 - in psoriatic spondylitis, 102
 - subluxation in, 104
- Cervical subluxation, subaxial, 101
- CH50 (total hemolytic complement). *See* Complement CH50
- Charcot-Leyden crystals, confusion with corticosteroid crystals, 1148
- Chelators, metal, and hyaluronic acid, 1469
- Chemokinetic migration, of polymorphonuclear leukocytes, *Yersinia* arthritis and, 655
- Childhood dermatomyositis, 126
- calcinosis in, 1094
 - gamma carboxyglutamic acid in, 1094
 - naifold capillary abnormalities in, 954
- Childhood lupus erythematosus. *See also* Central nervous system SLE; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Iatrogenic SLE; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- Childhood polydermatomyositis. *See also* Dermatomyositis; Myositis; Polymyositis
- histopathology in, 126
- Children with Chronic Arthritis* (book review), 1149
- Chinese-American populations, mortality from SLE in, 414
- Chlorambucil
- in RA, 699
 - in SLE, 383
- Chloroquine, and degradation of hyaluronic acid, 1469, 1473, 1475
- Choline magnesium trisalicylate, in RA, 464
- Chondritis, auricular, 266
- Chondrocalcinosis. *See also* Calcium pyrophosphate dihydrate crystal (CPPD) deposition disease; Hereditary chondrocalcinosis; Hereditary pyrophosphate arthropathy; Pseudogout
- familial pyrophosphate arthropathy and, 68
 - hereditary
 - pedigree of, 1258
 - vertebral ankylosis in, 1257
 - hydroxyapatite, 1244
 - knee effusions in, 356
 - in olecranon bursitis, 989
- Chondrocyte cloning, in cartilage after meniscectomy, 277
- Chondrocyte synthesis, lymphokine modulation of, 668
- Chondrocytes
- articular, 318, 531
 - effect of bacterial inoculation on, 444
 - Escherichia coli* and, 441
 - platelet-derived growth factor and, 1230
 - rabbit articular, effect of purified growth factors on, 1217, 1228
 - Staphylococcus aureus* and, 441
- Choroid plexus, in SLE, 883
- Choroidal function, in SLE, 862
- Chromatin, histones and, 781
- Chronic arthritis. *See also* Arthritis; Rheumatoid arthritis
- mycoplasma-induced, 937
 - in rats, 1066
- Chronic arthritis-susceptible rat studies, 1064
- Chronic back pain, in Reiter's disease, 249
- Chronic compensated hemolytic syndrome, as cause of juvenile metabolic gout, 1264
- Chronic dermatomyositis. *See also* Dermatomyositis; Myositis; Polydermatomyositis; Polymyositis
- childhood, 132, 137
 - naifold capillaries in, 954
- Chronic disease, treatment regimens in, 447
- Chronic granulomatous disease, respiratory burst and, 181

- Chronic inflammation. *See also* Inflammation
in mycoplasma-induced arthritis, 937
in streptococcal cell wall-induced polyarthritis in rats, 1064
- Chronic inflammatory connective tissue disease. *See also* Connective tissue disease; Mixed connective tissue disease; Overlap syndrome; Undifferentiated connective tissue disease
SS-B antibodies in, 662
- Chronic inflammatory joint disease. *See also* Joints salicylate concentrations in, 32
- Chronic liver disease. *See also* Hepatic; Liver
cryoprecipitates in, 1138
hydroxylation in, 845
Still's disease and, 579
- Chronic mycoplasma-induced arthritis, 937. *See also* Arthritis
- Chronic necro-inflammatory liver disease. *See also* Hepatic; Liver
Still's disease and, 579
- Chronic pain. *See also* Backache; Pain
pyrophosphate arthropathy and, 66
- Chronic polyarthritis. *See also* Arthritis; Rheumatoid arthritis
in rats, 1064
T cell leukemia and, 87
- Chronic renal failure. *See also* Renal
dialysis in, 38
in SLE, 56, 1127
- Chronic serum sickness
glomerulonephritis, immune complexes and, 785
in rabbits, 880
- Chronic urticaria, eosinophilic synovial effusion in, 708
- Chrysotherapy. *See also* Auranofin; Aurothiomalate; Gold salts; Gold sodium thiomalate; Gold therapy; Injectable gold preparations; Oral gold
in RA, 540, 914
- Chymotrypsin, platelet proteins and, 516
- Chymotrypsin digestion, ³H-serotonin secretion and, 516
- Circadian variations, in serum myoglobin levels, 1419
- Circulating antibodies, neuronal antigens and in SLE, 865
- Circulating anticoagulant, in SLE, 383
- Circulating antiRNP, in diabetes mellitus and MCTD, 458
- Circulating autoantibodies, Sjögren's syndrome and, 419
- Circulating DNA antigen, 753
- Circulating gonococcal organisms, in polyarthritis, 574
- Circulating immune complexes. *See also* Complement C1q binding assay; Cytotoxic immune complexes; Immune complexes; Serum immune complexes
in adult onset Still's disease, 647
antibodies and, 784
antigens and, 784
deposition of in glomeruli, 785
disease activity and, 1151
- Circulating immune complexes (*cont'd*)
in eosinophilic fasciitis, 1180
fluoroimmunoassay for, 799
in glomeruli, 783
membranous lupus nephritis and, 873
palindromic rheumatism and, 361
pathophysiology of, 783
in primary biliary cirrhosis with Sjögren's syndrome, 1250
in relatives of SLE children, 556
in SLE, 407, 410, 753, 828, 873, 894
Fc receptor function and, 48
- Circulating mononuclear cells, serum antinuclear antibodies, in SLE, 310
- Circulation, interferon in SLE and vasculitis, 396
- "Circulus articuli vasculosis," 334
- Cirrhosis, biliary, interferon in, 396
- Clinical remission of RA, T cell subsets in, 1507
- Clubbing, in hypertrophic osteoarthropathy, 1189
- CNS. *See* Central nervous system
- Cognitive dysfunction, from naproxen and ibuprofen, 1013
- Colchicine
and arthropathy of Behçet's disease, 1509
in familial Mediterranean fever, 227, 471
and pseudogout, 1509
in recurrent polyserositis, 227
in synovial pleocytosis in Behçet's disease, 235
- Cold activation of complement, in chronic liver disease, 1138
- Collagen
abnormal softening in articular cartilage and, 1209
antibodies to, 532
bacteria in, cartilage degradation and, 441
basement membrane. *See* Collagen, type IV
in CAEV arthritis in goats, 930
chondrocyte synthesis and, 668
in esophagus in systemic sclerosis, 1119
interstitial. *See* Collagen, type I; Collagen, type II
platelet responses to, 508
proteins in cartilage and, 1078
in scleroderma, 522
in SLE, 966
type I, 275
antibodies to in scleroderma, 522
type II, 266, 274, 1325
type III, after meniscectomy in rabbits, 274
homologous, after meniscectomy in rabbits, 274
type IV, antibodies to in scleroderma, 522
- Collagen arthritis
connective tissue disease and, 914
immunosuppressive drugs in, 532
as model for RA, 911
polychondritis in, 914
total lymphoid irradiation in, 532
- Collagen fibers
abnormal softening in articular cartilage and, 1209

Collagen fibers (*cont'd*)

- synovial membrane apatite deposits in, 1239
- Collagen-induced arthritis, human, 1024
- Collagen-induced auricular chondritis, 266
- Collagen-induced platelet aggregation, in SLE, 969
- Collagen peptides, type III, immunity to after meniscectomy in rabbits, 274

Collagen synthesis

- chondrocytes and, 673
- scleroderma and, 189

Collagenase

- in ascorbate stimulation of DNA, 318
- human cartilage and, 321

Colon, in SLE, 883

Complement. *See also* Hereditary complement deficiencies

C1

- activation, in progressive systemic sclerosis, 1174

C1q

- agglutination-inhibition, in eosinophilic fasciitis, 1180
- binding
 - IgG rheumatoid factor and, 1101
 - in JRA, 961
 - in progressive systemic sclerosis, 1167, 1174
 - pulmonary involvement and in scleroderma, 1167
- binding assay. *See also* Circulating immune complexes; Cytotoxic immune complexes; Immune complexes; Serum immune complexes
 - in gonococcal arthritis-dermatitis syndrome, 574
 - for immune complexes in RA, 1156
 - in post-mammoplasty connective tissue disease, 695
 - fluid phase binding assay (C1qBA), 788
 - membrane attack complex and, 876
 - in SLE, 624, 859
 - solid phase assay (C1qSP), 788

C2

- deficiency, in rheumatic diseases, 794
- inhibition of by gold sodium thiomalate, 288

C3, 793. *See also* Hypocomplementemia

- levels in RA synovial fluid, 1311
- in type II collagen-induced arthritis, 270

C3b, rheumatoid factor and, 297

C3d, in childhood dermatomyositis, 126

C4

- activation in relatives of SLE children, 556
- in arthritis-dermatitis syndrome, 575
- in connective tissue disease, 460
 - post-mammoplasty, 695
- IgG rheumatoid factors and, 1101
- radioimmunoassay for, 161
- in relatives of SLE children, 556
- in SLE, 624, 795
 - levamisole and, 471
 - serum, in women, 454

CH50 (total hemolytic complement)

Complement (*cont'd*)

- in connective tissue diseases, 460
- in relatives of SLE children, 556
- in SLE, 171, 383, 788, 796, 970
- in CNS SLE, 586
- cold activation of, 1138
- in collagen arthritis, 913
- in connective tissue diseases, 460
- in cranial arthritis, 75
- in DLE, 859
- DNA-anti-DNA complexes and, 791
- genetics and, 793
- in gonococcal arthritis-dermatitis syndrome, 574
- IgM rheumatoid factor and, 297
- in knee synovium, 913
- lupus erythematosus and, 793
- membrane attack complex of, 876
- in mycoplasma-induced arthritis, 940
- in RA, 913, 1158
- in rheumatic pericarditis, 1054
- rheumatoid factor induction by aggregated IgG and, 1112
- serum, interferon and in SLE, 401
- in SLE, 624, 788, 859
- SLE nephritis and, 877
- tubulointerstitial deposits of in lupus nephritis, 872

Complement abnormalities, antibodies and in SLE, 795

Complement activation

- human, by IgG rheumatoid factors, 1101
- IgM rheumatoid factor and, 297
- in Pima Indians, 165
- in progressive systemic sclerosis, 1174
- in relatives of SLE children, 556
- by rheumatoid factors, 161
- superoxide anion generation and, 174

Complement metabolism, 797

Complement protein, in SLE, 624

Compliance, 447

Computed tomography

- abuse of, 1147
- in central nervous system SLE, 583, 586

Concanavalin A

- in autoimmune mice, 727
- autologous mixed lymphocyte reaction and, 121
- blastogenic responses to cyanogen bromide peptides and, 284
- indomethacin and, 357

Concanavalin A-induced suppressor cell activity, after indomethacin, 357

Concanavalin A-stimulated human lymphocytes, in SLE, 168

Concanavalin A supernatant (CONS), 735

Congenital heart disease. *See also* Cardiac; Heart cyanotic, hypertrophic osteoarthropathy in, 1186

- Conglutinin binding assay, in progressive systemic sclerosis, 1174
- Conjugate-binding cytotoxic assay, 1440
- Conjunctivitis, in Yersinia arthritis, 253
- Connective tissue disease, 889. *See also* Mixed connective tissue disease; Overlap syndrome; Undifferentiated connective tissue disease
- autoantibodies and, 761
 - autoimmune, post-mammoplasty, 694
 - cancer in, 1130
 - collagen arthritis and, 914
 - complement in, 460
 - genetics and, 771
 - insulin resistance in, 458
 - interferon in, 396
 - keratoconjunctivitis sicca in, 156
 - laboratory studies of, 460
 - naifold capillary microscopy in, 597
 - post-mammoplasty, 694
 - prevalence of in private practice of rheumatology, 718
 - RA and, 914
 - rheumatoid factor in, 460
 - Ro antibodies in, 767
 - serum pepsinogen I in, 1059
 - SS-B antibodies in, 662
- Connective tissue disorders
- Paganini's hand, 1385
 - subcutaneous calcifications and gamma carboxyglutamic acid in, 1094
- Contracture, Dupuytren's, tiopronin for, 1505
- Cooperating Clinics for Systematic Studies of Rheumatic Diseases, 596
- Cord compression, in psoriatic spondylitis, 101
- Cortexelone, plasminogen activator activity and, 438
- Corticosteroid crystals, confusion with Charcot-Leyden crystals, 1148
- Corticosteroids. *See also* Steroids
- antiinflammatory, plasminogen activator activity and, 432, 438
 - in collagen arthritis, 913
 - Epstein-Barr virus in RA and, 427
 - in familial Mediterranean fever, 43
 - fish vertebrae and, 1073
 - in hemorrhagic pancreatitis in SLE, 1006
 - in polymyalgia rheumatica, 120
 - in RA, 465
 - in SLE, 411, 891
- Corticosterone, plasminogen activator activity and, 438
- Cortisol, in SLE in women, 454
- Counterimmunoelectrophoresis assay for dsDNA, 1425
- Coxsackie B5 virus, myositis in Behcet's disease and, 1025
- CP-20961-induced arthritis, in Sprague-Dawley rats, 268
- CPPD. *See* Calcium pyrophosphate dihydrate crystals
- Cranial arthritis, immunohistochemical findings in, 75
- Creatinine, serum, survival rate in SLE and, 601
- Creatinine clearance, diflunisal and, 475
- Crescents, in proliferative lupus nephritis, 871
- CREST syndrome
- erosive arthropathy in, 1026
 - metatarsophalangeal joint in, 1026
 - in progressive systemic sclerosis, 61, 1167
 - wrist erosions in, 1026
- Criteria, 1982 revised for classification of SLE, 1271
- Cryoglobulins, 776
- complement and, 796
 - in post-mammoplasty connective tissue disease, 695
- Cryoprecipitates, in chronic liver disease, 1138
- Cryoproteins, SLE, 776
- Crystal deposition disease, in SLE, 713
- Crystal phagocytosis, respiratory burst and, 181
- Crystals, apatite, in hemochromatosis, 1460
- CSF. *See* Cerebrospinal fluid
- Cutaneous abnormalities, in childhood dermatomyositis, 954
- Cutaneous involvement. *See also* Dermis; Skin
- in RA, 702
 - in SLE, 55, 410, 1127
- Cutaneous ulcers
- in Behcet's disease, 714
 - in scleroderma, 244
- Cutaneous vasculitis, interferon in, 396
- Cyanogen bromide cleavage, homologous type 3 collagen and, 274
- Cyanogen bromide peptides, T cells and, 284
- Cyanotic congenital heart disease. *See also* Cardiac; Heart
- hypertrophic osteoarthropathy in, 1186
- Cyclophosphamide
- in collagen arthritis, 532
 - in SLE, 893
- Cysts
- in adult onset Still's disease, 650
 - synovial, in RA, 1382
- Cytochalasin B, MSU-induced enzyme release and, 181
- Cytochrome C reduction, respiratory burst and, 181
- Cytomegalovirus, in Sjögren's syndrome, 260
- Cytosols, steroid receptors in adult canine articular cartilage and, 568
- Cytotoxic activity, in scleroderma, 1391
- Cytotoxic agents
- in RA, 427
 - in SLE, 893
- Cytotoxic immune complexes. *See also* Circulating immune complexes; Complement C1q binding assay; Immune complexes; Serum immune complexes
- complement and, 797
- Cytotoxic responses, of T cells, 826
- Cytotoxicity
- ascorbate stimulation of DNA and, 318, 531
 - lymphocytotoxic activity and, 774
 - monocyte, in RA, 10
 - in monozygotic twins discordant for SLE, 715

Cytotoxicity (*cont'd*)

- in SLE, 562
- native DNA antibodies to T cells and, 312
- of T cells, 825

D

- DA rats, adjuvant arthritis in, 1194
- DBA/2 mice, SLE in, 734
- DBA/2/*xid/xid* mice
 - B cell activators and autoantibodies in, 737
 - poly rI-rC injection in, 735
- Degenerative joint disease. *See also* Osteoarthritis
 - antiDNA in, 999
 - lactic acid in, 950
 - noncollagenous proteins in cartilage of, 1078
 - NSAID and cognitive dysfunction in elderly in, 1014
 - prevalence of in rheumatology practice, 718
 - succinic acid in, 950
- Dehydroepiandrosterone, in SLE in women, 454
- Dehydroepiandrosterone, in SLE in women, 454
- Dehydrotachysterol, in experimental hydroxyapatite calcification, 1239
- Delayed fracture union, dexamethasone nasal spray and, 599
- Delayed hypersensitivity, in post-mammoplasty connective tissue disease, 695
- Delbarre, Florian (In Memoriam), 1029
- Deossification
 - in diabetes, 338
 - epiphyseal articular, 337
 - in psoriatic arthritis, 335, 337
 - vascular influences on, 333
- Deoxycorticosterone, plasminogen activator activity and, 438
- Deoxyribonuclease (DNase), in SLE, 966, 970
- Deoxyribonucleic acid. *See* DNA
- Depression, NSAID and, 1014
- Dermal-epidermal function, in SLE, 624
- Dermal plexus, in adult onset Still's disease, 651
- Dermatitis
 - auranofin and, 596
 - gonococcal arthritis and, 574
- Dermatomyositis. *See also* Myositis; Polydermatomyositis; Polymyositis
 - childhood, 126
 - naifold capillary abnormalities in, 954
 - juvenile, calcinosis in, 1094
 - ulcerative, 131
- Dermis. *See also* Cutaneous involvement; Skin
 - in SLE, 884
- Dexamethasone
 - adult canine articular cartilage and, 568
 - DNA synthesis by rabbit articular chondrocytes and, 1217
 - plasminogen activator activity and, 432, 438
 - Dexamethasone nasal spray, delayed fracture union and, 599
- Diabetes mellitus
 - insulin-dependent, digital sclerosis in, 1357
 - in MCTD, 458
 - septic arthritis in, 948
 - surgical resection of fingers in, 338
- Diagnosis of Bone and Joint Disorders* (book review), 479
- Diarrhea, auranofin and, 596
- Diazepam
 - RA and, 465
 - unproven remedies and, 1146
- Diclofenac, clinical bleeding and, 599
- Diffuse capacity of lung in SLE, 883. *See also* Lung; Pulmonary
- Diffuse interstitial lung disease. *See also* Pulmonary
 - in Sjögren's-sicca syndrome, 159
- Diffuse proliferative glomerulonephritis, 877. *See also* Nephritis, Renal
- Diffuse proliferative lupus nephritis, 870. *See also* Glomerulonephritis; Renal
- Diffuse scleroderma, Raji cell assay in, 1167
- Diflunisal, allopurinol-like action and, 474
- Digestive system, in SLE, 410
- Digital sclerosis, in insulin-dependent diabetes mellitus, 1357
- Digital ulcers
 - in scleroderma, 525
 - nifedipine in, 1267
 - in scleroderma esophageal disease, 1118
- Digoxin, RA and, 465
- Dihydrotestosterone, in SLE, in women, 454
- Diisopropyl fluorophosphate, aspirin hydrolysis and, 550
- Diphenhydramine, in RA, 465
- Diphenylhydantoin, SLE triggered by, 1387
- Dipyrrone, as unproven remedy, 1146
- Discoid lupus erythematosus, 859. *See also* Childhood lupus erythematosus; Central nervous system SLE; Drug-induced LE-like syndrome; Iatrogenic SLE; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
 - antibodies to ssDNA and native DNA in, 639
 - in SLE, 383
- Discs, intervertebral
 - amyloid deposition in senescent mice, 710
 - hereditary pyrophosphate arthropathy and, 66
- Disease activity
 - circulating immune complexes and, 1151
 - in eosinophilic fasciitis, 1180
 - genetic predictors and in RA, 370
 - in gonococcal arthritis-dermatitis syndrome, 575
 - naifold capillary abnormalities in childhood dermatomyositis and, 954
 - in RA
 - genetic predictors and, 370
 - immune complexes and, 1156

- Disease activity (*cont'd*)
 serum pepsinogen I and, 1061
 in SLE, 50, 383, 891, 970
 histone antibodies and, 407
 immunoglobulins, complement and, 624
 interferon and, 401
- Disease modifying antirheumatic drugs, 596. *See also* Drugs
- Disseminated gonococcal infection, immune complexes in, 574
- Disulfiram, adverse effects of, 1494
- DLE. *See* Discoid lupus erythematosus
- DNA. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; Anti-ssDNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
- antibodies to, 747
 in proliferative lupus nephritis, 873
 in 1982 revised criteria for classification of SLE, 1271
 in SLE, 55, 381
- anti-H2A-H2b activity and, 782
- antinative. *See* Antinative DNA
- double-stranded. *See* Double-stranded DNA
- histones and, 781
- monoclonal antibodies and, 749
- monoclonal murine antibodies and, 751
- native. *See* Native DNA
- in polyarteritis nodosa, 1425
- single-stranded. *See* Single-stranded DNA
- skin response to, in SLE, 1284
- in SLE, 969
- T cells and, 304
- steroid receptors in adult canine articular cartilage and, 568
- DNA antibodies, 748. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
- antigenic specificity and, 748
- in BXSB mice, 749
- in human SLE, 754
- in MRL/lpr/lpr mice, 749
- nephritis and, 749
- in NZB/NZW F₁ mice, 749
- pathogenesis of, 747
- in post-mammoplasty connective tissue disease, 695
- in SLE, 383, 564
- nucleic acids and, 304
- DNA anti-DNA antibodies, 747
- DNA anti-DNA complexes
 in lupus nephritis, 873
 in SLE, 631, 788
- DNA anti-DNA immune complex, in lupus nephritis, 768
- DNA binding
 in autoimmune diseases, 634
 in DLE, 643
- DNA binding (*cont'd*)
 in normal sera, 634
 in SLE, 309, 894
- DNA formation, platelet derived growth factor stimulated
 radiosulfate incorporation and, 1228
- DNA synthesis
 ascorbate stimulation of, 318, 531
 chondrocyte synthesis and, 668
 glycosaminoglycan synthesis and in rabbit articular chondrocytes, 1228
 purified growth factors by rabbit articular chondrocytes, and 1217
- DNase. *See* Deoxyribonuclease
- Dorsal spine, in ankylosing spondylitis, 218
- Double-stranded DNA. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; Anti-ssDNA; DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
- antibodies to, 748
 monoclonal, 749
 in SLE, 631
 in MRL mice, 728
 in SLE, 410
- Double-stranded DNA antibodies, in SLE, thrombosis and, 117
- DR alleles, 833
- DR alloantigens, 835
- DR antigens, in seronegative RA, 502
- DR typing, in North American whites with lupus, 836
- Drug-induced interstitial nephritis, 872. *See also* Heymann nephritis; IgA nephritis; Immune complex-induced nephritis; Immune complex nephritis; Lupus nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
- Drug-induced LE-like syndrome, 857. *See also* Childhood lupus erythematosus; Central nervous system SLE; Discoid lupus erythematosus; Iatrogenic SLE; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- complement in, 796
- Drug reactions, in RA, 340
- Drug toxicity, mortality in RA and, 1020
- Drugs. *See also* Antiinflammatory drugs; Aspirin; Corticosteroids; Disease modifying antirheumatic drugs; Gold; Immunosuppressive therapy; Nonsteroidal antiinflammatory drugs; Salicylates; Steroid drugs
- allopurinol, 474
- Antabuse, 1494
- antibiotic, 947
- antiinflammatory, effect on hyaluronic acid, 1469
- antimalarial, 427, 699
- aspirin, 32, 464, 550, 595, 1098, 1333
- auranofin, 595

Drugs (*cont'd*)

aurothiomalate, 596
azathioprine 97, 893, 1149, 1269, 1388
benoxaprofen, 595, 1486
captopril, 241
chlorambucil, 383, 699
choline magnesium trisalicylate, 464
in CNS SLE, 586
colchicine, 227, 235, 471, 1509
corticosteroids, 120, 891
cyclophosphamide, 532, 893, 913
cytotoxic, 427, 893
dexamethasone, 432
diazepam, 465, 1146
diclofenac, 599
diflunisal, 474
digoxin, 465
diphenhydramine, 465
diphenylhydantoin, 1387
disulfiram, 1494
dyazide, 465
estrogen, 620
FDA Arthritis Advisory Committee and, 591
ferrous sulfate, 465
frentizole, 1291
glucocorticoids, 432, 438
hydralazine, 857
hydrocortisone, 1006
hydroxychloroquine, 465
hydroxyzine, 465
ibuprofen, 465, 1013
immunosuppressive, 57, 410, 411, 532
indomethacin, 357, 465
insulin, 1357
levamisole, 10, 470, 699, 714
meclofenamate, 359
methotrexate, 339
methyldopa, 465
naproxen, 465, 1013, 1016
nifedipine, 1267
noncompliance and, 448
nonsteroidal, 410
NSAID, 699
N-[2-mercaptopropionyl] glycine, 695
Oralex, 595, 1486
penicillamine, 111, 119, 247, 427, 465, 695, 917, 923, 1016
penicillin, 42
phenylbutazone, 1146
piroxicam, 370
plaquenil, 383
prednisone, 112, 120, 309, 383, 427, 465, 564, 621, 699,
701, 893, 970, 1006, 1096, 1146
procainamide, 238, 857
progesterone, 620

Drugs (*cont'd*)

pyrithioxine, 699
in RA, 340
mortality and, 1020
in SLE, 50, 970
slow acting, 698
steroid, 57, 410, 1146
sulfamethoxazole, 465
sulfhydryl, 695
sulfonamide, 350
5-thiopyridoxine, 699
tiopronin, 695, 923, 1505
tolmetin, 465, 1144
trimethoprim, 465
veterinary, dipyrrone, 1146
Dry eyes and mouth, in keratoconjunctivitis sicca, 156
dsDNA. *See* Double-stranded DNA
Dupuytren's contracture, tiopronin for, 1505
Dyazide, RA and, 465

E

E cells, in progressive systemic sclerosis, 390
E rosette formation
in RA, 17
in SLE, 384
Ear cartilage, collagen-induced inflammation in, 266
EBV. *See* Epstein-Barr virus
EBV-inducible autoantibody-secreting lymphocytes, 963
Ecotropic viruses, 850
NZB mice and, 853
Edema, in CAEV arthritis in goats, 930
Effusions
eosinophilic synovial, complication of chronic urticaria
and angioedema, 708
joint, diagnosis of, 98
knee, in psoriatic arthritis, 356
in septic arthritis, 947
synovial, 361
Elbow
olecranon bursitis in, 989
in RA, 486
Electromyographic findings, in progressive systemic sclerosis, 61
Electrophoresis, agarose gel, 1167, 1180
Electron microscopy, in experimental hydroxyapatite calcification, 1239
ELISA. *See* Enzyme-linked immunosorbent assay
Encephalopathy, in hypertensive scleroderma, 241
Endocarditis. *See also* Cardiac; Heart
bacterial, vertebral osteomyelitis and, 600
Endocrine factors, lymphocyte function and, 831

- Endothelial cell injury, in childhood dermatomyositis, 126
- Endothelial cell swelling, in psoriatic arthritis, 677
- Endovascular injury, in childhood dermatomyositis, 126
- End-stage ankylosing spondylitis, vertebral ankylosis in hereditary chondrocalcinosis and, 1257
- Enthesopathy. *See also* Arthropathy
in hereditary chondrocalcinosis, 1257
- Environmental factors, in SLE, 734
- Enzyme-labeled beta 2 microglobulin, 375
- Enzyme-linked immunosorbent assay
to detect antibodies to collagen in scleroderma, 522
for *Pseudomonas aeruginosa* antigen and antibody, 1404, 1406
in Sjögren's syndrome, 260
- Enzyme protein, hepatic xanthine oxidase in Sprague-Dawley rats and, 326
- Enzyme purification, in human articular cartilage, 983
- Enzymes
aspirin hydrolysis and, 550
hepatic xanthine oxidase activity and, 330
SLE, acute intermittent porphyria and, 1134
- Eosinophilic fasciitis
circulating immune complexes in, 1180
clinical features of, 1181
eosinophilotactic activity in, 1352
laboratory features of, 1180
- Eosinophilic synovial effusions, complicating chronic urticaria and angioedema, 708
- Epidemic
of histoplasmosis in Indianapolis, 1396
of synovitis from rapeseed oil, 1477
- Epidemiology of Osteoarthritis* (book review), 1150
- Epidermal growth factor
DNA synthesis by rabbit articular chondrocytes and, 1217
in sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Epigastric pain, in RA, 700
- Epinephrine, SLE and, 966
- Epiphyseal articular deossification
in diabetes, 338
in hyperparathyroidism, 337
- Epiphyseal-metaphyseal vascular system, deossification and, 333
- Episcleritis, in Yersinia arthritis, 253
- Epstein-Barr virus
lymphocytes and in JRA, 959
in RA, 427
- Epstein-Barr virus antibodies, in RA, 427
- Epstein-Barr virus-inducible IgM antiIgG in JRA, 961
- Erosions
in adult onset Still's disease, 650
in JRA, 1011
in RA, 48
gold therapy and, 540
temporomandibular joint in SLE, 597
- Erythema multiforme, sulfonamide hypersensitivity and, 350
- Erythema nodosum, in Yersinia arthritis, 253
- Erythrocyte autoantibodies, in NZB/*xid/xid* and DBA/2/*xid/xid* mice, 737
- Erythrocyte sedimentation rate
in eosinophilic fasciitis, 1180
in familial Mediterranean fever, 43
in JRA, 580
in RA, 151, 340, 486, 503, 699, 701, 1156
after penicillamine or tiopronin, 923
in Reiter's disease, 255
in salmonella arthritis, 251
in Yersinia arthritis, 251
- Erythrocytes
aspirin hydrolysis and, 550
in purine metabolism in secondary juvenile metabolic gout, 1264
in splenic RES Fc receptor functional activity in SLE, 48
- Escherichia coli*, cartilage degradation by, 441
- Esophageal dysfunction, in scleroderma, 1117
- Esophageal involvement, in scleroderma, 525
- Esophagus
in achalasia, 1120
in scleroderma, 1117
- Essential fatty acid deficiency, murine lupus and, 808
- Estradiol, 843
adult canine articular cartilage and, 568
in oral contraceptives in SLE, 618
- Estriol, in SLE, 844
- Estrogen contraceptives, in SLE, 618
- Estrogen metabolism, in SLE, 843
- Estrogen receptors, in adult canine articular cartilage, 568
- Estrogens, murine lupus and, 838
- Estrone, in SLE, 843
- Ethacrynic, in hypertensive scleroderma, 245
- Ethinyl-estradiol contraceptives, in SLE, 618
- Ethnic origin, survival in SLE and, 601
- Exercise, patient noncompliance and, 448
- Experimental collagen arthritis, 532, 911
- Experimental extraarticular chondritis, 266
- Experimental hydroxyapatite cartilage calcification, 1239
- Experimental intraarticular calcification, 1240
- Extensor tendon rupture, scleroderma, amyloidosis and, 1141
- Extraarticular chondritis, experimental, 266
- Extraarticular manifestations, of RA, assays for immune complexes and, 1156
- Extracellular matrix, DNA synthesis by articular chondrocytes and, 318, 531
- Extractable nuclear antigens, 755
in connective tissue diseases, 460
- Extraglandular involvement, in Sjögren's syndrome, 421
- Extrarenal immune deposits, 881
- Extrarenal lesions, in SLE, 880
- Extremities, swelling of, thyroid acropachy and, 588

Exudates, complement in, 796
Eye
 keratoconjunctivitis sicca and, 156
 in RA, 914
Eye disease, inflammatory, and HLA, 1431

F

- F344/N rats, streptococcal cell wall-induced polyarthritis in, 1064
(F344/N \times LEW/N) rats, polyarthritis in, 1064
(F344/N \times NSD/N) rats, polyarthritis in, 1064
Fab fragments, IgG and, 1112
F(ab')₂ fragments, platelet responses to urate and, 508
Factor B, inflammation and, 861
Familial Mediterranean fever, 1150
 amelioration of suppressor cell deficiency in by hemodialysis, 38
 colchicine in, 471
 plasma colchicine concentrations in, 227
 responder cells in, 471
 Schönlein-Henoch syndrome in, 42
Familial pyrophosphate arthropathy, 66
Farr assay
 for antibodies to anti-dsDNA, 634
 ssDNA/antiDNA complexes detected by, 642
Farr radioimmunoassay, in SLE, 997
Fasciitis, eosinophilic, circulating immune complexes in, 1180
Fatigue, in RA, 486
Fatty-acid-poor bovine serum albumin, DNA synthesis by rabbit articular chondrocytes and, 1219
Fatty acids
 in inflammation, 804
 salicylates and, 32
 short chain, in septic arthritis, 947
Fc fragments, IgG and, 1112
Fc receptor lymphocytes, 830
Fc receptors
 in SLE, 48
 DNA and, 304
 tubulointerstitial deposits and, 873
FDA Arthritis Advisory Committee Meeting, 595, 1124
Felty's syndrome, superoxide generation in, 1409
Femoral head, noncollagenous proteins in, 1078
Femur, collagen arthritis in, 911
Ferroketic studies, in juvenile metabolic gout, 1265
Ferrous chloride, in experimental hydroxyapatite calcification, 1239
Ferrous sulfate, RA and, 465
Fetus, maternal ankylosing spondylitis and, 140
Fever
 in adult onset Still's disease, 647
 Fever (*cont'd*)
 in chronic liver disease and Still's disease, 580
 in familial Mediterranean fever, 43
 in JRA, 580
 photophobia, in CNS SLE, 586
 in SLE, 383
FIAX fluorimetric immunoassay, in SLE, 997
Fibrin
 in childhood dermatomyositis, 126
 in collagen arthritis, 913
 in cranial arteritis, 78
 in RA, 913
Fibrin deposition, in adult onset Still's disease, 647, 651
Fibrin-fibronectin complexes, degradation of, 25
Fibrinogen
 in familial Mediterranean fever, 43
 in rheumatoid plasma, 25
 in type II collagen-induced arthritis, 270
Fibroblast interferon, antibodies to in SLE and vasculitis, 396
Fibroblasts
 in CAEV arthritis, 932, 935
 human synovial, plasminogen activator activity and, 432
 in scleroderma, 189
 in Sjögren's syndrome, 263
 skin, purine nucleotide synthesis and in juvenile metabolic gout, 1265
 in rheumatoid synovium, 690
Fibronectin, in rheumatoid synovial fluid, 25
Fibrosis
 in CAEV arthritis, 935
 in childhood dermatomyositis, 132
 in esophagus in scleroderma, 1117
 after joint surgery in rabbits, 276
 pulmonary, in Sjögren's syndrome, 421
 scleroderma and, 189
 spinal cord block in ankylosing spondylitis and, 218
 of subsynovial tissue in psoriatic arthritis, 677
Fibrositis
 definition of, 1506
 methodology errors in study of, 1389, 1390
 prevalence of in rheumatology practice, 718
 psychologic disturbance and, 213
FI phenotype, in JRA, 1010
Filipino American population, mortality from SLE in, 414
Fingers
 in adult onset Still's disease, 647
 in RA, gold therapy and, 544
Fischer rats, adjuvant arthritis in, 591, 1194
Fish vertebrae, 1073
Fluid-phase conglutinin assay, in progressive systemic sclerosis, 1174
Fluorescent antinuclear antibodies
 in connective tissue diseases, 460
 in 1982 revised criteria for classification of SLE, 1271

Fluoroimmunoassay, of soluble immune complexes, 799
 FM phenotype, in JRA, 1010
 Focal proliferative glomerulonephritis, 877, 879
 IgA immune deposits in, 144
 Focal segmental lupus nephritis, 869
 Folliculitis, necrotic pseudo, in Behçet's disease, 714
 Foot, in hypertrophic osteoarthropathy, 1189
 Fractionated total lymphoid irradiation, in collagen arthritis, 532
 Fractures, delayed union of, dexamethasone nasal spray and, 599
 Franklin, Edward C. (In Memoriam), 1029
 Free fatty acids, salicylates and, 32
 Frentizole in NZB/NZW mice, 1291
 Freund's complete adjuvant, collagen peptides and, 274
 Fumaric acid, in synovial fluid, 949
 Furosemide, in hypertensive scleroderma, 245
 Fv-1 gene, retroviruses and, 850, 852

G

Ga antigen, definition of, 1281
 GAG. *See* Glycosaminoglycans
 Galactosamine
 in articular cartilage, 979
 in cartilage protease, 986
 Galactosyl transferase, salicylates and in GAG synthesis, 1084
 Gamma carboxyglutamic acid, in juvenile dermatomyositis, 1094
 Gamma globulin
 human placenta-eluted, 17
 placental, in RA, 1024
 retroplacental, in RA, 17
 in RA, gold therapy and, 545
 Gamma interferon, in SLE and vasculitis, 398
 Gas liquid chromatography, analysis of synovial fluid by, 947
 Gastric ulcer, in RA, 702
 Gastritis, autoimmune, DNA binding in, 634
 Gastrointestinal bleeding, as cause of death in SLE, 613
 Gastrointestinal intolerance, penicillamine toxicity and, 920
 Gastrointestinal involvement
 in scleroderma, 243, 525
 in SLE, 564
 Gaucher's disease, type I
 hemorrhagic bursitis and bone crises in, 1369
 interphalangeal joints in, 706
 Gel electrophoresis, in study of noncollagenous proteins, 1078
 Gelling arthralgia, in RA, 485
 General practitioners, referrals to rheumatologists by, 718
 Genetics
 adult onset Still's disease and, 647
 ankylosing spondylitis in African blacks and, 716

Genetics (cont'd)

anti-Ro and, 769, 771
 in autoimmunity, 741
 complement and, 793
 in connective tissue disease, 771
 hereditary chondrocalcinosis, 1257
 immune responses and in spondylarthropathies, IgA nephropathy and, 144
 interleukin-2 deficiency and in SLE, 838
 major histocompatibility complex and in adjuvant arthritis, 1194
 mortality in RA and, 1020
 murine SLE and, 722, 724
 NSAID in RA and, 370
 retroviruses and, 851
 SLE and, 734, 830, 833
 SLE-like disease and, 726
 viruses and, 851
 Giant cell arteritis
 progressive systemic sclerosis and, 717
 treatment of, 120
 Giant cell valvulitis, in Reiter's syndrome, 232
 Glanzmann's thrombasthenia
 urate-associating membrane proteins and, 514
 in urate crystal membrane protein interactions, 508
 Glomerular lesions, proliferative, in lupus nephritis, 872
 Glomerular sclerosis, 871
 Glomerular thrombosis, 872
 in SLE, 117
 Glomerulonephritis. *See also* Drug-induced interstitial nephritis; Heymann nephritis; IgA nephritis; Immune complex nephritis; Immune complex-induced nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
 in BXSb bone marrow, 723
 chronic serum sickness, and immune complexes, 785
 complement in, 795
 diffuse proliferative, 876
 focal proliferative, 144, 877
 human neutrophils and, 878
 immune complexes and, 785
 lymphocytic choriomeningitis virus, interferon and in Swiss mice, 803
 membrane attack complex and, 876
 in MRL mice, 727
 in MRL/Mp-1pr/1pr mice, 728
 in SLE, vi
 thrombi in, 872
 Glomerulus
 antibodies in, 750
 circulating immune complexes in, 875
 human, inhibition of IgG in by rheumatoid factor, 297
 in IgA nephropathy, 145
 immune complexes in, 783, 785
 in lupus nephritis, 871

Glomerulus (*cont'd*)

- membrane attack complex in, 876
- in membranous lupus nephritis, 873
- in RA, 1017

Glucocorticoid receptors, in adult canine articular cartilage, 568

Glucocorticoids, antiinflammatory, plasminogen activator activity and, 432

Glucuronides, estradiol and, 844

Glucosamine

- in articular cartilage, 979
- in cartilage protease, 986

Glucose

- in cerebrospinal fluid, 583
- in psoriatic arthritis, 678
- in septic arthritis, 947
- in synovial fluid, 951

Glucuronide metabolites, benoxaprofen and, 595

Glutaraldehyde, cartilage wear and, 974

Glycopeptides, in T cell leukemia, 87

Glycoproteins

- in urate crystal membrane protein interactions, 508
- viruses and, 847

Glycosaminoglycan (GAG) synthesis

- heat-inactivated fetal bovine serum and, 1228
- salicylates and xyloside in, 1084

Glycosaminoglycans

- cartilage, effect of bacteria on, 441
- chondrocyte synthesis and, 668
- xyloside and in cartilage, 1084

GMENAC. *See* Graduate Medical Education National Advisory Committee

Goat studies, CAEV arthritis in, 910

Gold, 596. *See also* Auranofin; Aurothiomalate; Chrysotherapy; Gold sodium thiomalate; Gold therapy; Injectable gold preparations; Oral gold

Gold salts. *See also* Auranofin, Aurothiomalate; Chrysotherapy; Gold sodium thiomalate; Gold therapy; Injectable gold preparations; Oral gold

- inhibition of C2 by, 288
- intraarticular, in RA, 1148
- penicillamine and, 917
- in RA, 699, 702

Gold sodium thiomalate. *See also* Auranofin; Aurothiomalate; Chrysotherapy; Gold salts; Gold therapy; Injectable gold preparations; Oral gold

- and degradation of hyaluronic acid, 1469, 1473, 1475
- inhibition of C2 by, 288
- monocyte responsiveness and, 288
- phagocyte function and, 294
- in RA, 1148

Gold therapy, 372. *See also* Auranofin; Aurothiomalate; Chrysotherapy; Gold salts; Gold sodium thiomalate; Injectable gold preparations; Oral gold

- influence of on adverse effects of penicillamine in RA, 917

Gold therapy (*cont'd*)

- in RA, 427, 540
- toxicity in, 547

Gold toxicity, penicillamine and, 917

Gonococcal arthritis, 574, 950

Gonococcal arthritis-dermatitis syndrome, 574

Goodpasture's syndrome, 785

Gout

- aspiration of asymptomatic metatarsophalangeal joint in, 209
- coexistent, SLE and, 618, 1505, 1506
- inflammatory arthritis and, 948
- juvenile metabolic, caused by chronic compensated hemolytic syndrome, 1264
- lactic acid in, 950
- polyarticular, tophi in, 472
- succinic acid in, 950
- tophi in, 472

Gouty arthritis, tophaceous polyarticular, nodules in, 478.

See also Arthritis; Gout

Graduate Medical Education National Advisory Committee, 2

Gram negative arthritis, 950

Gram positive arthritis, 950

Granulomatous angiitis of nervous system, 342

Granulomatous disease, 181

Grave's disease, thyroid acropachy in, 588

Grip strength, in RA, 486, 699, 701

Guanethidine, in hypertensive scleroderma, 245

Guanidinium chloride, cartilage wear testing and, 974

H

H-2 major histocompatibility locus, lymphoma and, 851

Hand

- in CREST syndrome, 1027
- in hereditary chondrocalcinosis with vertebral ankylosis, 1259
- in psoriatic spondylitis, 102
- in RA, 503
 - gold therapy and, 544
- in T cell leukemia, 88
- in thyroid acropachy, 588

Hand splints, patient noncompliance and, 448

Haptens, immune responses and in SLE, 824

Hawaiian population, mortality from SLE in, 414

³H-dexamethasone binding, in canine articular cartilage, 570

³H-DNA/anti-DNA complexes, 631. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; Anti-ssDNA; DNA; Double-stranded DNA; Native DNA; Single-stranded DNA

Head tilt in RA, nonreducible rotational, 1316

Headache, in CNS SLE, 586

Health status, Arthritis Impact Measurement Scales and, 1048

- Heart. *See also* Cardiac; Endocarditis
 giant cell valvulitis, 232
 immune deposits in, 882
 in scleroderma, 243, 525
 in SLE, 564
 vertebral osteomyelitis and bacterial endocarditis, 600
- Heart disease, cyanotic congenital, hypertrophic osteoarthropathy in, 1186
- Heat-inactivated fetal bovine serum
 glycosaminoglycan synthesis and, 1128
 in sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Hemarthrosis after hemodialysis, 1387
- Hematocrit
 aspirin half-life and, 552
 aspirin hydrolysis and, 550
 in hypertrophic osteoarthropathy, 1191
 survival in SLE and, 601
- Hematologic involvement, in SLE, 410
- Hemochromatosis, degenerative arthropathy of, 1460
- Hemocytopenia. *See also* Anemia; Hemolytic anemia; Hypocupremia-related hypochromic anemia; Thrombocytopenia
 in SLE, 55, 1127
- Hemodialysis
 amelioration of suppressor cell deficiency in familial Mediterranean fever by, 38
 nephritis and survival in SLE, 612
- Hemoglobin
 in hypertrophic osteoarthropathy, 1191
 in Reiter's disease and reactive arthritis, 251
- Hemolysis, secondary juvenile metabolic gout and, 1264
- Hemolytic anemia. *See also* Anemia; Hemocytopenia; Hypocupremia-related hypochromic anemia; Thrombocytopenia
 DNA binding in, 634
 immune, anti-SS-B antibodies in, 473
- Hepatic dysfunction, in Still's disease, 579
- Hepatic xanthine oxidase, in Sprague-Dawley rats, 326
- Hepatosplenomegaly, in chronic liver disease and Still's disease, 580
- Hereditary chondrocalcinosis. *See also* Calcium pyrophosphate dihydrate crystal (CPPD) deposition disease; Chondrocalcinosis; Hereditary pyrophosphate arthropathy; Pseudogout
 pedigree of, 1258
 vertebral ankylosis in, 1257
- Hereditary complement deficiencies, 794. *See also* Complement
- Hereditary pyrophosphate arthropathy, 66. *See also* Arthropathy
- ³H-estradiol binding, in adult canine articular cartilage, 570
- Heymann nephritis, 873. *See also* Drug-induced interstitial nephritis; IgA nephritis; Immune complex-induced nephritis; Immune complex nephritis; Lupus nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
- "Hidden" seropositive JRA, IgM antiIgG B lymphocytes in, 959
- Hilar adenopathy in "pseudosarcoidosis," 1396
- Hip
 bony ankylosis of, in PSS, 1497
 in familial pyrophosphate arthropathy, 69
 in JRA, 1269
 in lower limb amputees, 80
 total arthroplasty of amyloid in osteoarthritis, 204
- Histiocytes, in adult onset Still's disease, 651
- Histone antibodies, in SLE, 407
- Histones, antibodies and, 779
- Histopathology, in childhood polydermatomyositis, 126
- Histoplasma capsulatum*, and histoplasmosis, 1396
- Histoplasmosis, "pseudosarcoidosis" subset of, 1396
- HLA allotypes, beta 2 microglobulin and in ankylosing spondylitis, 375
- HLA antigen, 835
 complement and, 794
- HLA specificities and psoriatic arthritis, 1389
- HLA-A antigens
 in post-mammoplasty connective tissue disease, 695
 in Reiter's disease, 252
 in salmonella arthritis, 252
 in Yersinia arthritis, 252
- HLA-B antigens
 in adult onset Still's disease, 652
 alpha₁-antitrypsin phenotypes in eye disease and, 1431
 in ankylosing spondylitis in African blacks, 716
 anterior uveitis and, 1431
 inflammatory eye disease and, 1431
 in JRA, 1045
 knee effusions and, 356
 peripheral arthritis in monozygotic twins and, 1490
 in Pima Indian men with sacroiliitis, 235
 in post-mammoplasty connective tissue disease, 695
 in psoriatic arthritis, 678
 in reactive arthritis, 249
 in Reiter's disease, 249, 252
 in salmonella arthritis, 252
 seronegative arthropathies, 356
 and enthesopathy in children, 1041
 in Yakima Indians with RA, 1435
 in Yersinia arthritis, 252, 655
- HLA-C antigens, 252
- HLA-D antigens
 immune function of synovial cells and, 488
 in RA subpopulations, 1435
 SS-B antibodies and in Sjögren's syndrome, 662
- HLA-DR antigens
 in adult onset Still's disease, 652
 autologous mixed lymphocyte reaction and, 121
 in blacks with SLE, 1036
 human synovial cells and, 488
 lack of in Yakima Indians with RA, 1435
 in post-mammoplasty connective tissue disease, 695
 in progressive systemic sclerosis, 390

- HLA-DR antigens (*cont'd*)
 in psoriatic arthritis, 678
 in RA, 372
 IgM rheumatoid factor and, 150
 seropositive, 502, 504
 in SLE, 770
 in blacks, 1036
 seroreactivity and, 1031
- HLA typing, in relatives of SLE children, 556
- ³H-leucine
 gold sodium thiomalate, C2 and, 293
 plasminogen activator activity and, 435
- Homologous cartilage proteoglycan. *See also* Proteoglycans
 blastogenic responses to, 283
- Homologous type I collagen. *See also* Collagen
 blastogenic responses to, 278
- Homologous type II collagen. *See also* Collagen
 blastogenic responses to, 280
- Homologous type III collagen. *See also* Collagen
 blastogenic responses to, 282
 immunity to after meniscectomy, 274
- Homologous type III cyanogen bromide peptides, T cells
 and, 284
- Hormonal therapy, in SLE, 618
- Hormones, plasma, in female SLE patients, 454
- Horseradish peroxidase staining, of PGE in rheumatoid
 synovium, 685
- ³H-serotonin secretion
 chymotrypsin and, 516
 platelet membrane proteins and, 517
- ³H-thymidine
 in ascorbate stimulation of DNA, 318, 531
 DNA synthesis by rabbit articular chondrocytes and,
 1219, 1220
 fibroblasts and in scleroderma, 192
- ³H-thymidine incorporation assay, immunity to homologous
 type III collagen after meniscectomy in rabbits and,
 274
- ³H-thymidine uptake, mycoplasma-induced arthritis and,
 943
- Human adjuvant disease. *See also* Adjuvant arthritis
 mammoplasty and, 694
- Human articular cartilage. *See also* Cartilage
 adult, ascorbate stimulation of DNA synthesis and, 318,
 531
 neutral metalloprotease in, 981
- Human blood mononuclear cells. *See also* Mononuclear
 cells
 cytotoxic activities of, 10
- Human cartilage. *See also* Cartilage
 effect of ascorbate and collagenase on, 322
- Human collagen-induced arthritis, 1024. *See also* Arthritis;
 Collagen
- Human complement activation. *See also* Complement
 by IgG rheumatoid factors, 1101
- Human glomerulus. *See also* Glomerulus
 inhibition of IgG in by rheumatoid factor, 297
- Human hereditary complement deficiencies, 794. *See also*
 Complement
- Human interferon, 802. *See also* Interferon
- Human lupus autoantibodies. *See also* Autoantibodies
 monoclonal, 745
- Human major histocompatibility complex, 835. *See also*
 Major histocompatibility complex
- Human mixed lymphocyte reaction. *See also* Mixed lympho-
 cyte reaction
 antilymphocyte antibodies and, 811
- Human monocytes. *See also* Monocytes
 inhibition of C2 by gold sodium thiomalate and, 288
- Human neutrophils. *See also* Neutrophils
 respiratory burst in, 181
 superoxide anion generation and, 174
- Human peripheral blood mononuclear leukocytes. *See also*
 Peripheral blood mononuclear leukocytes
 induction of rheumatoid factor in by aggregated IgG, 1108
- Human peripheral blood T lymphocytes. *See also* Peripheral
 blood lymphocytes; T cells
 ARFT and, 826
- Human placenta-eluted gamma globulin. *See also* Gamma
 globulin
 in RA, 17
- Human polymorphonuclear leukocytes. *See also* Polymor-
 phonuclear leukocytes
 superoxide anion generation and, 174
- Human retrovirus in SLE, 853
- Human rheumatoid factor. *See also* Rheumatoid factor
 induction of by aggregated IgG, 1108
- Human sera reactivities, viruses and, 853
- Human serum, effect of on response of chondrocytes to
 platelet-derived growth factor, 1232
- Human serum albumin
 aspirin hydrolysis and, 550
 salicylates and in chronic inflammatory joint disease, 32
- Human synovial cells. *See also* Synovial
 immune function of, 488
- Human synovial fibroblasts. *See also* Fibroblasts; Synovial
 plasminogen activator activity and, 432
- Humoral immunity. *See also* Cellular immunity
 to collagen after total lymphoid irradiation, 532
 in SLE, 810
- ³H-uridine, plasminogen activator activity and, 435
- Hyaluronic acid, effect of antiinflammatory drugs on,
 1469
- Hybridoma autoantibodies, 744. *See also* Autoantibodies
 Hydralazine, 857
 in hypertensive scleroderma, 245
- Hydrocortisone, plasminogen activator activity and, 438
- Hydrocortisone sodium succinate, in pancreatitis in SLE,
 1006
- Hydroxyapatite, nitroblue tetrazoleum reduction and, 183
- Hydroxyapatite cartilage calcification. *See also* Cartilage
 experimental, 1239

Hydroxyapatite chondrocalcinosis, 1244. *See also* Chondrocalcinosis

Hydroxychloroquine, in RA, 465

16 α -hydroxyestrone, in SLE, 843

Hydroxylation, in first degree relatives of SLE patients, 843

Hydroxyproline, cartilage degradation and, 443

Hydroxyurea, mononuclear cells and in SLE, 312

Hydroxyzine, in RA, 465

Hypergammaglobulin. *See also* Gamma globulin

in Sjögren's-sicca syndrome, 159

Hypergammaglobulinemia

B cells and, 830

in eosinophilic fasciitis, 1180

in murine lupus, 729

Hyperglobulinemia, in SLE, 1031

Hyperimmunoglobulinemia, in monozygotic twins, 834

Hyperplasia, in CAEV arthritis, 930

Hypersensitivity, delayed, in collagen arthritis, 535, 537

Hypertension

malignant

in proliferative lupus nephritis, 872

in scleroderma, 241

pulmonary, in Sjögren's syndrome, 421

in scleroderma, 241

Hypertrophic osteoarthropathy

clinical features of, 1189, 1191

in cyanotic congenital heart disease, 1186

Hypertrophy, in CAEV arthritis, 930

Hyperuricemia

aspiration of asymptomatic metatarsophalangeal joint in, 209

diffusional and, 474

Hyperuricosuria, hemolysis and in secondary juvenile metabolic gout, 1266

Hypocellularity, in cartilage after meniscectomy in rabbits, 277

Hypocomplementemia. *See also* Complement C3

in progressive systemic sclerosis, 1176

in SLE, 55, 790

Hypocupremia-related hypochromic anemia. *See also* Anemia; Hemocytopenia; Hemolytic anemia; Thrombocytopenia

penicillamine and, 119

I

Ia alloantigens

disease susceptibility and, 836

lupus and, 835

Ia antigens, 833, 835

autologous mixed lymphocyte reaction and, 121

T cell leukemia and, 87

T cells and, 835

Iatrogenic SLE. *See also* Central nervous system SLE; Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kid-

ney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus

histone antibodies in, 407

Ibuprofen, cognitive dysfunction and, 1013

in RA, 465

Idiopathic polymyositis. *See also* Polymyositis

similarities to tropical pyomyositis, 107

Idiopathic thrombocytopenic purpura. *See also* Thrombocytopenia

DR2 antigen and, 836

Idiotypic anti-idiotypic interactions, 745

Idiotypic anti-idiotypic mechanisms, in SLE, 812

IgA. *See also* Anti-IgG; Anti-IgM; IgG; IgM; Immunoglobulin

auranofin and, 596

in cranial arthritis, 75

in post-mammoplasty connective tissue disease, 695

in RA, 26

in SLE, 624, 780

IgA nephritis. *See also* Drug-induced interstitial nephritis; Heymann nephritis; Immune complex-induced nephritis; Immune complex nephritis; Lupus nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis

seronegative spondylarthropathies and, 144

IgA rheumatoid factor

in RA, 1307

in rheumatoid synovial tissue, 1445

IgA SS-B antibodies. *See also* Antibodies

in connective tissue diseases, 662

IgD-bearing B cells in SLE, 1451

IgG. *See also* Anti-IgG; Anti-IgM; IgA; IgM; Immunoglobulin

aggregated, induction of human rheumatoid factor by, 1108

antibodies to, 1108

anti-F(ab')₂ antibodies, in RA and SLE, 1298

anti-human, antibodies to beta 2 microglobulin and, 375

in complement activation, 1101

in cranial arthritis, 75

in CSF fluid in SLE, 863

Fab fragments and, 1112

Fc fragments and, 1112

membrane attack complex and, 876

in MRL mice, 728

in mycoplasma-induced arthritis, 940

placenta-eluted gamma globulins and, in RA, 17

in post-mammoplasty connective tissue disease, 695

in RA, 26

rheumatoid factor inhibition in human glomerulus, 297

in rheumatic pericarditis, 1054

in Sjögren's syndrome, 421

in SLE, 624, 779, 881

- IgG (*cont'd*)
 nucleic acids and, 304
 superoxide anion generation and, 174
 T cells and, 313
- IgG absorption, in Sjögren's syndrome, 263
- IgG antibodies
 to beta 2 microglobulin
 in ankylosing spondylitis, 375
 in SLE, 375
 in circulating immune complexes, 783
 histones and in SLE, 779
 in Sjögren's syndrome, 260
- IgG antihistone activity, in SLE, 780
- IgG antineuronal antibody, in lupus CNS disease, 774
- IgG rheumatoid factor. *See also* Rheumatoid factor; IgM rheumatoid factor
 in adult onset Still's disease, 647
 in complement activation, 161, 1101
 in RA, 1158, 1307
 in rheumatoid synovial tissue, 1445
- IgG SS-B antibodies, in connective tissue diseases, 662
- IgM. *See also* Anti-IgG; Anti-IgM; IgA; IgG; Immunoglobulin
 anti-human, antibodies to beta 2 microglobulin and, 375
 auranofin and, 596
 in binding of IgG in human glomerulus, 297
 in childhood dermatomyositis, 126
 complement fixation and, 1103
 in cranial arthritis, 75
 gonococcal arthritis-dermatitis syndrome and, 574
 in JRA, 962
 membrane attack complex and, 876
 in post-mammoplasty connective tissue disease, 695
 in RA, 150
 in Sjögren's syndrome, 424
 in SLE, 624, 799
- IgM anti-beta 2 microglobulin, 375
- IgM antibodies
 in rheumatic pericarditis, 1054
 in Sjögren's syndrome, 260
 in SLE, 1451
 to ssDNA in DLE, 639
- IgM anti-F(ab')₂ antibodies in RA and SLE, 1298
- IgM antihistone activity, 781
 in rheumatic disease, 780
- IgM anti-IgG B lymphocytes, in JRA, 959
- IgM rheumatoid factor. *See also* IgG rheumatoid factor; Rheumatoid factor
 in binding of IgG in human glomerulus, 297
 in complement activation, 161
 in RA, 150, 1307
 in rheumatoid synovial tissue, 1445
- IgM SS-B antibodies, in connective tissue diseases, 662
- IL-2. *See* Interleukin 2
- IM phenotype, in JRA, 1010
- Immobilization, effect of aspirin on cartilage during, 1333
- Immune complex assays
 in RA, 1156
 in SLE, 788
- Immune complex deposition, extrarenal lesions in animals, 882
- Immune complex deposits, in SLE, 872
- Immune complex disease, 783, 880
 animal models of, 880
 rheumatoid factors and, 297
 SLE as prototype of, 796
- Immune complex-induced acute vascular injury, 864
- Immune complex-induced disorders, murine lupus and, 725
- Immune complex-induced nephritis. *See also* Drug-induced interstitial nephritis; Heymann nephritis; IgA nephritis; Immune complex nephritis; Lupus nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
 PGE1 and, 807
- Immune complex-mediated vascular injury, adult onset Still's disease and, 647
- Immune complex-mediated vasculitis, lupus CNS disease and, 777
- Immune complex nephritis. *See also* Drug-induced interstitial nephritis; Heymann nephritis; IgA nephritis; Immune complex-induced nephritis; Lupus nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
 in mice, 882
- Immune complex vasculitis, cranial arteritis and, 75
- Immune complexes, 1151. *See also* Circulating immune complexes; Complement C1q binding assay; Cytotoxic immune complexes; Serum immune complexes
 in adult onset Still's disease, 647
 antibodies in, 784
 antibodies to collagen in scleroderma and, 522
 antigens in, 784
 B cells and, 830
 chronic serum sickness, glomerulonephritis and, 785
 complement activation and, 1101
 in discoid lupus erythematosus, 860
 in familial Mediterranean fever, 42
 fluoroimmunoassay for, 799
 glomerular deposition of, 785
 glomeruli and, 750, 785
 in gonococcal arthritis-dermatitis syndrome, 574
 inflammation and, 1151
 in liver of mice, 784
 in lupus nephritis, 872
 membrane attack complex and, 876, 877
 in MRL mice, 728
 in murine lupus, 729
 pathophysiology of, 783

Immune complexes (*cont'd*)

- in post-mammoplasty connective tissue disease, 695
- in primary biliary cirrhosis with Sjögren's syndrome, 1250
- in progressive systemic sclerosis, 1167, 1174
- in *Pseudomonas* osteomyelitis, 1403
- in renal glomeruli, 783
- in rheumatic diseases, 1156
- rheumatoid factor in binding of, 297
- in Schönlein-Henoch syndrome, 42
- in scleroderma, 1167
- in SLE, 564, 799, 858, 894, 1031
 - kidney and, 880
 - in splenic RES Fc receptor functional activity, 48
- in spleen of mice, 784

Immune deposits

- in heart, 883
- IgA, in focal proliferative glomerulonephritis, 144
- liver and, 884
- in lung, 882
- in lupus, 884
- in lupus nephritis, 870
- nuclear antigens in, 882
- in peritoneum, 884
- SLE and, 880, 882
- in spleen, 884

Immune derangement, in SLE, 810

Immune function, of human synovial cells, 488

Immune hemolytic anemia, anti-SS-B antibodies in, 473

Immune reactants in RA, 1307

Immune regulation

- beta 2 microglobulin and in SLE, 375
- interleukin-2 and, 838
- of mouse, 740
- in SLE, 810

Immune response factor, in SLE, 562

Immune responses

- gonococcal arthritis-dermatitis syndrome and, 574
- to hapten-modified self in SLE, 824
- in IgA nephritis in spondylarthropathies, 144
- in mycoplasma-induced arthritis, 937
- natural killers augmentation in SLE and, 562
- PGE1 and in NZB/W mice, 807
- prostaglandins
 - inflammation and, 804
 - murine lupus and, 804
- SS-B antibodies and, 662

Immune system, 896

Immunobiology, of SLE-like disease, 726

Immunoblastic lymphadenopathy, polyarthritis in, 1481

Immunocompetent cells, autologous mixed lymphocyte reaction and, 121

Immunoelectron microscopy, PGE in rheumatoid synovium and, 685

Immunoendocrinology, 841

Immunofluorescence

- patterns of antinuclear antibodies, 1278

Immunofluorescence (*cont'd*)

- in Sjögren's syndrome, 422
- in SLE, 410
- to test for antibodies to dsDNA, 634

Immunogenetics, 896

- in anterior uveitis, 1431
- seronegative rheumatoid arthritis and, 502

Immunoglobulin. *See also* Anti-IgG; Anti-IgM; IgA; IgG; IgM

- B cells and, 830
- in cranial arthritis, 75
- in DLE, 860
- in lupus, 859
- membrane attack complex and, 876
- in post-mammoplasty connective tissue disease, 695
- in RA, 1158
- in rheumatic pericarditis, 1054
- serum in primary biliary cirrhosis and Sjögren's syndrome, 1251
- in SLE, 307, 384, 624, 894
 - B cells and, 168
 - in CSF, 864
- spontaneous, 830
- T cell leukemia and, 87
- tubulointerstitial deposits of in lupus nephritis, 872
- in type II collagen-induced arthritis, 270
- urate crystal membrane proteins and, 518

Immunoglobulin synthesis

- in monozygotic twins discordant for SLE, 715
- in Sjögren's syndrome, 419

Immunoglobulin-secreting B cells, in SLE, 168

Immunohistochemical findings in cranial arthritis, 75

Immunologic reactions, prostaglandins in, 807

Immunologic regulation, autoimmune disease and, 841

Immunologic specificities of antinuclear antibodies, 755

Immunologically mediated diseases, interferon in, 396

Immunology, 896

- of SLE, vi

Immunomodulating effect of gamma globulin, in RA, 17

Immunomodulation, interferon and, 401

Immunopathogenesis, in SLE, 859

Immunopathology

- adult onset Still's disease and, 647
- of murine lupus, 723
- of rheumatic pericarditis, 1054
- of SLE, 880

Immunoperoxidase, in Sjögren's syndrome, 421

Immunoprecipitation, of neuronal antigens, 776

Immunoproliferative disease, interferon and, 396

Immunoregulatory drugs, in murine lupus, 1291

Immunosuppression

- autologous mixed lymphocyte reaction and, 121
- in collagen arthritis, 532

Immunosuppressive compounds, 596

Immunosuppressive drugs

- in collagen arthritis, 532

- Immunosuppressive drugs (*cont'd*)
 in SLE, 57, 410
- Immunosuppressive therapy, in SLE, 1127
- Inborn enzyme abnormalities, juvenile metabolic gout and, 1264
- Indianapolis, histoplasmosis epidemic in, 1396
- Indians, Yakima, HLA antigens in, 1435
- Indomethacin
 concanavalin A-induced suppressor cell activity and, 357
 in RA, 465
- Infection
 as cause of death in SLE, 612
 in central nervous system SLE, 583
Shigella sonnei, reactive arthritis after, 1267
- Infectious mononucleosis, interferon and, 396
- Inflammation
 absence of and bacteria in cartilage degradation, 411
 in CAEV arthritis in goats, 930
 in childhood dermatomyositis, 126
 chronic
 in mycoplasma-induced arthritis, 937
 in streptococcal cell wall-induced polyarthritis in rats, 1064
 in chronic liver disease, Still's disease and, 579
 collagen-induced, type II, 266
 complement and, 797
 in disseminated gonococcal infections, 574
 immune complexes and, 1151
 immune deposits and, 882
 in lupus, 884
 NSAID and, 596
 in palindromic rheumatism, 361
 in pancreatitis in SLE, 1006
 prevalence of in private practice of rheumatology, 718
 in primary Sjögren's syndrome, 419
 prostaglandin E and, 805
 prostaglandins, immune responses and, 804, 808
 in psoriatic arthritis, 677
 in RA, 805
 in SLE, 858
 spinal cord block in ankylosing spondylitis and, 218
 superoxide anion generation and, 174
 in *Yersinia* arthritis, 655
- Inflammatory arthritis, knee effusions in, 357
- Inflammatory bowel disease, in children, 1041
- Inflammatory eye disease, immunogenetic factors in, 1431
- Inflammatory joint disease, 83. *See also* Joints
 chronic, salicylate concentrations in, 32
- Inflammatory muscle disease, 107
- Inherited complement abnormalities, 793
- Inherited complement deficiency disease, 795
- Injectable gold preparations. *See also* Auranofin; Aurothiomalate; Chrysotherapy; Gold salts; Gold sodium thiomalate; Gold therapy; Oral gold
 auranofin and, 596
- Insulin
 DNA synthesis and, 1223
 DNA synthesis by rabbit articular chondrocytes and, 1217
 in sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Insulin-dependent diabetes mellitus, and digital sclerosis in children, 1357
- Insulin receptor antibodies, in diabetes mellitus and MCTD, 458
- Insulin resistance, in connective tissue disease, 458
- Insurance company decisions, RA and, 1020
- Interferon
 anti-DNA binding and in SLE, 401
 autoimmune disease and, 401
 gamma, 398
 in immunologically mediated diseases, 396
 in RA, 396
 in scleroderma, 396
 serum, anti-DNA binding and, 403
 in SLE, 401
 in Sjögren's syndrome, 396
 in SLE, 396, 802
 disease activity and, 401
 natural killer augmentation and, 562
 serum complement and, 401
 type I (alpha), 401
 in vasculitis, 396
- Interleukin 2
 in autoimmune mice, 727
 deficiency in SLE, 838
- Intermittent peritoneal dialysis, in familial Mediterranean fever, amyloidosis, and chronic renal failure, 38
- Interphalangeal joints
 in adult onset Still's disease, 647
 in Gaucher's disease, type I, 706
- Interstitial (type I) collagen, antibodies to in scleroderma, 522
- Interstitial, synovial membrane apatite deposits in, 1239
- Intervertebral discs
 amyloid deposition in senescent mice, 710
 in hereditary pyrophosphate arthropathy, 66
- Intestinal tract, immune deposits in SLE, 884
- Intraarticular calcification, experimental, 1240
- Intraarticular calciphylaxis, with cartilage and synovial calcification, 1239
- Intracellular protein, gold sodium thiomalate, C2 and, 293
- Intravenous methotrexate, in RA, 339
- Iritis
 beta 2 microglobulin and in ankylosing spondylitis, 375
 in *Yersinia* arthritis, 253
- Iron deposits in hemochromatosis, 1460

J

- Japanese American population, mortality from SLE in, 414
- Jaundice, in chronic liver disease and Still's disease, 580

- Jaw, bruxism, CPPD and, 353
- Joint aspiration, in gout, 211
- Joint calcifications, pyrophosphate arthropathy and, 66
- Joint contractures, in insulin-dependent diabetes mellitus, 1357
- Joint deformities
- in RA, gold therapy and, 540
 - in SLE, 383
- Joint disease
- chronic inflammatory, salicylate concentrations in, 32
 - hydroxyapatite calcification and, 1239
 - peripheral, collagen arthritis as, 911
- Joint effusions
- in CNS SLE, 586
 - diagnosis by rapid electron microscopic analysis, 98
- Joint fusion, in adult onset Still's disease, 650
- Joint involvement
- in collagen arthritis, 914
 - in CREST syndrome, 1026
 - in JRA, 1045
 - in progressive systemic sclerosis, 1026
 - pyrophosphate arthropathy and, 66
 - in seronegative enthesopathy and arthropathy in children, 1041
- Joint pain
- in "pseudosarcoidosis," 1396
 - in RA, 481
- Joint space narrowing, in adult onset Still's disease, 650
- Joint surgery, immunity to collagen after, 274
- Joint swelling
- in RA, 481
 - gold therapy and, 540
- Joint tenderness, in RA, 481
- Joint widening, thyroid acropachy and, 588
- Joints
- in CAEV arthritis in goats, 933
 - carpal, 1254
 - in collagen arthritis, 535, 913
 - elbow, 989
 - in familial Mediterranean fever, 43
 - histologic assessment of, 276
 - inflammation in, 805
 - interphalangeal
 - in adult onset Still's disease, 647
 - in Gaucher's disease, type I, 706
 - proximal, 478
 - in RA, 699, 701
 - knee, in mycoplasma-induced arthritis, 937
 - metacarpal, in thyroid acropachy, 588
 - metacarpophalangeal, 478, 650
 - in RA, 486
 - in scleroderma, 525
 - metatarsophalangeal, 209, 472, 974, 1026
 - in progressive systemic sclerosis, 1026
 - proximal, in scleroderma, 525
 - phalangeal, in thyroid acropachy, 588
- Joints (*cont'd*)
- in psoriatic arthritis, 677
 - in pyrophosphate arthropathy, 66
 - in RA, 340, 486
 - radionuclide scintigraphy of, 83
 - in Reiter's disease, 249
 - sacroiliac, 69, 221, 1260
 - in salmonella arthritis, 249
 - in scleroderma, 525
 - in SLE, 564
 - sternoclavicular, 467
 - temporomandibular, 353, 597
 - in yersinia arthritis, 249
- Joints and Synovial Fluid*, Volume II (book review), 1270
- Juvenile metabolic gout, caused by chronic compensated hemolytic syndrome, 1264
- Juvenile onset Still's disease, 647. *See also* Adult onset Still's disease; Rheumatic fever
- Juvenile rheumatoid arthritis. *See also* Rheumatoid arthritis
- alpha₁-antitrypsin phenotypes and, 1010
 - Epstein-Barr virus-inducible IgM anti-IgG in, 961
 - erythrocyte sedimentation rate in, 580
 - Gaucher's disease, type I, and interphalangeal joints in, 706
 - hip in, 1269
 - joints in, alpha₁-antitrypsin phenotypes and, 1011
 - lymphocytes in, 959
 - pauciarticular, 1045
 - pauciarticular-onset, IgM anti-IgG B lymphocytes in, 959
 - polyarticular, 1045
 - seronegative, tolmetin-induced thrombocytopenia in, 1144
 - polyarticular-onset
 - alpha₁-antitrypsin phenotypes in, 1011
 - IgM anti-IgG B lymphocytes in, 959
 - salicylates in, 32
 - seronegative
 - IgM anti-IgG B lymphocytes in, 959
 - polyarticular, tolmetin-induced thrombocytopenia in, 1144
 - systemic-onset, IgM anti-IgG B lymphocytes in, 959
 - seronegative enthesopathy and arthropathy in children and, 1144
 - seropositive, IgM anti-IgG B lymphocytes in, 959
 - systemic-onset
 - alpha₁-antitrypsin phenotypes in, 1011
 - IgM anti-IgG B lymphocytes in, 959
- Juxtaarticular deossification, in psoriatic arthritis, 335

K

- Kaolin absorption, in Sjögren's syndrome, 263
- Keratitis, in yersinia arthritis, 253
- Keratoconjunctivitis sicca
- dry mouth and, 157
 - Sjögren's sicca complex and, 156

Keratoconjunctivitis sicca (*cont'd*)
 Sjögren's syndrome and SS-B antibodies in, 662

Kidney. *See also* Renal
 in familial Mediterranean fever, 44
 immune complexes and in SLE, 880
 lupus thrombosis in, 117
 membrane attack complex and, 876
 in scleroderma, 525

Kidney disease
 interferon and, 396
 in SLE, 880

Kidney transplantation, interferon and, 396

Knee
 arthritis in caused by metastatic melanoma, 223
 canine, effect of salicylates on GAG synthesis in, 1084
 in hereditary chondrocalcinosis with vertebral ankylosis, 1259
 homologous type III collagen and, 274
 in hypertrophic osteoarthropathy, 1189
 in mycoplasma-induced arthritis, 937
 periostitis in, 1190
 tophi in, in gout, 472
 total arthroplasty of, amyloid in, in osteoarthritis, 204

Knee effusions, in psoriatic arthritis, 356

Knee joints, in mycoplasma-induced arthritis, 937

L

LA antibodies
 in neonatal lupus, 768
 in SLE, 767

LA antigens
 definition of, 1280
 molecular nature of, 770

Lability, pH, interferon and, 398

Lactic acid
 as marker for septic arthritis, 947
 in synovial fluid, 949

Lactic dehydrogenase
 in chronic liver disease and Still's disease, 580
 MSU-induced lysozymes and, 185

Late onset Still's disease. *See also* Adult onset Still's disease; Rheumatic fever; Still's disease
 tarsal arthritis with ankylosis in, 1254

LE. *See* Systemic lupus erythematosus

LE cells, in Reiter's syndrome, 238

Leg, in hypertrophic osteoarthropathy, 1190

Leukemia
 Gross virus and, 851
 T cell, presenting as chronic polyarthritis, 87

Leukocyte interferon, antibodies to in SLE and vasculitis, 396

Leukocytes
 in collagen arthritis, 913
 induction of rheumatoid factor in by aggregated IgG, 1108
 neutrophil, in adult onset Still's disease, 651

Leukocytes (*cont'd*)
 in palindromic rheumatism, 361
 polymorphonuclear, in CNS SLE, 586
 in psoriatic arthritis, 678
 in RA, 913
 in SLE, 381

Leukocytoclastic vasculitis, IgA and in spondylarthropathies, 144

Leukopenia
 penicillamine toxicity and, 920
 in SLE, 1036

Levamisole
 in Behçet's disease, 714
 in RA, 699
 monocyte cytotoxicity and, 10
 in SLE, 470

LEW/N rats, streptococcal cell wall-induced polyarthritis in, 1064

(LEW/N × F344/N) rats, chronic polyarthritis in, 1069

L-glutamine, DNA synthesis by rabbit articular chondrocytes and, 1217

Light microscopy, in experimental hydroxyapatite calcification, 1239

Link proteins, in cartilage, 1078

Lip biopsy, in Sjögren's syndrome, 419

Liver. *See also* Hepatic
 in arthritis-susceptible rats, 1068
 immune complexes in, 784
 immune deposits and, 884
 PEG assay in, 631
 Still's disease and, 579
 xanthine oxidase activity in Sprague-Dawley rats, 326

Liver biopsy, in chronic liver disease and Still's disease, 580

Liver disease
 autoimmune
 DNA binding in, 634
 PEG assay in, 631
 chronic, cryoprecipitates in, 1138

Liver function, in chronic liver disease and Still's disease, 580

Liver toxicity
 aspirin and, 1124
 NSAID and, 1124

Liver xanthine oxidase, in rats, 326

Localized subchondral resorption, in RA, 336

Low back pain. *See also* Backache
 in JRA, 1045
 in seronegative enthesopathy and arthropathy in children, 1041

Lpr gene, interleukin-2 and, 838

Lumbar spine, in psoriatic spondylitis, 102

Lung
 diffusion capacity of, 883
 in familial Mediterranean fever, 44
 hypertrophic osteoarthropathy in cyanotic congenital heart disease and, 1186

Lung (*cont'd*)

- immune deposits in, 882
- in scleroderma, 243, 522
- in Sjögren's-sicca syndrome, 159
- in SLE, 881
- Lung lesions, in progressive systemic sclerosis, 1174
- Lupus. *See* Discoid lupus erythematosus; Systemic lupus erythematosus
- Lupus autoantibodies, monoclonal, human, 744
- Lupus CNS disease, IgG antineuronal antibody in, 774
- Lupus erythematosus. *See* Central nervous system SLE; Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- Lupus exacerbations, oral contraceptives and, 618
- Lupus kidney. *See also* Central nervous system SLE; Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- thrombosis in, 117
- Lupus-like syndrome, in mice, 880, 882
- Lupus nephritis. *See also* Drug-induced interstitial nephritis; Heymann nephritis; IgA nephritis; Immune complex nephritis; Immune complex-induced nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
- classification of, 867
- complement in, 795
- DNA-anti-DNA complexes in, 873
- DNA-anti-DNA immune complexes in, 768
- focal segmental, 869
- glomerular sclerosis in, 871
- immune complexes in, 872
- immune deposits in, 870
- membrane attack complex in, 876
- membranoproliferative glomerulonephritis type I and, 869
- membranous, 869
- mesangial, 869
- pathologic features of, 867
- prognosis of, 870
- progression of, 870
- progressive renal failure in, 871
- proliferative glomerular lesions in, 872
- pyelonephritis in, 877
- renal abnormalities in, 870
- renal biopsy in, 867
- renal disease and, 869
- Ro-anti-Ro system in, 768
- transitions among forms of, 870, 873
- treatment of, 893
- tubulointerstitial changes in, 872

- Lupus nephropathy, oral contraceptives in, 618
- Lupus-related organic brain syndrome, 865. *See also* Childhood lupus erythematosus; Central nervous system SLE; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kidney; Lupus-like disease; Murine lupus; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- Lupus-related organ system involvement, as cause of death in SLE, 612
- Lupus Survival Study Group, 601
- Lymphadenopathy
- in chronic liver disease and Still's disease, 580
- immunoblastic, polyarthritis in, 1481
- Lymphatic obstruction, complication of thyroid acropachy, 588
- Lymphoblasts, in palindromic rheumatism, 362
- Lymphocyte blastogenesis, in steroid-treated RA, 713
- Lymphocyte membrane determinants, in SLE, 811
- Lymphocytes, 121
- in adult onset Still's disease, 651
- in ankylosing spondylitis, 221
- blastogenic responses to cyanogen bromide peptides and, 284
- in collagen arthritis, 914
- concanavalin-A-stimulated human, 168
- gold salts and, 288
- human, in SLE, 168
- immune function and, 488
- joint surgery and, 276
- in JRA, 959
- in palindromic rheumatism, 362
- peripheral blood, in Sjögren's syndrome, 419
- presenting as chronic polyarthritis in T cell leukemia, 87
- in RA, 914
- cytotoxicity and, 10
- in SLE, 811, 816, 828
- natural killer augmentation and, 562
- TNP auto-MLR and in SLE, 825
- Lymphocytic choriomeningitis virus. *See also* Viruses
- glomerulonephritis, interferon and in Swiss mice, 803
- Lymphocytotoxic antibodies, 830
- brain reactive, 773
- in SLE, 774, 828
- autologous mixed leukocyte reaction and, 381
- Lymphocytotoxicity
- in SLE, 817
- antibodies to beta 2 microglobulin and, 375
- Lymphoid cells, in SLE-like disease, 726
- Lymphoid hyperplasia, in murine lupus, 729
- Lymphokines
- in inhibition of C2 by gold sodium thiomalate, 288
- modulation of chondrocyte synthesis by, 668
- Lymphokine-stimulated human monocytes, inhibition of C2 by gold sodium thiomalate and, 288
- Lymphoma, spontaneous, Akv, Fv-1 and Rgv-1 loci and, 850

Lysosomes
 macrophages in RA and, 685
 in rat synovial cells, 913
Lysozymes, lactic dehydrogenase and, 185

M

- Macrophages
 autologous mixed lymphocyte reaction and, 820
 in cranial arthritis, 75
 human synovial cells and, 488
 in rheumatoid synovium, 685
 in SLE, 384
Major histocompatibility complex, 833
 in adjuvant arthritis, 1194
 mixed lymphocyte culture and, 1195
 in rat studies, 1065
Major histocompatibility complex-mediated immune hyper-responsiveness, SLE and, 1031
Malar rash, in SLE, 1036
Malignancy, SLE and, 612
Malignant hypertension
 in proliferative lupus nephritis, 872
 in scleroderma, 241
Malignant melanoma, in systemic necrotizing vasculitis, 475
Malondialdehyde, in SLE, 966
Malonic acid, in synovial fluid, 949
Mammoplasty, connective tissue disease after, 694
Manual of Rheumatology and Outpatient Disorders: Diagnosis and Therapy (book review), 1030
Mast cell degranulation, in adult onset Still's disease, 647
Mast cells, in adult onset Still's disease, 651
MB alloantigens, 835
MB phenotype, in SLE, 1031
MCTD. *See* Mixed connective tissue disease
Meclofenamate, thrombocytopenia and, 359
Melanoma
 malignant, in systemic necrotizing vasculitis, 475
 metastatic, arthritis caused by, 223
Membrane attack complex
 in discoid lupus erythematosus, 859
 in SLE, 858
 in SLE nephritis, 876
Membranoproliferative glomerulonephritis, type I, lupus nephritis and, 869
Membranous lupus nephritis, 868, 872. *See also* Drug-induced interstitial nephritis; Glomerulonephritis; Heymann nephritis; IgA nephritis; Immune complex nephritis; Immune complex-induced nephritis; Lupus nephritis; Mesangial lupus nephritis; Nephritis; Proliferative lupus nephritis
Membranous nephropathy, 876
Memory loss, NSAID and, 1013
Mendelian genetics, 833
Meniscectomy, immunity to homologous type III collagen after, in rabbits, 274
Meniscus, in mycoplasma-induced arthritis, 940
Mesangial deposits
 in membranous lupus nephritis, 873
 in SLE, 869
Mesangial lupus nephritis, 867. *See also* Drug-induced interstitial nephritis; Glomerulonephritis; Heymann nephritis; IgA nephritis; Immune complex nephritis; Immune complex-induced nephritis; Lupus nephritis; Membranous lupus nephritis; Nephritis; Proliferative lupus nephritis
Metabolic gout, juvenile, caused by chronic compensated hemolytic syndrome, 1264
Metacarpophalangeal joints
 adult onset Still's disease and, 650
 in RA, 486
 in scleroderma, 525
Metal chelators and hyaluronic acid, 1469
Metalloprotease, in human articular cartilage, 981
Metaphyseal bands, deossification and, 333
Metaphyseal cutback, 335, 337, 338
Metastatic melanoma, arthritis caused by, 223
Metatarsophalangeal joints
 articular cartilage in, 974
 asymptomatic, aspiration of in gout, 209
 in CREST syndrome, 1026
 tophi and in gout, 472
Methotrexate, intravenous, in RA, 339
Methyl methacrylate, cartilage loss and, 974
Methyldopa, in hypertensive scleroderma, 245
 RA and, 465
Mexican population, survival in SLE in, 608
Microglobulin, beta 2, antibodies to
 in ankylosing spondylitis, 375
 in SLE, 375
Minnesota Multiphasic Personality Inventory, to assess factors in fibrositis, 213
Mitogen activated PBM, in SLE sera, 818
Mitogen responsiveness, in RA, 17
Mitogen stimulated human PBM, in SLE sera, 817
Mitogen-stimulated mononuclear cells, DNA and in SLE, 304
Mitogens, autologous mixed lymphocyte reaction and, 121
Mitral valve, giant cell valvulitis in, 232
Mixed connective tissue disease, 754, 756, 889. *See also* Connective tissue disease; Overlap syndrome; Undifferentiated connective tissue disease
 anti-DNA in, 99
 cancer in, 1132
 diabetes mellitus and, 458
 expectation of cancer in, 1131
 extractable nuclear antigens and, 757
 nRNP antibodies in, 754, 758
 renal pathology in children, 758

- Mixed lymphocyte culture. *See also* Allogeneic mixed lymphocyte culture; Autologous mixed lymphocyte culture gold salts and, 288
major histocompatibility complex and in adjuvant arthritis, 1195
- Mixed lymphocyte reaction, 830. *See also* Allogeneic mixed lymphocyte reaction; Autologous mixed lymphocyte reaction
antigens in, 390
autologous, in SLE, 820
immune function of synovial cells and, 488
rheumatoid synovial cells and, 488
in SLE, 381
- MM phenotype, in JRA, 1010
- Molecular weight, of protein in cartilage, 1078
- Monarthritis, in RA, 485
- Monoclonal antibodies, 745, 765
autologous mixed lymphocyte reaction and, 821
DNA and, 750
to dsDNA, 749
to nucleic acid, 764
in Sjögren's syndrome, 419
T cells and, 822
- Monoclonal anti-DNA antibodies, 749
- Monoclonal autoantibodies, idiotypic analysis of, 745
- Monoclonal lupus autoantibodies, 744
- Monoclonal murine antibodies, to DNA, 751
- Monoclonal rheumatoid factor inhibition assay (mRF), 788
for immune complexes, in RA, 1156
- Monocyte complement stimulator, inhibition of C2 by gold sodium thiomalate and, 288
- Monocyte cytotoxicity, in RA, 10
- Monocyte/mononuclear cells, autologous mixed leukocyte reaction and, in SLE, 381
- Monocyte responsiveness, gold sodium thiomalate and, 288
- Monocytes
cytotoxicity of in RA, 10
gold salts and, 288
human, inhibition of C2 by gold sodium thiomalate and, 288
in palindromic rheumatism, 362
- Mononuclear cells
blastogenic responses of
to cartilage proteoglycan, 284
to collagen, 279, 281, 283
in CAEV arthritis in goats, 930
natural killer cell activity of, 1440
in palindromic rheumatism, 361
peripheral blood, chondrocyte synthesis and, 668
in progressive systemic sclerosis, 390
in SLE, 168, 304
abnormal nucleic acids in, 304
autologous mixed leukocyte reaction and, 381
circulating, serum antinuclear antibodies and, 310
mitrogen-stimulated, DNA and, 304
nucleic acid in, 306
- Mononuclear leukocytes, IgM and IgM rheumatoid factors in RA, 150
- Mononuclear phagocytes, immobilization by benoxaprofen, 1486
- Mononuclear phagocytes system, 783
- Mononucleosis, infectious, interferon and, 396
- Monosodium urate, superoxide anion generation and, 174
- Monosodium urate crystals (MSU)
platelet stimulation of and protein interactions, 508
respiratory burst and, 181
superoxide anion generation and, 174
- Monozygotic twins, HLA-B27 in, 1490
- Morning stiffness, in RA, 340, 481, 699, 701
- Mortality. *See also* Survival rates
in murine lupus, 721
RA and, 1020
in SLE, 601
in Asians, 414
- Mouse studies, 749. *See also* AKR mice; BXSB mice; BXSB/Mp mice; C57BL6 mice; C57BL6-1pr mice; C57BR mice; C3H/Bi mice; CBA/N mice; DBA/2 mice; DBA/2/xid/xid mice; 1pr/1pr mice; MRL mice; MRL/l mice; MRL-1pr mice; MRL/1pr/1pr mice; MRL-+/+ mice; MRL/Mp-1pr/1pr mice; MRL/Mp/1pr/1pr mice; MRL/Mp-+/+ mice; Murine autologous mixed lymphocyte reaction; Murine lupus; New Zealand mice; NIH mice; NZB mice; (NZB \times DBA/2) F₁ mice; (NZB \times NZW) F₁ mice; NZB \times W mice; ZB \times WF₁ mice; NZB/W mice; NZB/W F₁ mice; NZB/NZW F₁ mice; NZB/xid mice; NZB/xid/xid mice; NZW mice; Recombinant inbred (RI) lines of mice; Swiss mice
immune regulation in, 740
intervertebral discs of, 710
lupus-like syndrome in, 880, 882
spontaneous lupus-like disease in, 880
- Mouth ulcers, penicillamine toxicity and, 920
- MP phenotype, in JRA, 1010
- MPG. *See* Tiopronin
- mRF. *See* Monoclonal rheumatoid factor inhibition assay
- MRL mice
antibodies in, 764
cellular characteristics of, 729
glomerulonephritis in, 727
IgG in, 728
immune complexes in, 728
interleukin-2 and, 838
nRNP antibodies in, 759
Sm antibodies in, 759
T cells in, 728
thymus in, 726
MRL/1 mice, 721
anti-Sm antibody in, 761
T cells in, 726
- MRL-1pr mice
autoimmune disease in, 839
interleukin-2 and, 840

- MRL/lpr/lpr mice
 DNA antibodies and, 749
 effect of *xid* gene on, 737
 SLE-like disease in, 734
- MRL-+/+ mice, interleukin-2 and, 839
- MRL/Mp/lpr/lpr mice, neonatal thymectomy in, 736
- MRL/Mp-lpr/lpr mice
 bacterial lipopolysaccharide in, 726
 bone marrow transfers in, 731
 glomerulonephritis in, 728
 lipopolysaccharide in, 726
 pathogenetic factors in SLE in, 734
 SLE-like disease in, 729
 survival rates of, 727
 thymus in, 726
- MRL/Mp-+/+ mice
 bone marrow transfers in, 731
 SLE in, 734
 survival rates of, 727
 thymus in, 726
- MS phenotype, in JRA, 1010
- MSU. *See* Monosodium urate crystals
- MT phenotype, in SLE, 1031
- MT alloantigens, 835
- Mucocutaneous manifestations, in Reiter's disease, 249
- Multicenter Lupus Survival Study Group, 601
- Multiplication-stimulating activity, DNA synthesis by rabbit articular chondrocytes and, 1217
- Multivitamins, in RA, 465
- Mumps virus, IgG and IgM antibodies to in Sjögren's syndrome, 262
- Murine autologous mixed lymphocyte reaction, 124
- Murine lupus, 721. *See also* Central nervous system SLE; Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Neonatal lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
 essential fatty acid deficiency and, 808
 frentizole treatment of, 1291
 genetic analysis and, 724
 prostaglandins, immune response and, 804
 sex steroid hormones and, 838
 thymus in, 726
- Murine lymphoid organs, production of interleukin-2 by, 840
- Murine monoclonal antibodies
 in BXSB mice, 750
 DNA and, 749
- Murine SLE. *See* Murine lupus
- Muscle
 in childhood dermatomyositis, 126
 in progressive systemic sclerosis, 61
 in tropical pyomyositis, 107
- Muscle biopsy, in childhood dermatomyositis, 126
- Muscle damage, myoglobin levels in, 1419
- Muscle fibers, in esophagus in scleroderma, 1117
- Muscle involvement, in SLE, 564
- Muscle strain, prevalence of in private practice of rheumatology, 718
- Musculoskeletal inflammation, NSAID and, 596
- Musculoskeletal pain, psychologic disturbance and in fibrositis, 213
- Musculoskeletal system, in scleroderma, 243
- Myalgia, in Sjögren's syndrome, 421
- Myasthenia gravis
 DNA binding in, 634
 interferon and, 396
 PEG assay in, 631
- Mycobacterium in adjuvant polyarthritis, 1325
- Mycoplasma arthritidis*, in chronic arthritis in rabbits, 937
- Mycoplasma antigens, in chronic arthritis, 937
- Myocardial infarction, SLE and, 612
- Myocarditis, diagnosis of, 474
- Myoglobin, circadian variations in, 1419
- Myopathy, in childhood dermatomyositis, 126
- Myositis. *See also* Dermatomyositis; Polydermatomyositis; Polymyositis
 in Behçet's disease, 1025
 localized, presenting as pseudothrombophlebitis, 1374
 in scleroderma, 525
- MZ phenotype, in JRA, 1010

N

- Nailfold capillary abnormalities
 in childhood dermatomyositis, 954
 in Raynaud's phenomenon, 889
- Nailfold capillary microscopy, in connective tissue diseases, 597
- Naproxen, cognitive dysfunction and, 1013
 in RA, 465
 and renal disease, 1016
- National Center for Health Statistics, mortality from SLE in Asians and, 414
- National Institutes of Health, 896
- Native DNA. *See also* Anti-DNA; Anti-dsDNA; Antinative DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Single-stranded DNA
 antibodies to, 1003
 DLE and, 639
 in murine lupus, PGE1 and, 806
 mononuclear cells and in SLE, 311
- Native DNA antibodies, 753
 in SLE, 304, 312, 788
- Native DNA IgG antibody, mononuclear cells and in SLE, 312
- Natural killer activity
 cellular cytotoxicity in RA and, 10
 of mononuclear cells, 1440
 in SLE, 562
- Natural killer (NK) cells, in SLE, 562, 811
- nDNA. *See* Native DNA

- Neck, noncollagenous proteins in, 1081
- Necrosis, in CAEV arthritis, 930
- Necrotic pseudo folliculitis, in Behcet's disease, 714
- Necrotizing arteritis, in proliferative lupus nephritis, 872
- Neisseria gonorrhoeae*
gonococcal arthritis-dermatitis syndrome and, 575
in septic arthritis, 948
- Neonatal lupus, 768. *See also* Central nervous system SLE;
Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Subacute lupus erythematosus; Systemic lupus erythematosus
- Neonatal thymectomy, SLE-like disease and, 734, 735
- Neoplasia, systemic vasculitis and, 475
- Nephritis. *See also* Drug-induced interstitial nephritis; Heymann nephritis; IgA nephritis; Immune complex nephritis; Immune complex-induced nephritis; Lupus nephritis; Membranous lupus nephritis; Mesangial lupus nephritis; Proliferative lupus nephritis
active, as cause of death in SLE, 612
anti-Ro and, 768
DNA antibodies and, 749
Heymann, 873
IgA, seronegative spondylarthropathies and, 144
immune complex, 882
interferon and, 396
in SLE, 383, 410, 768, 795, 1035
steroid bolus treatment in, 892
- Nephropathy
in ankylosing spondylitis, 1510
lupus, oral contraceptives in, 618
- Nephrotoxicity, membrane attack complex and, 876
- Nerve fibers, in esophagus in systemic sclerosis, 1120
- Nerve growth factor, DNA synthesis by rabbit articular chondrocytes and, 1217
- Nervous system. *See also* Central nervous system
cauda equina syndrome and, 349
granulomatous angiitis of, 342
- N-ethylmaleimide, in SLE, 966
- Neurocytotoxic antibodies, SLE and, 773
- Neurologic involvement, in SLE, 410
- Neuronal antigens
immunoprecipitation of, 776
in SLE, circulating antibodies and, 865
- Neuronal cell membranes, in SLE, antibodies to, 774
- Neuropathy, peripheral, in Sjögren's syndrome, 421
- Neuropsychiatric involvement, in SLE, 410
- Neutrophil lysis, in adult onset Still's disease, 647
- Neutrophils
in adult onset Still's disease, 651
human
respiratory burst in, 181
superoxide anion generation and, 174
human glomerulonephritis and, 878
PGE1 and, 807
- Neutrophils (*cont'd*)
in Yersinia arthritis, 655
- Newborn infants, maternal ankylosing spondylitis and, 140
- New Zealand mice. *See also* NZ; NZB; NZW
retroviruses in, 852
type C virus particles in, 850
- Nicotinamide adenine dinucleotide, hepatic xanthine oxidase in Sprague-Dawley rats and, 326
- Nifedipine, in digital ulcers in scleroderma, 1267
- NIH mice, viruses in, 850
- Nitrates, in hypertensive scleroderma, 245
- Nitroblue tetrazolium reduction, respiratory burst and, 181
- Nitroprusside, in hypertensive scleroderma, 245
- N-[2-mercaptopropionyl] glycine, in RA, 698
- Nodular polyarthritis, 88
- Nodules
biopsy of, in RA, 481
dermohypodermic, in Behcet's disease, 714
in RA, 485
gold therapy and, 546
subcutaneous, 151, 481, 502
rheumatoid, 478
T cell leukemia and, 87
tophaceous, 478
- Noncollagenous protein, 1078
- Noncompliance, in RA, 700
- Nonhistone antigens, antibodies to, 754, 755
- Nonmodified autologous non-T cells (auto-MLR), 824
- Nonreducible rotational head tilt in RA, 1316
- Nonsteroidal antiinflammatory drugs (NSAID), 596. *See also* Antiinflammatory drugs; Aspirin; Buffered aspirin; Drugs; Salicylates
benoxaprofen, 595, 1486
cognitive dysfunction in elderly and, 1013
liver toxicity and, 1124
penicillamine and, 1016
in RA, 112, 699
Epstein-Barr virus and, 427
genetic predictors and, 370
in SLE, 410
- Nonsteroidal oral contraceptive therapy, in SLE, 618
- nRNP. *See* Nuclear ribonucleoprotein
- NSAID. *See* Nonsteroidal antiinflammatory drugs
- NSD/N rats, polyarthritis in, 1069
(NSD/N \times F344/N rats), chronic polyarthritis in, 1069
- Nuclear antigens, 755
in extrarenal immune deposits, 882
nonhistone, 754
in Sjögren's syndrome, 767
- Nuclear fractions, steroid receptors in adult canine articular cartilage and, 568
- Nuclear proteins, 762
- Nuclear ribonucleoprotein (nRNP)
antibodies to, 1003
clinical disease and, 757
- Nuclear ribonucleoprotein (nRNP) antibodies, 754

Nuclear ribonucleoprotein (nRNP) antibodies (*cont'd*)
 in insulin-resistant connective tissue disease, 458
 in mixed connective tissue disease, 754
 in MRL mice, 759
 in rheumatic diseases, 758
 Nuclear ribonucleoprotein (nRNP) antigens, biochemical characterization of, 859
 Nucleic acid, in peripheral blood mononuclear cells in SLE, 304
 Nucleic acids, 762, 764
 as antigens and adjuvants, 739
 chondrocyte synthesis and, 668
 monoclonal antibodies to, 764
 in SLE, antibodies to, 739
 Null cells, autologous mixed leukocyte reaction and in SLE, 381
 NZ mice, 726. *See also* New Zealand mice
 NZB mice, 724. *See also* New Zealand mice
 B cell hyperactivity and autoimmunity in, 727
 ecotropic viruses and, 853
 frentizole treatment in, 1291
 interleukin-2 and, 840
 murine SLE in, 734
 spontaneous xenotropic virus in, 853
 (NZB \times DBA/2) F₁ mice. *See also* New Zealand mice
 tolerance to bovine gamma globulin in, 736
 (NZB \times NZW) F₁ mice. *See also* New Zealand mice
 effect of thymectomy on, 729, 736
 SLE-like disease in, 734
 NZB \times W mice, SLE-like disease in, 730. *See also* New Zealand mice
 NZB \times WF₁ mice, 721. *See also* New Zealand mice
 NZB/NZW F₁ mice, 749. *See also* New Zealand mice
 DNA antibodies and, 749
 interleukin-2 and, 838
 NZB/W mice. *See also* New Zealand mice
 PGE₁ and immune responses in, 806
 T and B cell activity and PGE₁ in, 806
 NZB/W F₁ mice. *See also* New Zealand mice
 thymus in, 726
 NZB/*xid* mice. *See also* New Zealand mice
 autoimmune markers in, 737
 NZB/*xid/xid* mice, 735. *See also* New Zealand mice
 NZW mice. *See also* New Zealand mice
 SLE in, 734

O

OA. *See* Osteoarthritis
 Ocular inflammation, in RA, 914
 ODFR. *See* Oxygen-derived free radicals
 Oil, rapeseed, toxic synovitis from, 1477
 OKT-positive cells, in Sjögren's syndrome, 419, 422
 OKT5 suppressor lymphocytes, 830
 Olecranon bursitis, CPPD and, 989

Oligoarthropathy, seronegative enthesopathy and arthropathy, in children, 1041
 Oncogenicity, antirheumatic drugs and, 596
 Oraflex. *See* Benoxaprofen
 Oral contraceptives, in SLE, 618
 Oral gold. *See also* Auranofin; Aurothiomalate; Chrysotherapy; Gold salts; Gold sodium thiomalate; Gold therapy; Injectable gold preparations
 in RA, 595
 Oral prednisone, in SLE, 893
 Organic psychosis, survival in SLE and, 606
 Oriental populations, survival in SLE in, 608
 Oropharyngeal Epstein-Barr virus excretion, in RA, 427
 Orthopedic surgeons, referrals to rheumatologists by, 718
 Osteoarthritis. *See also* Degenerative joint disease
 amyloid and CPPD in, 204
 amyloid deposits and, 204
 benoxaprofen in, 595
 epidemiology of, 1150
 Epstein-Barr virus and, 427
 immunity to proteoglycans and, 274
 knee effusions in, 356
 liver toxicity from NSAID in, 1124
 metalloprotease and, 981
 plasminogen activator activity and, 435
 proteoglycans in, 125
 septic arthritis in, 948
 in Sjögren's-sicca syndrome, 159
 unproven remedies in, 1145
 Osteoarthropathy, hypertrophic, in cyanotic congenital heart disease, 1186
 Osteomalacia, fish vertebrae in, 1073
 Osteomyelitis
Pseudomonas aeruginosa, 1403
 sternum, 346
 vertebral, bacterial endocarditis and, 600
 Osteopenia, in RA, 914
 Osteopetrosis, "rugger jersey" and, 1028
 Osteoporosis
 fish vertebrae in, 1073
 in lower limb amputees, 80
 periarticular, 1482
 Overlap syndromes. *See also* Connective tissue disease; Mixed connective tissue disease; Undifferentiated connective tissue disease
 histone antibodies in, 407
 Oxygen, arterial, in hypertrophic osteoarthropathy, 1186
 Oxygen consumption, monosodium urate stimulated, 181
 Oxygen-derived free radicals (ODFR), and degradation of hyaluronic acid, 1469

P-Q

Paganini, the hand of, 1385
 Pain
 chronic, pyrophosphate arthropathy and, 66

- Pain (*cont'd*)
 epigastric, 700
 joint, and "pseudosarcoidosis," 1396
 in RA, 699, 701
- Palindromic rheumatism, clinical, synovial fluid and biopsy studies in, 361
- Pancake vertebrae, 1077
- Pancreatitis
 azathioprine-induced, 1149
 in SLE, 1006
- Pannus, in collagen arthritis and RA, 913
- Pannus invasion of bone, after meniscectomy in rabbits, 277
- Paramyxovirus nucleocapsids, 847
- Paraparesis, spinal cord block in ankylosing spondylitis and, 218
- Parathyroid hyperplasia, in pyrophosphate arthropathy, 66
- Parotid gland
 in primary biliary cirrhosis and Sjögren's syndrome, 1251
 swelling, in Sjögren's-sicca syndrome, 159
- Pasteurella multocida*, in septic sternoclavicular arthritis, 467
- Pathophysiology of circulating immune complexes, 783
- Patient Compliance* (book review), 1390
- Patient education
 improving cooperation in treatment regimens, 447
 package inserts in new drugs, 1124
- Pauciarticular onset JRA
 alpha₁-antitrypsin phenotypes in, 1011
 B cells in, 959
 seronegative, IgM anti-IgG B lymphocytes in, 962
- PBM. *See* Peripheral blood mononuclear cells
- PEG assay. *See* Polyethylene glycol assay
- Pelvis
 above knee cartilage in above-knee amputees, 81
 in ankylosing spondylitis, 221
- "Pencil pointing," in radiologic diagnosis of arthritis, 333
- Penicillamine
 chemical structure of, 699
 in collagen arthritis, 913
 and degradation of hyaluronic acid, 1469, 1473
 hypocupremia-related hypochromic anemia and, 119
 NSAID and, 1016
 in RA, 111, 427, 465
 influence of gold therapy on adverse effects of, 917
 renal disease induced by, 1016
 in scleroderma, 247
 tiopronin and, 695, 923
 toxicity, gold therapy and, 917
- Penicillin, Schönlein-Henoch syndrome in familial Mediterranean fever and, 42
- Pepsinogen I, in rheumatic disease, 1059
- Peptic ulcers, NSAID and, in RA, 370
- Peptide growth factors, purified, effect on sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Peptides
 cyanogen bromide, T cells and, 284
- Peptides (*cont'd*)
 homologous type III collagen and, 274
- Periarticular osteoporosis, 1482
- Pericarditis
 rheumatic, immunopathology of, 1054
 in SLE, 410
- Periosteal new bone formation, in collagen arthritis, 914
- Periosteum, in hypertrophic osteoarthropathy, 1186, 1187
- Periostitis, in hypertrophic osteoarthropathy, 1188
- Peripheral arthritis, beta 2 microglobulin and in ankylosing spondylitis, 375
- Peripheral blood leukocytes, in T cell leukemia presenting as chronic polyarthritis, 87
- Peripheral blood lymphocytes
 concanavalin A-induced suppressor cell activity and in RA, 358
 immune function of synovial cells and, 488
 in JRA, 959
 plaque-forming cells in, 815
 in Sjögren's syndrome, 419
- Peripheral blood mononuclear cells. *See also* Mononuclear leukocytes
 chondrocyte synthesis and, 668
 in familial Mediterranean fever, 471
 in progressive systemic sclerosis, 390
 in SLE, 168
 abnormal nucleic acids in, 304
- Peripheral blood mononuclear leukocytes, human, rheumatoid factor, aggregated IgG and, 1108
- Peripheral joint disease, collagen arthritis as, 911
- Peripheral loop deposits, in SLE, 873
- Peritoneal dialysis, in familial Mediterranean fever, amyloidosis, and chronic renal failure, 38
- Perivascular fibrin deposition, in adult onset Still's disease, 647
- Perivascular space, in adult onset Still's disease, 651
- Peritoneum
 immune deposits in, 884
 in SLE, 882
- Peritubular deposits, of membrane attack complex, 876
- Personality changes, in elderly from NSAID, 1013
- PGE. *See* Prostaglandin E
- PGE1. *See* Prostaglandin E1
- PGE2. *See* Prostaglandin E2
- pH lability, interferon and, 398
- Phagocytes
 immobilization by benoxaprofen, 1486
 in palindromic rheumatism, 361
- Phagocytic function, effect of gold sodium thiomalate on, 294
- Phagocytosis
 gold salts and, 288
 in palindromic rheumatism, 361
 respiratory burst and, 181
- Pharyngitis, in chronic liver disease and Still's disease, 580
- Phenotypes, alpha₁ antitrypsin and eye disease, 1431

- Phenylbutazone, unproven remedies and, 1146
- Philadelphia, Pennsylvania, medical traditions in, 895
- Phospholipids, antinuclear antibody reactions and, 745
- Phytohemagglutinin
 chondrocyte synthesis and, 668
 in SLE, 304
- Pima Indians
 complement activation in, 175
 men, HLA-B27 positive, sacroiliitis in, 235
- Piroxicam, genetics and in RA, 370
- Pituitary fibroblast growth factor
 DNA synthesis by rabbit articular chondrocytes and, 1217
 in sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Placenta-eluted gamma globulins in RA, 17
 clinical data, 19
- Placental gamma globulins, in RA, 1024
- Plaque-forming cells
 induced by aggregated IgG, 1108
 in SLE, 168, 815
 spontaneous, 307
- Plaquenil, in SLE, 383
- Plasma
 fibronectin in, 25
 rheumatoid, fibrinogen and, 25
- Plasma androgens, in women with SLE, 454
- Plasma creatinine, in women with SLE, 455
- Plasma exchange therapy. *See* Plasmapheresis
- Plasma fibronectin, molecular weight of, 25
- Plasma hormone, in women with SLE, 454
- Plasma renin, in hypertensive scleroderma, 243-244
- Plasmapheresis, in SLE, 894
- Plasminogen activator activity, of human synovial fibroblasts by retinoids, 432
- Plasterer's tophi, 472
- Platelet aggregation, in SLE, 966
- Platelet-derived growth factor
 DNA synthesis by rabbit articular chondrocytes and, 1217
 in sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Platelet lysate, DNA synthesis, GAG synthesis and, 1228
- Platelet membrane proteins, antibodies, ³H-serotonin and, 517
- Platelet membrane stimulation, urate crystal, protein interactions and, 508
- Platelet-poor human plasma, effect of on response of chondrocytes to platelet-derived growth factor, 1232
- Platelet proteins, chymotrypsins and, 515
- Platelet response, to urate, 508
- Platelet stimulation, by MSU crystals, 508
- Pleocytosis
 in central nervous system SLE, 583
 synovial, in Behcet's disease, 235
- Pleurisy, in SLE, 383, 410
- PMN. *See* Polymorphonuclear leukocytes
- Podagra, in gout, 211
- Pokeweed mitogen
 IgM and IgM rheumatoid factors and in RA, 150
 T cells and in Sjögren's syndrome, 419
- Poly I-poly C, 811
- Polyarteritis nodosa, antidiuretic hormone secretion in, 118
- Polyarthralgia, 83
- Polyarthritis, 769. *See also* Arthritis; Monarthritis
 in adult onset Still's disease, 647
 with birefringent lipid, 1365
 chronic, in rats, 1064
 CP-20961 induced, 271
 in immunoblastic lymphadenopathy, 1481
 nodular, 88
 in RA, 485
 in SLE, 1036
 streptococcal cell wall-induced in rats, 1064
 synovial fluid immune complexes in, 574
 T cell leukemia and, 87
- Polyarteritis nodosa, 1425
- Polyarticular gout, tophi in, 472
- Polyarticular gouty arthritis, tophaceous, nodules in, 478
- Polyarticular-onset JRA
 alpha₁-antitrypsin phenotypes in, 1011
 IgM anti-IgG B lymphocytes in, 962
- Polychondritis, in collagen arthritis, 914
- Polyclonal B cell activators, 734, 737
- Polyclonal B cell hyperactivity, 847
- Polydermatomyositis. *See also* Dermatomyositis; Myositis;
 Polymyositis; Pyomyositis
 childhood, histopathology in, 126
- Polyethylene glycol assay, ssDNA/anti-DNA complexes detected by, 642
- Polyethylene glycol precipitation assay, to measure antibodies to dsDNA in SLE, 631
- Polymorphonuclear leukocytes
 in CNS SLE, 586
 in collagen arthritis, 913
 human, superoxide anion generation and, 174
 in palindromic rheumatism, 362
 in psoriatic arthritis, 678
 in RA, 913
 in yersinia arthritis, 655
- Polymyalgia rheumatica, 83
 anti-DNA in, 999
 treatment of, 120
- Polymyositis, 1131. *See also* Dermatomyositis; Myositis;
 Polydermatomyositis; Pyomyositis
 cancer in, 1132
 circadian variations of myoglobin in, 1419
 heart in, 473
 idiopathic, resemblance to tropical pyomyositis, 107
- Polypeptides, urate crystals and in protein interactions, 508
- Polyserositis, recurrent, 1150
 plasma colchicine concentrations in, 227
- Polytropic viruses, 850
- Population studies, lupus and, 834

- Porphyria, acute intermittent, SLE and, 1134
 Post-mammoplasty connective tissue disease, 694
 Postpartum anterior uveitis, ankylosing spondylitis and, 140
 Prazosin, in hypertensive scleroderma, 245
 Prednisolone, plasminogen activator activity and, 438
 Prednisone
 in juvenile dermatomyositis, 1096
 in pancreatitis in SLE, 1008
 in polymyalgia rheumatica, 120
 in RA, 112, 427, 465, 699, 701
 in SLE, 309, 383, 564, 893, 970
 oral contraceptives and, 621
 unproven remedies and, 1146
 Pregnancy
 ankylosing spondylitis during, 140
 SLE and, 410
 Primary biliary cirrhosis, 1250
 Primary Sjögren's syndrome, lymphocytes in, 419
 Private practice of rheumatology, 718
 Procainamide, 857
 suppressor cell activity and, 238
 Progesterones
 canine articular cartilage and, 568
 plasminogen activator activity and, 438
 Progesterone oral contraceptives, in SLE, 618
 Progressive glomerular sclerosis, in lupus nephritis, 872
 Progressive renal failure. *See also* Renal failure
 in lupus nephritis, 871
 sclerosis and in SLE, 871
 Progressive systemic sclerosis, 1131. *See also* Scleroderma;
 Systemic sclerosis
 allogeneic mixed lymphocyte reaction in, 390
 arthropathy of, 1026
 autoantibodies in, 1174
 autologous mixed lymphocyte reaction in, 390
 bony ankylosis of hips in, 1497
 cancer in, 1132
 circulating immune complexes in, 1174
 clinical features of, 1175
 complement in, 1174
 CREST syndrome in, 1168
 diffuse, 1167
 E rosettes in, 390
 electromyographic findings in, 61
 esophagus in, 1117
 extensor tendon rupture, amyloid and, 1141
 fluid-phase conglutinin assay in, 1174
 giant cell arteritis and, 717
 HLA-DR5 in, 390
 immune complexes in, 1167, 1174
 joint changes in, 1026
 lung involvement in, 1174
 mononuclear cells in, 390
 myocarditis in, 473
 peripheral blood mononuclear cells in, 390
 serum immune complexes in, 1167
 Progressive systemic sclerosis (*cont'd*)
 sheep red blood cell rosettes and, 390
 T cells in, 390
 Proinsulin, DNA synthesis by rabbit articular chondrocytes
 and, 1224
 Prolactin, in adjuvant arthritis, 591
 Proliferative glomerulonephritis, focal, 144
 Proliferative lupus nephritis, 867. *See also* Drug-induced
 interstitial nephritis; Heymann nephritis; IgA nephritis;
 Immune complex-induced nephritis; Immune complex
 nephritis; Lupus nephritis; Membranous lupus nephri-
 tis; Mesangial lupus nephritis; Nephritis
 antibodies to DNA in, 873
 crescents in, 871
 diffuse, 870
 arteriolitis in, 872
 necrotizing arteritis in, 872
 glomerular sclerosis in, 871
 vasculitis in, 872
 Proliferative responses, in SLE, 825
 Proliferative T cell responses, immune function and, 495,
 499, 826
 Properdin, inflammation and, 861
 Properdin system. *See* Complement C3
Propionibacterium acnes, as cause of osteomyelitis of cervi-
 cal spine, 346
 Propranolol, in hypertensive scleroderma, 245
 Prostaglandin E
 inflammation and, 805
 in rheumatoid synovium, 685
 Prostaglandin E1, 805
 Prostaglandin E2
 in collagen arthritis, 913
 collagen-producing fibroblasts and in scleroderma, 189
 ³H-thymidine and, 194
 in RA, 913
 in rats, 805
 Prostaglandins
 immune response, murine lupus and, 804
 in SLE, 966
 Prostanoid acid, 805
 Protease
 in human articular cartilage, 981
 plasminogen activator activity and, 432
 Protein
 aggregated, 785
 anticomplementary activity and, 1139
 in baboon studies, 1078
 in cartilage, 1078
 articular, 979
 cerebrospinal fluid in, 586
 chondrocyte synthesis and, 668
 enzyme, hepatic xanthine oxidase in Sprague-Dawley rats
 and, 326
 gamma carboxyglutamic acid in, in childhood dermatomy-
 ositis, 1094

Protein (*cont'd*)

- gold sodium thiomalate, C2 and, 293
- interferon, in SLE and vasculitis, 396
- noncollagenous, 1078
- nuclear, 762
- platelet stimulation by urate crystals and, 508
- in rheumatoid plasma and synovial fluid, 26
- serum, in RA, gold therapy and, 540
- in SLE, 624
- in synovial fluid, 951
- xanthine oxidase, in Sprague-Dawley rats, 326
- Protein adsorption, superoxide anion generation and, 174
- Protein interactions, urate crystals and, 508
- Protein synthesis
 - in CSF in SLE, 864
 - fibroblasts and, 191
 - plasminogen activator activity and, 432
 - salicylate and xyloside in, 1084
- Proteinase degradation, homologous type III collagen and, 274
- Proteinuria
 - auranofin and, 596
 - penicillamine toxicity and, 920
 - in RA, 700, 702
 - in SLE, 893
 - oral contraceptives, 621
 - survival and, 601
- Proteoglycan synthesis
 - cartilage, blastogenic responses to, 283-284
 - effect of aspirin on, 1337
 - effect of beta-D-xylopyranoside and salicylates on, 1089
 - immunity to after meniscectomy in rabbits, 274
 - rheumatoid synovial cells and, 196
 - sulfated, effect of purified growth factors on rabbit articular chondrocytes in, 1228
- Proteoglycans
 - in human articular cartilage, 981
 - in OA cartilage, 125
 - sulfated, in rheumatoid synovial cells, 196
 - xyloside and in cartilage, 1084
- Proximal interphalangeal joints, 478
 - in RA, 699, 701
- Pseudogout. *See also* Calcium pyrophosphate dihydrate crystal (CPPD) deposition disease; Chondrocalcinosis; Hereditary chondrocalcinosis; Hereditary pyrophosphate arthropathy and colchicine, 1509
 - inflammatory arthritis in, 948
 - joint effusions in, 98
 - lactic acid in, 950
 - succinic acid in, 950
- Pseudolymphoma, in Sjögren's syndrome, 419
- Pseudomonas aeruginosa* osteomyelitis, immune complexes in, 1403
- "Pseudosarcoidosis," clinical description of, 1396

Pseudothrombophlebitis

- in Behcet's syndrome, 477
- localized myositis presenting as, 1374
- Psoriasis
 - IgA nephropathy and, 144
 - microvascular changes in, 677
- Psoriatic arthritis
 - deossification in, 335, 337
 - HLA typing in, 678, 1389
 - inflammatory arthritis in, 948
 - knee effusions in, 346
 - lactic acid in, 950
 - succinic acid in, 950
 - vascular changes in, 677
- Psoriatic arthritis synovium, vascular changes in, 677
- Psoriatic spondylitis, subaxial cervical subluxation and cord suppression in, 101
- Psychologic disturbance, fibrositis and, 213
- Psychological stress, in collagen arthritis, 913
- Psychosis, organic, survival in SLE and, 606
- Puerto Rican population, survival in SLE in, 608
- Pulmonary blood flow, in hypertrophic osteoarthropathy, 1191
- Pulmonary capillary bed, hypertrophic osteoarthropathy and, 1186
- Pulmonary diffusion capacity, antibodies to collagen in scleroderma and, 522
- Pulmonary embolism, as cause of death in SLE, 613
- Pulmonary involvement. *See also* Lung
 - in scleroderma, 522, 1167
 - in scleroderma esophageal disease, 1118
- Purified growth factors, effect of on rabbit articular chondrocytes, 1217, 1228
- Purified peptide growth factor, effect of on sulfated proteoglycan synthesis on rabbit articular chondrocytes, 1228
- Purine metabolism, erythrocytes in, in secondary juvenile metabolic gout, 1265
- Purine nucleotide synthesis, in skin fibroblasts in juvenile metabolic gout, 1265
- Purpura, 769
- Putrescine, DNA synthesis by rabbit articular chondrocytes and, 1217
- Pyelonephritis, 872
 - in SLE nephritis, 877
- Pyomyositis. *See also* Dermatomyositis; Myositis; Polydermatomyositis
 - tropical, 107
- Pyrimethamine, chemical structure of, 699
- Pyrophosphate arthropathy, 66
- Pyruvic acid, in synovial fluid, 949

Q

- Questionnaires, in rheumatology education, 92

R

- RA. *See* Rheumatoid arthritis

- Rabbit articular chondrocytes, effect of purified growth factors on, 1217, 1228
- Rabbit studies
 ascorbate stimulation of DNA synthesis, 318, 531
 chronic mycoplasma-induced arthritis in, 937
 chronic serum sickness, 880
 experimental hydroxyapatite calcification, 1239
 immunity to homologous type III collagen after meniscectomy in, 274
 neuronal membrane antigens, 777
- Race, SLE and, 55
 survival in, 601
- Radicals, oxygen-derived free, and degradation of hyaluronic acid, 1469
- Radioimmunoassay
 for anti-F(ab')₂ antibodies, 1299
 for C4, 161
 to detect anti-Sm activity, 765
 in post-mammoplasty connective tissue disease, 695
 quantitation of rat liver xanthine oxidase by, 326
 in RA, 799
 for soluble immune complexes, 801
- Radiologic vignette
 fish vertebrae, 1073
 vascular influence on patterns of deossification, 333
- Radionuclide joint scintigrams, predictive value of, 83
- Radiosulfate
 ascorbate stimulation of DNA and, 322
 proteoglycan synthesis and, 1128
- Raji cell assay
 in diffuse scleroderma, 1167
 in eosinophilic fasciitis, 1180
 in progressive systemic sclerosis, 1167
 in RA, 1156
- Rapeseed oil, synovitis from 1477
- Rapid electron microscopic analysis, in diagnosis of joint effusions, 98
- Rash
 in adult onset Still's disease, 647
 in chronic liver disease and Still's disease, 580
 malar
 in CNS SLE, 586
 in SLE, 383, 1036
 penicillamine toxicity and, 920
 photosensitive, in SLE, 1036
 in RA, 700, 702
 in SLE, 383, 410, 1036
- Rat liver xanthine oxidase, quantitation of by radioimmunoassay, 326
- Rat studies. *See also* Adjuvant arthritis; F344/N rats; (F344/N × LEW/N) rats; (F344/N × NSD/N) rats; Fischer rats; LEW/N rats; (LEW/N × F344/N) rats; (NSD/N) rats; (NSD/N × F344/N) rats; Rat liver xanthine oxidase; Sprague-Dawley rats
 PGE1 in adjuvant arthritis, 805
 streptococcal cell wall-induced polyarthritis, 1064
- Raynaud's phenomenon, 769
 anti-DNA in, 999
 in connective tissue disease, 889
 in scleroderma, 244, 247, 525, 1267
 in scleroderma esophageal disease, 1118
 in Sjögren's-sicca complex, 159
 in SLE, 1036, 1127
- Reactive arthritis
 in children, 1041
 inflammation in disseminated gonococcal infections and, 574
 Reiter's disease and, 249
 after *Shigella sonnei* infection, 1267
- Receptor antibodies, insulin-resistant connective tissue disease and, 458
- Recombinant inbred (RI) lines of mice, 734
 NZB genetics in, 738
- Recurrent polyserositis, colchicine in, 227
- Red blood cells, immune complexes and, 784
- "Reiter's" cells, in palindromic rheumatism, 362
- Reiter's disease, 255
 acne in, 346
 anti-DNA in, 999
 clinical findings in, 251
 giant cell valvulitis in, 232
 IgA nephropathy and, 144
 inflammatory arthritis in, 948
 lactic acid in, 950
 LE cells in, 239
 osteomyelitis of cervical spine in, 346
 reactive arthritis and, 249
 in seronegative enthesopathy and arthropathy in children, 1043
 succinic acid in, 950
- Relapsing polychondritis, human, type II collagen-induced auricular chondritis in Sprague-Dawley rats and, 266
- Remission of RA, T cell subsets in, 1507
- Renal. *See* Kidney
- Renal abnormalities, in lupus nephritis, 870
- Renal amyloidosis, in adult onset Still's disease, 647
- Renal basement membranes, membrane attack complex and, 876
- Renal biopsy
 in lupus nephritis, 867
 in renal disease, 872
 in SLE, 869, 872
 antibody response and, 117
- Renal biopsy scoring system, 872
- Renal cortex, in RA, 1017
- Renal crises, in scleroderma, 241
- Renal disease
 anti-La in, 771
 anti-Ro in, 771

- Renal disease (*cont'd*)
 lupus nephritis and, 869
 penicillamine-induced in RA, 1016
 PGE1 and in NZB/W mice, 806
 naproxen-induced in RA, 1016
 renal biopsy and, 872
 in SLE, 55, 891, 893, 1127
 beta 2 microglobulin and, 375
 as cause of death, 614
 complement and, 795
 viruses and, 847
- Renal failure
 chronic
 dialysis in, 38
 in SLE, 1127
 progressive, 871
 in scleroderma, 241
 tubulointerstitial changes and in lupus nephritis, 872
 urate crystals in, 209
- Renal function
 in scleroderma, 241
 in SLE, 383, 791, 893
- Renal insufficiency, tubulointerstitial damage and in lupus nephritis, 872
- Renal involvement
 in RA, 702
 in scleroderma, 525
 in SLE, 564, 613, 618, 970
 anti-DNA in, 999
- Renal lesions
 anti-Ro and, 768
 complement and, 797
 drug-induced, 1016
 in frentizole-treated NZB/NZW mice, 1291
 in SLE, 871
- Renal pathology, in mixed connective tissue disease in children, 758
- RES. *See* Reticuloendothelial system
- Resorption
 bone, 333
 subchondral, in RA, 336
- Respiratory burst, in human neutrophils, 181
- Responder cells, in familial Mediterranean fever, 471
- Reticuloendothelial system. *See also* Mononuclear phagocyte system
 in SLE, 48
- Reticuloendothelium, sex steroid hormones and, 840
- Retinoic acid, all-trans, plasminogen activator activity and, 432
- Retroviral gp 70, in murine lupus, 729
- Retrovirus-induced arthritis, in goats, 930
- Retroviruses
 autoimmune disease and, 852
 Fv-1 gene and, 850, 852
 genetics and, 851
 in New Zealand mice, 852
- Retroviruses (*cont'd*)
 in SLE, 847
 type C, 850
- Reverse hemolytic plaque assay, T cells and, 814
 in SLE, 168
- RF. *See* Rheumatoid factor
- Rgv-1 gene, viruses and, 852
- Rheumatic diseases. *See also* Autoimmune diseases
 anti-DNA levels in, 999
 autologous mixed lymphocyte reaction in, 121
 complement allotypes and, 795
 Epstein-Barr virus and, 427
 histone antibodies in, 407
 immune complexes in, 1156
- Rheumatic fever. *See also* Adult onset Still's disease; Late onset Still's disease; Still's disease
 acute, pericarditis in, 1054
- Rheumatic pericarditis, immunopathology of, 1054
- Rheumatism Review (24th)*, azathioprine in RA, 1269
- Rheumatoid arthritis, 1131. *See also* Juvenile rheumatoid arthritis
 ageusia in, 700, 702
 alpha-1 antitrypsin in, 372
 antibodies to beta 2 microglobulin in, 375
 anti-DNA in, 999
 anti-F(ab')₂ antibodies in, 1298
 antimalarial drugs in, 427
 aphthae in, 702
 ARA criteria for, 481
 aspirin in, 464
 buffered, 464
 azathioprine in, 97, 1269
 benoxaprofen in, 595
 bovine conglutinin assay for, 1156
 cancer in, 1132
 cervical spine involvement in, 1316, 1378
 choline magnesium trisalicylate in, 464
 classic, 481
 HLA typing in, 502, 1435
 immune function in, 488
 mortality in, 1020
 palindromic onset of, 361
 clinical features of, 151, 699, 701
 clinical syndrome of, 485
 collagen in, 525
 collagen arthritis and, 914
 collagen arthritis as model for, 911
 complement in, 1158
 C1q binding assay for immune complexes in, 1156
 C4 in, 161
 complement activation by IgM rheumatoid factor in, 161
 in Pima Indians, 165
 concanavalin A-induced suppressor cell activity after indomethacin in, 357
 current definition of, 913
 cutaneous involvement in, 702

Rheumatoid arthritis (*cont'd*)

- cytotoxic drugs in, 427
- definite, 481, 502, 1020
- deossification of bone in, 335
- disease activity in, immune complexes and, 1156
- DNA binding in, 634
- epigastric pain in, 700
- Epstein-Barr virus antibodies in, 427
- equivocal, 481
- erosions in, 481
 - gold therapy and, 540
- ESR in, 340, 503, 1156
- extraarticular manifestations of, assays for immune complexes and, 1156
- fibroblasts in synovium in, 690
- fibronectin in, 25
- fingers in, gold therapy and, 544
- gamma globulin in, 17
 - placental, 1024
- genetic predictors, NSAID and, 370
- glomerulus in, 1017
- gold salts in, intraarticular, 699, 702, 1148
- gold sodium thiomalate in, 288, 1148
- gold therapy in, 372, 427, 540, 544
- hand in, 503
 - gold therapy and, 544
- histone antibodies and, 407
 - HLA-DR phenotype in, 372
 - HLA-DR4 antigen in, 150, 502
- HLA antigens in, 1435
- HLA typing in, 502
- human placenta-eluted gamma globulins in, 17
- hydroxylation in, 844
- Ia alloantigens and, 836
- IgA rheumatoid factors in, 1307
- IgG rheumatoid factor in, 1101, 1158, 1307
- IgM rheumatoid factor in, 150, 1307
- immune complex assays in, 1156
- immune function in, 488
- immune reactants in, 1307
- immunoglobulins in, 1158
- immunologic studies of, 695
- influence of gold therapy on adverse effects of penicillamine in, 917
- insurance company decisions and, 1020
- interferon in, 396
- joint deformities in, gold therapy and, 540
- joint involvement in, 340
- joint pain in, 481
- joint swelling in, 481
 - gold therapy and, 540
- joint tenderness in, 481
- laboratory tests for, 699, 701, 1158
- lactic acid in, 950
- liver toxicity from NSAID in, 1124

Rheumatoid arthritis (*cont'd*)

- lymphocyte blastogenesis and steroid drugs in, 618
- macrophages in synovium in, 685
- methotrexate in, 339
- monoclonal rheumatoid factor inhibition assay for immune complexes in, 1156
- monocyte cytotoxicity in, 10
- morning stiffness in, 340, 481
- mortality and, 1020
- N-[2-mercaptopropionyl] glycine in, 698
- naproxen-induced renal disease in, 1016
- nodules in
 - gold therapy and, 546
 - subcutaneous, 481
- nonreducible rotational head tilt in, 1316
- NSAID and cognitive dysfunction in elderly in, 1014
- oropharyngeal Epstein-Barr virus in, 427
- pathogenetic factors in, 10
- penicillamine in, 111, 427, 923, 1016
- PGE in synovium in, 685
- prednisone in, 427
- preliminary criteria for remission in, 1144
- probable, 481
- prostaglandins in, 799, 804
- proteinuria in, 700, 702
- proteoglycans and, 196
- psychologic disturbance and, 213
- Raji cell assay for immune complexes in, 1156
- rash in, 700, 702
- remission of, T cell subsets in, 1507
- renal cortex in, 1017
- renal involvement in, 702
- rheumatoid factor in, 481, 1158, 1307, 1445
 - gold therapy and, 545
- secondary Sjögren's syndrome and, SS-B antibodies in, 662
- sensory involvement in, 702
- septic arthritis and, 948
- seronegative
 - B cells in, 959
 - immunogenetics and, 502
 - polyarticular, B cells in, 959
- seropositive, 484
 - adult, Epstein-Barr virus-inducible IgM anti-IgG in, 961
 - B cells in, 959
 - HLA-DR antigens in, 502
 - nodules in, 478
 - tiopronin and penicillamine in, 923
 - vasculitis in, 502
- serum pepsinogen I in, 1059
- serum proteins in, gold therapy and, 540
- serum salicylate concentrations in, 464
- Sjögren's syndrome in, 1160
- slow-acting antirheumatic drugs in, 698
- SS-B antibodies in, 662

Rheumatoid arthritis (*cont'd*)

- staphylococci binding assay for immune complexes in, 1156
- subchondral resorption in, 336
- succinic acid in, 950
- superior luxation of C1 in, 1378
- Surgery in Rheumatoid Arthritis* (book review), 719
- Surgical Treatment of Rheumatoid Arthritis* (book review), 719
- synovial biopsy in, 481
- synovial cyst of hip in, 1382
- synovitis in, during gold therapy, 540
- taste in, 700, 702
- therapy of, long-term, 465
- thrombocytopenia in, 700
- thrombopenia in, 702
- tiopronin in, 923
- toxicoderma in, 702
- treatment dropouts in, 701
- trophoblastic cells in, 17
- ulcerogenic drugs in, 370
- ulcers in, gastric, 702
- unproven remedies in, 1145
- vasculitis in, 1160
- wrist in, 503, 544
- in Yakima Indians, 1435

Rheumatoid factor. *See also* IgG rheumatoid factor; IgM

- rheumatoid factor
 - absence of in RA, 502
 - arthritis and in MRL/1 mice, 723
 - in arthritis-dermatitis syndrome, 575
 - auranofin and, 596
 - complement activation by, 161
 - complement and, 796
 - in connective tissue disease, 460
 - hidden, 150
 - in JRA, 961
 - induced by aggregated IgG, 1108
- IgG. *See also* IgG rheumatoid factor
 - in adult onset Still's disease, 647
 - human complement activation by, 1101
- IgG complex binding in human glomerulus and, 297
- IgM. *See also* IgM rheumatoid factor
 - in RA, 150
- immune complex disease and, 297
- in JRA, 959
 - alpha₁-antitrypsin phenotypes and, 1011
- in Pima Indians, 165
- in post-mammoplasty connective tissue disease, 695
- quantitation of, in RA, 1445
- in RA, 481, 699, 1158
 - gold therapy and, 545
 - beta 2 microglobulin and, 375
- relationship to anti-F(ab')₂ antibodies in RA and SLE, 1298

Rheumatoid factor (*cont'd*)

- in scleroderma, 1167
- in Sjögren's-sicca syndrome, 159
- Sjögren's syndrome and, 419
- in SLE, 383, 1031
- Rheumatoid nodules, 478
- Rheumatoid plasma, 25
- Rheumatoid synovial cells
 - immune function and, 488
 - proteoglycan synthesis by, 196
- Rheumatoid synovial fluid, fibronectin in, 25
- Rheumatoid synovial tissue, immune function and, 496
- Rheumatoid synovium
 - immune function and, 497
 - PGE in, 685
- Rheumatoid tissue, HLA-DR expressing, macrophage-like cells in, 488
- Rheumatologists, need for, 2, 3
- Rheumatology, private practice of, 718
- Rheumatology education
 - evaluation of, 92
 - in medical schools, 1149
 - package inserts in new drugs and, 1124
 - to recognize radiologic sacroiliitis, 1147
 - unproven remedies and, 1145
- Rheumatology manpower, 1
- Rheumatology patients, in evaluation of rheumatology education, 92
- Rheumatology practice, 4
- RHPA. *See* Reverse hemolytic plaque assay
- RI. *See* Recombinant inbred lines of mice
- RIA. *See* Radioimmunoassay
- Ribonuclease (RNase), in SLE, 969
- Ribonucleic acid (RNA)
 - skin response to, in SLE, 1284
 - in SLE, 304
- Ribonucleoprotein (RNP), 763
- RNA. *See* Ribonucleic acid
- RNA-containing lupus antigen, 761
- RNA-protein complexes, 762
- RNase. *See* Ribonuclease
- RNA splicing, 763
- RNA synthesis
 - chondrocyte synthesis and, 668
 - plasminogen activator activity and, 432
- RNA tumor viruses, 850
- RNP. *See* Ribonucleoprotein
- RNP antibodies, in post-mammoplasty connective tissue disease, 695
- RNP antigens
 - antibodies and, 765
 - definition of, 1280
 - molecular characterization of, 1278
- RNP complexes, 765

Ro antibodies
 in connective tissue disease, 767
 in SLE, 767, 1036
 Ro antigen
 molecular nature of, 770
 in primary biliary cirrhosis and Sjögren's syndrome, 1252
 Ro/anti-Ro immune complexes, in primary biliary cirrhosis with Sjögren's syndrome, 1250
 Ro-anti-Ro system, in lupus nephritis, 768
 Rotational head tilt in RA, nonreducible, 1316
 "Rugger jersey," osteopetrosis and, 1028

S

Sacroiliac joints
 in ankylosing spondylitis, 221
 in familial pyrophosphate arthropathy, 69
 in hereditary chondrocalcinosis with vertebral ankylosis, 1260
 Sacroiliitis
 in HLA-B27 Pima Indian men, 236
 in osteomyelitis of cervical spine, 347
 in Reiter's disease, 249
 in salmonella arthritis, 249
 in yersinia arthritis, 249
 Salicylates. *See also* Aspirin; Buffered aspirin
 in chronic inflammatory joint disease, 32
 and degradation of hyaluronic acid, 1469, 1473
 gamma carboxyglutamic acid in childhood dermatomyositis and, 1094
 serum, in RA, 464
 xyloside and in GAG synthesis, 1084
 Salivary gland
 in Sjögren's-sicca syndrome, 159
 in Sjögren's syndrome, 419
 Salmonella arthritis, Reiter's disease and, 249
 Sarcoidosis
 diagnosis of, 1396
 interferon and, 396
 Schmorl's nodes, fish vertebrae and, 1073
 Schölein-Henoch syndrome, in familial Mediterranean fever, 42
 SCLE. *See* Subacute lupus erythematosus
 Scleroderma. *See also* Progressive systemic sclerosis; Systemic sclerosis
 amyloidosis, extensor tendon rupture and, 1141
 antibodies to collagen in, 522
 cytotoxic activity of sera from, 1391
 diffuse, 1167
 DNA binding in, 634
 esophagus in, 1117
 fibroblasts in, 189
 gamma carboxyglutamic acid and subcutaneous calcifications in, 1096

Scleroderma (*cont'd*)
 hypertension in, 241
 immune complexes in, 1167
 interferon in, 396
 nifedipine in digital ulcers in, 1267
 plasma renin activity in, 243
 pulmonary diffusion capacity in, 522
 Raynaud's phenomenon in, 247, 1267
 renal crises in, 241
 serum creatinine in, 244
 skin in, 247, 525
 visceral involvement in, 61
 Sclerosis
 in adult onset Still's disease, 650
 glomerular, in progressive glomerular disease, 872
 in SLE, 871
 Seizures, survival in SLE and, 606
 Selenous acid, DNA synthesis by rabbit articular chondrocytes and, 1217
 Self antigens, in SLE, 824
 Senescence, in mice, amyloid deposition in intervertebral discs and, 710
 Sensory involvement, in RA, 702
 Septic arthritis, markers for, 947
 Septic sternoclavicular arthritis, with *Pasturella multocida* and *Streptococcus sanguis*, 467
 Seronegative enthesopathy and arthropathy, in children, 1041
 Seronegative monarthritis, in RA, 485
 Seronegative JRA, IgM anti-IgG B lymphocytes in, 959
 Seronegative polyarthritis, in RA, 485
 Seronegative rheumatoid arthritis
 B cells in, 959
 HLA typing in, 502
 HLA-DR antigens in, 502
 IgM rheumatoid factor in, 150
 immunogenetics and, 502
 peripheral, in B27+ monozygotic twins, 1490
 Seronegative spondylarthropathies
 in children, 1041
 Epstein-Barr virus and, 427
 IgA nephropathy associated with, 144
 Seropositive arthralgia, in RA, 485
 Seropositive JRA, "hidden" RF, IgM anti-IgG B lymphocytes in, 959
 Seropositive monarthritis, in RA, 485
 Seropositive polyarthritis, in RA, 485
 Seropositive rheumatoid arthritis, 484
 Epstein-Barr virus-inducible IgM anti-IgG in, 961
 HLA-DR antigens in, 502
 IgM rheumatoid factor in, 150
 nodules in, 478
 subcutaneous, 502
 tiopronin and penicillamine in, 923
 vasculitis in, 502

- Seroreactivity, in SLE, 1031
- Serositis, in SLE, 55, 1036, 1127
- Serotonin, in SLE, 966
- Serum, DNA synthesis by articular chondrocytes and, 318, 531
- Serum albumin
- human, aspirin hydrolysis and, 550
 - salicylates and in chronic inflammatory joint disease, 32
- Serum antinuclear antibodies, circulating mononuclear cells and in SLE, 310
- Serum beta 2 microglobulin, 375
- Serum complement
- interferon and in SLE, 401
 - in relatives of SLE children, 558
- Serum creatinine, in hypertensive scleroderma patients, 244
- Serum immune complexes. *See also* Circulating immune complexes; Complement C1q binding assay; Cytotoxic immune complexes; Immune complexes; Soluble immune complexes
- in eosinophilic fasciitis, 1180
 - in gonococcal arthritis-dermatitis syndrome, 574
 - in progressive systemic sclerosis, 1167
- Serum immunoglobulins, in SLE, 894
- Serum interferon
- anti-DNA binding and, 403
 - in SLE, 401
- Serum pepsinogen I, in rheumatic diseases, 1059
- Serum protein, in RA, gold therapy and, 540
- Serum salicylate concentrations, in RA, 464
- Serum sickness, chronic, in rabbits, 880
- Sex chromatin, in SLE, 843
- Sex hormones
- hepatic xanthine oxidase activity in Sprague-Dawley rats and, 326
 - (NZB \times DBA/2) F₁ mice, 736
- Sex-steroid enzyme interactions, xanthine oxidase activity in rats and, 326
- Sex steroid hormones, murine lupus and, 838
- Sham surgery, immunity to homologous type III collagen after in rabbits, 274
- Sheep red blood cell rosettes, progressive systemic sclerosis and, 390
- Sheep red blood cells
- IgM rheumatoid factor and, 297
 - rheumatoid factor induction by aggregated IgG and, 1108
- Shigella sonnei* infection, reactive arthritis after, 1267
- Shoulder, in adult onset Still's disease, 650
- Shunt, right-to-left, in hypertrophic osteoarthropathy, 1191
- Sicca complex
- in Sjögren's syndrome, keratoconjunctivitis and, 156
 - in SLE, 1035
 - anti-Ro and, 1031
- Sicca syndrome
- serum pepsinogen I and, 1059
 - in SLE, 383
- Single-stranded DNA. *See also* Anti-DNA; Anti-dsDNA; Anti-native DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA/anti-DNA complexes
- antibodies to in DLE, 639
 - HLA-DR antigens and in SLE, 1035
 - in MRL mice, 728
- Single-stranded DNA/anti-DNA complexes. *See also* Anti-DNA; Anti-dsDNA; Anti-native DNA; Anti-ssDNA; DNA; Double-stranded DNA; ³H-DNA/anti-DNA complexes; Native DNA; Single-stranded DNA
- in SLE and DLE, 641
- Sjögren's sicca complex, in keratoconjunctivitis sicca, 156
- Sjögren's sicca syndrome, clinical and laboratory findings in, 159
- Sjögren's syndrome
- anti-DNA in, 999
 - antigens and, 421
 - antinuclear antibodies in, 421
 - autoantibodies in, 419
 - cytomegalovirus in, 260
 - DNA binding in, 634
 - extraglandular manifestations of, 421
 - IgG in, 421
 - IgM in, 424
 - immune complexes in, 1250
 - immunoglobulin synthesis in, 419
 - interferon in, 396
 - primary biliary cirrhosis and, 1250
 - primary, lymphocytes in, 419
 - in RA, 1160
 - rheumatoid factor and, 419
 - serum pepsinogen I in, 1059
 - SS-A autoantibodies in, 421
 - SS-B antibodies in, 662
 - SS-B autoantibodies in, 421
 - T cells in, 419
 - thrombocytopenia and, 1510
- Sjögren's syndrome-sicca complex, keratoconjunctivitis sicca and, 156
- Skeletal muscle enzymes, in tropical pyomyositis, 107
- Skeleton, seronegative enthesopathy and arthropathy in children and, 104
- Skin. *See also* Dermis
- benoxaprofen and, 595
 - penicillamine toxicity and, 920
 - response to DNA and RNA in SLE, 1284
 - in scleroderma, 243, 257, 525
 - in SLE, 55, 624, 861, 884, 1036
 - sulfonamide hypersensitivity and, 350
- Skin biopsy
- in adult onset Still's disease, 651
 - repeat, in SLE, 624
- Skin fibroblasts, purine nucleotide synthesis and in juvenile metabolic gout, 1265

- Skin lesions**
 complement and, 797
 vasculitis, in SLE, 383
- Skin rash, in gonococcal arthritis-dermatitis syndrome, 575**
- Skin tumors, arthritis, metastatic melanoma and, 223**
- SLE. *See* Systemic lupus erythematosus**
- SLE cryoglobulins, antineuronal activity in, 776**
- SLE cryoprotein, 776**
- SLE-like disease**
 in BXSB mice, 730
 immunobiology of, 726
 in MRL/MP-1pr/1pr mice, 729
- SLE syndrome, in mice, 721**
- Slow-acting antirheumatic drugs, 698**
- Sm antibodies, 754**
 clinical diseases and, 757
 in MRL mice, 759
 in 1982 revised criteria for classification of SLE, 1271
 in SLE, 759
- Sm antigen**
 antibodies and, 765, 1003
 biochemical characterization of, 759
 definition of, 1280
 localization of, 761
- Small bowel involvement, in scleroderma esophageal disease, 1118**
- Small ribonucleoprotein (snRNP) complexes, 761**
- snRNP. *See* Small ribonucleoprotein complexes**
- Socioeconomic status, survival in SLE and, 601**
- Sodium aurothiomalate, effect of on toxicity of penicillamine, 917**
- Sodium dodecyl sulfate-polyacrylamide gel electrophoresis, 508**
- Sodium salicylate**
 effect of on GAG synthesis in cartilage, 1087
 proteoglycans and, 1089
- Soft tissue inflammation, NSAID and, 596**
- Soft tissue swelling, in Gaucher's disease, 707**
- Soft tissues, collagen arthritis in, 911**
- Soluble antigens, immune function of synovial cells and, 488**
- Soluble immune complex mediated disease, 796**
- Soluble immune complexes. *See also* Circulating immune complexes; Complement C1q binding assay; Cytotoxic immune complexes; Immune complexes; Serum immune complexes**
 assays by RIA and FIA, 801
 complement activation and, 1101
 IgM rheumatoid factor and, 164
- Somatostatin, DNA synthesis by rabbit articular chondrocytes and, 1224**
- Spinal cord block, in ankylosing spondylitis, 218**
- Spinal puncture, in CNS SLE, 586**
- Spine**
 cervical
- Spine (*cont'd*)**
 in hereditary chondrocalcinosis with vertebral ankylosis, 1261
 osteomyelitis of, 346
 in psoriatic spondylitis, 102, 104
 dorsal, in ankylosing spondylitis, 218
 fish vertebrae and, 1073
 in hereditary chondrocalcinosis, 1257
 involvement of, in RA, 1316, 1378
 lumbar, 1028
 in psoriatic spondylitis, 102
 lumbosacral, in seronegative enthesopathy and arthropathy in children, 1043
 in psoriatic arthritis, 678
 thoracic, in hereditary chondrocalcinosis with vertebral ankylosis, 1261
- Spleen**
 blastogenic responses and, 278, 280
 chronic inflammation in streptococcal cell wall-induced polyarthritis in rats, 1064
 immune complexes in, 784, 785
 immune deposits in, 884
 interleukin-2 and, 840
 in MRL mice, 728
 in SLE, 48, 882
- Spleen cells**
 collagen peptides and, 274
 murine lupus and, 731
- Splenic reticuloendothelial system Fc receptor function, in SLE, 48**
- Spondylarthropathy, seronegative, 144**
 Epstein-Barr virus and, 427
- Spondylitis, psoriatic, 101**
- Spontaneous immunoglobulin secretion, in SLE, 830**
- Spontaneous killer activity. *See* "Natural" killer activity**
- Spontaneous lupus-like disease, in mice, 880, 882**
- Spontaneous lymphoma**
 Akv, Fv-1 and Rgv-1 loci, 852
 viruses and, 850
- Spontaneous plaque-forming cells, in SLE, 307**
- Spontaneous xenotropic virus, in NZB mice, 853**
- Sprague-Dawley rats**
 collagen-induced auricular chondritis in, 266
 liver xanthine oxidase activity in, 326
 streptococcal cell wall-induced polyarthritis in, 1064
 total lymphoid irradiation in collagen arthritis in, 532
- SS phenotype, in JRA, 1010**
- SS-A antibodies, 754**
 in Sjögren's-sicca syndrome, 159
- SS-A antigen, in Sjögren's syndrome, 767**
- SS-A autoantibodies, in Sjögren's syndrome, 421**
- SS-A/Ro antibody, 755**
 in rheumatic diseases, 768
- SS-B antibodies**
 in connective tissue diseases, 662

- SS-B antibodies (*cont'd*)
 in Sjögren's-sicca syndrome, 159
 SS-B antigen, in Sjögren's syndrome, 767
 SS-B autoantibodies, in Sjögren's syndrome, 421
 SS-B (La) antibodies, in rheumatic diseases, 768
 SS-B/La antigen, antibodies to, 1003
 ssDNA. *See* Single-stranded DNA
 ssDNA/anti-DNA complexes
 detected by Farr assay, 642
 detected by PEG assay, 642
 Staphylococcal protein A fluoroimmunoassay, for immune complexes, 799
 Staphylococci binding assay, for immune complexes in RA, 1156
Staphylococcus aureus, cartilage degradation by, 441
 Sternoclavicular arthritis, septic, with *Pasteurella multocida* and *Streptococcus sanguis*, 467
 Sternum osteomyelitis, from *Propionibacterium acnes* in Reiter's syndrome, 346
 Steroid bolus treatment, in SLE, 892
 Steroid drugs. *See also* Corticosteroids
 complications of, 346
 in pancreatitis in SLE, 1006
 in RA
 lymphocyte blastogenesis, 713
 tiopronin, penicillamine and, 924
 retinoic acid-stimulated plasminogen activator activity and, 439
 in SLE, 57, 410, 564, 1127
 unproven remedies and, 1146
 Steroid receptors, in adult canine articular cartilage, 568
 Stiffness, psychologic disturbance and in fibrositis, 213
 Still's disease. *See also* Adult onset Still's disease; Late onset Still's disease; Rheumatic fever
 adult onset, 647
 chronic liver disease and, 579
 clinical features of, 580
 late onset, tarsal arthritis with ankylosis in, 1254
 liver biopsy in, 580
 Streptococcal cell wall-induced polyarthritis, in rats, 1064
Streptococcus sanguis, in septic sternoclavicular arthritis, 467
 Stress-related arthritis, 478
 Subacute lupus erythematosus, 768. *See also* Central nervous system SLE; Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kidney; Lupus-like syndrome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Systemic lupus erythematosus
 Subaxial cervical subluxation, in psoriatic spondylitis, 101
 Subchondral resorption, in RA, 336
 Subclavian artery thrombosis in SLE, 1501
 Subcutaneous calcifications, gamma carboxyglutamic acid, in childhood dermatomyositis, 1094
 Subcutaneous nodules, in RA, 151, 481, 914
 seropositive, 502
 Subluxation, subaxial cervical, 101
 Subsynovial tissue, fibrosis of in psoriatic arthritis, 677
 Succinic acid, as marker for septic arthritis, 947
 Sulfamethoxazole, in RA, 465
 Sulfated glycosaminoglycans, xyloside and in cartilage, 1084
 Sulfated proteoglycan synthesis, effect of purified growth factors on rabbit articular chondrocytes in, 1228
 Sulfated proteoglycans, rheumatoid synovial cells and, 196
 Sulfhydryl compounds, in RA, 695
 Sulfonamide hypersensitivity, erythema multiforme secondary to, 350
 Superior luxation in RA, 1378
 Supernatant hemolytic complement activity, 301
 Superoxide anion generation, 174
 respiratory burst and, 181
 Superoxide dismutase
 MSU-induced enzyme release and, 186
 nitroblue tetrazolium reduction and, 184
 Superoxide generation by neutrophils, 1409
 Suppressor cell activity, procainamide and, 238
 Suppressor cell deficiency in familial Mediterranean fever, 38
 Suppressor cell function
 in familial Mediterranean fever, 471
 in SLE, 810
 Suppressor cells
 in active SLE, 824
 genetics and, 830
 indomethacin therapy, concanavalin A and, 357
 mixed autologous lymphocyte reaction and, 121
 Surface-surface membrane products, 817
 Surgery, joint, immunity to collagen after, 274
Surgery in Rheumatoid Arthritis (book review), 719
Surgical Treatment of Rheumatoid Arthritis (book review), 719
 Survival rates
 in murine lupus, 727, 729, 731
 in SLE, 55, 601, 887, 893, 1127
 Swiss mice, lymphocytic choriomeningitis virus, glomerulonephritis and interferon in, 803
 Synovial biopsy
 in predicting RA, 361
 in psoriatic arthritis, 679
 in RA, 481
 Synovial calcification, experimental hydroxyapatite, 1239
 Synovial calciphylaxis, 1240
 Synovial cells
 rheumatoid, immune function and, 488
 sulfated proteoglycans and, 196
 Synovial cyst of hip, in RA, 1382
 Synovial effusions
 eosinophilic, complicating chronic urticaria and angioedema, 708
 in palindromic rheumatism, 361
 Synovial fibroblasts, human, plasminogen activator activity and, 432

- Synovial fluid
 in adult onset Still's disease, 647
 birefringent lipid in polyarthritis, 1365
 complement activation in, 161
 diagnosis of joint effusions and, 99
 fibronectin in, 25
 gas liquid chromatography analysis of, 947
 immune reactants in, 1307
 LE cells in Reiter's syndrome, 240
 in palindromic rheumatism, 361
 in RA, 481
 rheumatoid, fibronectin in, 25
 T cell leukemia and, 87
 urate crystals in gout, 211
- Synovial fluid immune complexes, in gonococcal arthritis-dermatitis syndrome, 574
- Synovial hyperplasia, after joint surgery in rabbits, 276
- Synovial intima, HLA-DR expressing, macrophage-like cells in immune function of synovial cells, 488
- Synovial lesions, in CAEV arthritis in goats, 930
- Synovial lining cells
 immune function and, 494
 in palindromic rheumatism, 362
- Synovial membrane
 amyloid in osteoarthritis, 204
 apatite deposits, calcification and, 1239
 in CAEV arthritis in goats, 932
 in intraarticular calcification, 1239
 vascular changes in psoriatic arthritis and, 677
- Synovial pleocytosis, in Behcet's disease, 235
- Synovial tissue
 fibronectin from, 25
 metastatic melanoma in, 223
 prostaglandin E in, 688, 691
 sulfated proteoglycans and, 196
 T cell leukemia and, 87
- Synoviocytes, immune function and, 488
- Synovitis
 in RA, during gold therapy, 540
 toxic, from rapeseed oil, 1477
- Synovium
 amyloid, in osteoarthritis, 205
 in collagen arthritis, 911
 inflammation and in streptococcal cell wall-induced polyarthritis in rats, 1064
 in mycoplasma-induced arthritis, 940
 psoriatic, vascular changes in, 677
 rheumatoid, PGE in, 685
- Systemic blood flow, in hypertrophic osteoarthropathy, 1186
- Systemic immune complex deposition, 882
- Systemic immune complex disease, 880
 SLE as, 884
- Systemic lupus erythematosus, 83, 895, 1131. *See also*
 Central nervous system SLE; Childhood lupus erythematosus; Discoid lupus erythematosus; Drug-induced LE-like syndrome; Lupus kidney; Lupus-like syn-
- Systemic lupus erythematosus (*cond't*)
 drome; Lupus-related organic brain syndrome; Murine lupus; Neonatal lupus; Subacute lupus erythematosus
 acute intermittent porphyria and, 1134
 adenosine diphosphate in, 968
 age of onset and, 55
 albumin in, 864
 allogeneic mixed leukocyte reaction and, 386
 16 α -hydroxysterone in, 844
 alpha interferon in, 401
 antibodies in, 410, 753, 864
 to beta 2 microglobulin, 375
 to DNA, 55, 381
 to dsDNA, 631
 to La, 767
 to neuronal cell membranes, 774
 to Ro, 767
 to T cells, 814
 anti-DNA in, 310, 624, 1031
 lack of in, 1126
 oral contraceptives and, 619
 anti-DNA antibodies in, 50, 812, 997
 detection of, 997
 in women, 454
 anti-dsDNA in, 631, 970
 anti-F(ab')₂ antibodies in, 1298
 antigens in, 811
 anti-H2A-H2B activity in, 779
 anti-histone antibodies in, 779
 anti-La in, 1034
 anti-lymphocyte antibodies in, 383, 556, 715, 811, 824
 anti-native DNA in, 1034, 1127
 anti-neuronal antibodies in, 773, 864
 anti-nRNP in, 1034
 antinuclear antibodies in, 383, 556, 768
 anti-Ro in, 770, 1031
 antisera and, 811
 anti-Sm in, 1034
 anti-ssDNA in, 970
 anti-T cell antibodies in, 826
 atypical flares of, infection in, 583
 autoantibodies in, 752, 773, 818, 858, 1031
 autologous mixed lymphocyte reaction in, 121, 381, 820
 autologous non-T cells in, 824
 azathioprine in, 893, 1388
 B cells in, 168, 381, 816
 B plus null cells in, 381
 blood brain barrier in, 863, 865
 brain in, 862, 865
 cancer in, 1132
 causes of death in, 612
 cell mediated immunity in, 810
 cellular factors in, 734
 cellular immune function in, 810
 central nervous system in, 56, 463, 583, 606, 609, 612, 862, 884, 1127

Systemic lupus erythematosus (*cont'd*)

- central nervous system disease in, 776
- cerebritis in, 1035, 1036
- cerebrospinal fluid in, 863
- cerebrovascular accident in, 613
- chlorambucil in, 383
- choroidal function in, 862
- circulating antibodies in, 865
- circulating immune complexes in, 410, 556, 753, 828, 873, 894
- clinical assessment of, 892
- clinical features of, 55, 383, 525, 887, 970, 1031, 1127
- coexistent gout and, 713, 1505
- collagen in, 966
- colon and, 883
- complement in, 454, 624, 788
 - C1q in, 624
 - C3 in, 50, 56, 58, 309, 556, 564, 624, 1127
 - C4 in, 556, 624, 796
- corticosteroids in, 411, 891
- criteria, 1982 revised, for classification of, 1271
- crystal deposition disease in, 713
- cutaneous involvement in, 55, 1127
- cyclophosphamide in, 893
- cytotoxic agents in, 893
- cytotoxicity in, 562, 715
- deoxyribonuclease in, 966, 970
- dermal-epidermal junction in, 624
- dermis and, 884
- diphenylhydantoin and, 1387
- disease activity in, 50, 309, 383, 624, 970
 - histone antibodies and, 407
- disease severity and survival in, 601
- DNA in, 969
- DNA antibodies in, 383, 564, 754
- DNA-anti-DNA complexes in, 788
- DNA binding in, 309, 634, 894
- DR typing in North American whites with, 836
- drugs in, 50
- dsDNA in, 410
- environmental factors in, 734
- epinephrine and, 966
- Epstein-Barr virus excretion and, 427
- E-rosette formation in, 384
- estriol in, 844
- estrogen contraceptives in, 618
- estrogen metabolism in, 843
- extrarenal lesions in, 880
- Farr radioimmunoassay in, 997
- FIAX fluorometric immunoassay in, 997
- gamma carboxyglutamic acid and subcutaneous calcification in, 1096
- gastrointestinal bleeding in, 613
- genetics and, 734, 833, 838

Systemic lupus erythematosus (*cont'd*)

- glomerular thrombosis in, 117
- hematocrit in, 601
- hemocytopenia in, 56, 1127
- hemodialysis for nephritis in, survival and, 612
- histone antibodies in, 407
- HLA typing in, 556
- HLA-DR antigens in, 770, 1031
- hormone therapy in, 618
- humoral immunity in, 810
- hyperglobulinemia in, 1031, 1034
- hypocomplementemia in, 55, 790
- Ia alloantigens and, 835
- iatrogenic, histone antibodies in, 407
- idiotype anti-idiotype mechanisms in, 812
- IgA in, 624, 780
- IgD-bearing cells in, 1451
- IgG in, 624, 779, 863
- IgM in, 624, 779
- immune complex assays in, 788
- immune complexes in, 564, 799, 859, 872, 894
- immune deposits and, 880, 882, 884
- immune regulation in, 810
- immune response factor in, 562
- immune responses in, 824, 1031
- immunofluorescence in, 410
- immunoglobulins in, 168, 384, 624, 715, 864
 - intracytoplasmic, 307
- immunopathogenesis of, 858
- immunopathology of, 723, 880
- immunosuppressive drugs in, 57, 410
- immunosuppressive therapy in, 1127
- infection in, as cause of death, 612
- inflammation in, 858, 884
- interferon in, 396, 802
- interleukin-2 and, 838
- laboratory features of, 56
- levamisole in, 470
- lung in, 881
- lymphocytes in, 811, 816, 828
- lymphocytotoxic antibodies in, 381, 774, 828
- lymphocytotoxicity in, 817
- macrophages in, 384, 820
- major histocompatibility complex-mediated immune hyperresponsiveness and, 1031
- malar rash in, 383, 586, 1036
- malignancy and, 612
- malondialdehyde in, 966
- management of, 891
- MB phenotypes in, 1031
- membrane attack complex and, 858
- mesangial deposits in, 869
- monoclonal autoantibodies in, 744
- monocyte/mononuclear cells in, 381

Systemic lupus erythematosus (*cont'd*)

- mononuclear cells in, 168, 304, 381
- in monozygotic twins, 834
- mortality in Asians with, 414
- mortality rates in, 601
- MT phenotypes in, 1031
- murine model, 721
- myocardial infarction and, 612
- native DNA in, 311
- native DNA antibody in, 312
- natural killer (NK) cells in, 562, 811
- neonatal, 768
- nephritis in, 383, 410, 768, 795, 1035, 1036
 - as cause of death, 612
- N-ethylmaleimide in, 966
- neurocytotoxic antibodies and, 773
- neuronal antigens in, 865
- nonsteroidal oral contraceptive therapy in, 618
- NSAID in, 410
- nucleic acids in, 304
- null cells in, 381
- oral contraceptives in, 618
- organic psychosis in, 606
- outcome in, 601
- pancreatitis in, 1006
- pathogenesis of, 735, 747
- PEG assay in, 631
- peripheral loop deposits in, 873
- peritoneum and, 882
- phytohemagglutinin in, 304
- plaque-forming cells in, 168, 816
 - spontaneous, 307
- plaquenil in, 383
- plasma androgens in women with, 454
- plasmapheresis in, 894
- platelet aggregation in, 966
- prednisone in, 309, 383, 564, 893, 1006
- prevalence of, 887
- progestogen oral contraceptives in, 618
- prognosis in, 887
- prostaglandins in, 804, 808, 966
- protein in, 624
- protein synthesis in, 864
- proteinuria in, 601, 893
 - oral contraceptives and, 621
- pulmonary embolism in, 613
- race and, 55
- radioimmunoassay in, 799
- Raynaud's phenomenon in, 56
- renal biopsy in, 869, 872
- renal disease in, 55, 891, 893, 1127
 - as cause of death in, 614
- renal failure in, chronic, 56, 1127
- renal function in, 791, 893
- renal involvement in, 56, 612, 618, 871
 - anti-DNA in, 999

Systemic lupus erythematosus (*cont'd*)

- retroviruses in, 847
- rheumatoid factor in, 1031
- ribonuclease in, 969
- RNA in, 304, 1284
- Ro antibody in, 1036
- secondary Sjögren's syndrome and, SS-B antibodies in, 662
- seizures in, 606
- self antigens in, 824
- septic arthritis in, 948
- serositis in, 55
- serotonin in, 966
- serum creatinine in, 601
- serum immunoglobulins in, 894
- serum pepsinogen I in, 1059
- sex chromatin in, 843
- sicca complex in, 1035
- skin in, 55, 624, 1284
- skin biopsies in, repeat, 624
- skin manifestations of, 861, 884
- Sm antibody in, 759
- socioeconomic status and survival in, 601
- spleen in, 882
- splenic RES Fc receptor functional activity in, 48
- SS-B antibodies in, 662
- ssDNA in, 1035
- steroid drugs in, 57, 410, 564
- subclavian artery thrombosis in, 1501
- suppressor cells in, 810, 824
- survival rates in, 57, 601, 612, 887, 893, 1127
 - as systemic immune complex disease, 884
- T cells in, 168, 381, 715, 810, 816, 826
- temporomandibular joint erosions in, 597
- therapy for, 57
- tissue injury in, 810, 858
- total hemolytic serum complement (CH50) in, 383, 556, 796
- vasculitis in, 1035, 1036
- viruses and, 824, 847
- white blood count in, 383
- Systemic necrotizing vasculitis, malignant melanoma in, 475
- Systemic-onset JRA, IgM anti-IgG B lymphocytes in, 962
- Systemic polyarteritis nodosa. *See* Polyarteritis nodosa
- Systemic sclerosis. *See also* Progressive systemic sclerosis;
Scleroderma
 - antibodies in
 - to collagen, 522
 - histone, 407
 - esophagus in, 1119
- Systemic vasculitis
 - interferon in, 396
 - neoplasms and, 475
- Systemic venous circulation, hypertrophic osteoarthropathy and, 1186
- SZ phenotype, in JRA, 1010

T

T cell leukemia, presenting as chronic polyarthritis, 87
T cells, 828

- antibody synthesis and, 830
- in anti-DNA production, 739
- in autoimmune mice, 727
- autologous
 - immune function of synovial cells and, 486
 - mixed lymphocyte reaction and, 121, 381, 820
- in Behçet's disease, 1343
- blastogenic responses of, 284
- chondrocyte synthesis and, 824
- complement and, 797
- cytotoxicity of, 825
- detection by reverse hemolytic plaque assay, 815
- hapten-modified self antigens and, 824
- human synovial cells and, 488
- Ia antigens and, 835
- IgG and, 313
- immune regulation and, 740
- interleukin-2 and, 838
- leukemia and, 87
- modified reverse hemolytic plaque assay in, 814
- in monozygotic twins discordant for SLE, 715
- in MRL mice, 728
- native DNA antibodies in SLE and, 312
- in (NZB × DBA/2) F₁ mice, 737
- in post-mammoplasty connective tissue disease, 695
- in progressive systemic sclerosis, 390
- proliferation of, 826
- prostaglandins and, 806
- in Sjögren's syndrome, 419
- in SLE, 168, 810, 816, 820
 - antibodies to, 814
 - levamisole and, 470
 - nucleic acids and, 304
- in SLE prone mice, 726
- specificity of, 822
- subsets
 - in Behçet's disease, 1343
 - in remission of RA, 1507

Ty cells, 829

- in post-mammoplasty connective tissue disease, 695
- in T cell hyperplasia, 89

T μ cells, 829

Tar cells, 830

Tarsal arthritis, with ankylosis, in late onset Still's disease, 1254

Taste. *See also* Ageusia

- penicillamine toxicity and, 920
- in RA, 700, 702

TE22 alloantigen, 835, 836

Telangiectasia, in scleroderma esophageal disease, 1118

Temporomandibular arthritis, acute, bruxism, CPPD and, 353

Temporomandibular joint erosions, in SLE, 597

Tendon friction rubs, Raji cell assay and in scleroderma, 1167, 1171

Tendon rupture, extensor, scleroderma, amyloidosis and, 1141

Tendons

- extensor, amyloid in, 1141
- in olecranon bursitis, 989

Testosterone

- plasminogen activator activity and, 438
- in SLE, in women, 454

Testosterone propionate, hepatic xanthine oxidase activity in Sprague-Dawley rats and, 326

Tetraethylthiuram disulfide. *See* Disulfiram

Thigh, in tropical pyomyositis, 109

Thiomalic acid, 288, 293

5-thiopyridoxine, chemical structure of, 699

Thoracic spine, in hereditary chondrocalcinosis with vertebral ankylosis, 1261

Thoracic vertebral ankylosis, in hereditary chondrocalcinosis, 1257

Thrombin

- DNA synthesis by rabbit articular chondrocytes and, 1217
- platelet responses to urate and, 508

Thrombocytopenia. *See also* Anemia; Hemocytopenia; Hemolytic anemia; Hypocupremia-related hypochromic anemia

- auranofin and, 596
- meclofenamate and, 359
- penicillamine toxicity and, 920
- in RA, 700
- in Sjögren's syndrome, 1510
- in SLE, 383, 970, 1036
- tolmetin-induced, in seronegative polyarticular JRA, 1144

Thrombopenia, in RA, 702

Thrombosis

- glomerular, 872
- in lupus kidney, 117
- subclavian artery, in SLE, 1501

Thrombus

- in childhood dermatomyositis, 133
- palindromic rheumatism and, 366
- in rheumatic pericarditis, 1056

Thumb, 478

- deossification of bone in, 334

Thymectomy, 734

Thymic atrophy, in SLE mice, 727

Thymic epithelium, sex steroid hormones and, 840

Thymocyte abnormalities, in NZB mice, 737

Thymocytes, in T cell hyperplasia, 89

Thymus

- in murine lupus, 726
- sex steroid hormones and, 838

Thyroid acropathy, complicated by lymphatic obstruction, 588

Thyroid disease, autoimmune, DNA binding in, 634

- Tibial plateau, homologous type III collagen after surgery of, 277
- Tiopronin
chemical structure of, 699
for Dupuytren's contracture, 1505
in RA, 695
penicillamine and, 923
- Tissue
adipose, in ankylosing spondylitis, 218
in childhood dermatomyositis, 126
synovial, sulfated proteoglycans and, 197
- Tissue injury
prostaglandins in, 808
in SLE, 810, 858
- TNP. *See* Trinitrophenyl modified non-T cells
- TNP auto-MLR, autologous rosette forming T lymphocytes and, 826
- Tolmetin, in RA, 465
- Tolmetin-induced thrombocytopenia, in seronegative polyarticular JRA, 1144
- Tophaceous polyarticular gouty arthritis, nodules in, 478
- Tophi, in gout, 211, 472
- Total hip and knee arthroplasty, amyloid in osteoarthritis, 204
- Total lymphoid irradiation, in collagen arthritis, 532
- Toxic synovitis, from rapeseed oil, 1477
- Toxicity
to penicillamine, 917
to tiopronin, 695
- Toxicoderma, in RA, 702
- Tragus, inflammation of, 268
- Transferrin
DNA synthesis by rabbit articular chondrocytes and, 1217
levels in RA, 1309
- Transudates, complement in, 796
- Traumatic arthritis, 950
- Trimethoprim, in RA, 465
- Trinitrophenyl modified non-T cells, in SLE, 824
- Trophoblastic cells, in RA, 17
- Tropical pyomyositis, 107
- Trypsin, in ascorbate stimulation of DNA, 318
- Tubular deposits, membrane attack complex and, 876, 878
- Tubulointerstitial damage, renal insufficiency and in lupus nephritis, 872
- Tubulointerstitial deposits, in lupus nephritis, 873, 877
- Tubuloreticular structures, 848
- Tumors, arthritis caused by, 223
- Twins, monozygotic
discordant for SLE, 715
HLA-B27 and peripheral arthritis, 1490
- Type C RNA retrovirus, 850, 853
- Type I, II collagen. *See* Collagen types
- Ulcerogenic drugs, in RA, 370
- Ulcers
cutaneous
in Behçet's disease, 714
in scleroderma, 244
digital
nifedipine in scleroderma, 1267
in scleroderma, 525
in scleroderma esophageal disease, 1118
gastric, in RA, 702
mouth
penicillamine toxicity and, 920
in SLE, 383
peptic, NSAID and in RA, 370
- Ultracentrifugation, collagen activity and, 528
- Ultrasonography, in tropical pyomyositis, 107
- Ultrasound, in identifying tophaceous nodules, 478
- Ultrastructure of caprine arthritis-encephalitis virus, 931
- Undifferentiated connective tissue disease, 889. *See also* Connective tissue disease; Mixed Connective tissue disease; Overlap syndrome
- Unproven remedies, in RA, 1145
- Urate, platelet response to, 508
- Urate clearance, diflunisal and, 475
- Urate crystals
in gout, 209, 472
in hyperuricemia, 209
platelet membrane proteins and, 518
platelet stimulation and, 508
platelet surface proteins and, 514
protein interactions and, 508
- Urethritis, in yersinia arthritis, 253
- Uricosuria
diflunisal and, 475
secondary juvenile metabolic gout and, 1264
- Urine, glucuronide metabolites in after benoxaprofen, 595
- Urine excretion, penicillamine and, 114
- Urine fractionation of glucuronides, after estradiol injection, 844
- Urine protein, survival in SLE and, 604
- Urine sediment, in SLE, 383
- Urologic abnormalities, in Reiter's disease, 249
- Urticaria, chronic, eosinophilic synovial effusions in, 708
- Uveitis
anterior
immunogenetic factors in, 1431
in JRA, 1011
in Behçet's disease, 714
interferon and, 396
postpartum anterior, ankylosing spondylitis and, 140

V

- Valve replacement, in giant cell valvulitis, 232
- Valvulitis, giant cell, in Reiter's syndrome, 232
- Vascular changes, in psoriatic arthritis, 677

U

- Ulcerative childhood dermatomyositis, 131
- naifold capillary abnormalities in, 954

Vascular injury, acute, immune complex induced, 864
 Vascular permeability, PGE1 and, 807
 Vascular system, in scleroderma, 243
 Vasculitic skin lesions, in SLE, 383
Vasculitides (book review), 479
 Vasculitis, 769. *See also* Wegener's granulomatosis
 anti-Ro in, 768
 in childhood dermatomyositis, 126
 cutaneous, interferon in, 396
 familial Mediterranean fever and, 44
 granulomatous angiitis and, 342
 IgA nephropathy and in spondylarthropathies, 144
 immune complex, cranial arteritis and, 75
 interferon in, 396
 leukocytoblastic, 144
 in pancreatitis in SLE, 1008
 in proliferative lupus nephritis, 872
 in RA, 914, 1160
 seropositive, 502
 in SLE, 1035, 1036
 systemic, interferon in, 396
 systemic necrotizing, malignant melanoma in, 475
 Vertebrae
 fish, 1073
 flattening of, 1077
 "rugger jersey" vertebral body, 1028
 Vertebral ankylosis, in hereditary chondrocalcinosis, 1257
 Vertebral osteomyelitis, bacterial endocarditis and, 600
 Viral proteins, human sera reactivities with, 853
 Viruses
 in AKR mice, 852
 Akv genes and, 850, 852
 in C3H/Bi mice, 850
 C57BR mice and, 850
 Coxsackie B5, myositis in Behçet's disease and, 1025
 ecotropic, 850, 853
 genetics and, 851
 glycoproteins and, 847
 leukemia and, 851
 in NIH mice, 850
 polytropic, 850
 oropharyngeal Epstein-Barr, in RA, 427
 Rgv-1 gene and, 852
 RNA tumor, 850
 spontaneous lymphoma and, 850
 in SLE, 824, 847
 type C, 853

Visceral involvement, in scleroderma, 61
 Vitamins
 C, DNA synthesis by articular chondrocytes and, 318, 531
 D, in RA, 465
 Vulvovaginitis, in Reiter's disease, 251

W

Wear rates, of articular cartilage, 974
 Wegener's granulomatosis. *See also* Vasculitis
 interferon and, 396
 Weight loss, in RA, 486
 White blood cells
 in CNS SLE, 586
 in palindromic rheumatism 362
 in reactive arthritis, in Reiter's disease, 251
 in septic arthritis, 947
 in SLE, 383
 in synovial fluid, 951
 Wrist
 in adult onset Still's disease, 647
 erosions, in CREST syndrome, 1026
 in RA, 503
 gold therapy and, 544
 tarsal arthritis with ankylosis in late onset Still's disease, 1255

X-Z

Xanthine oxidase protein, in Sprague-Dawley rats, 326
 Xerostomia
 keratoconjunctivitis sicca and, 156
 Sjögren's syndrome and SS-B antibodies in, 662
xid (gene)
 effect of on MRL/lpr/lpr mice, 737
 effect of on NZB mice, 737
 in SLE-like disease, 734, 737, 741
 Xyloside, in reversal of salicylate-induced inhibition of GAG
 synthesis in articular cartilage and, 1084
 Xylosyl transferase, salicylates and, 1091
 Yakima Indians, HLA antigens in, 1435
 Yersinia arthritis
 chemotaxis in, 655
 clinical findings in, 251
 Reiter's disease in, 249
Yersinia enterocolitica, arthritis and, 655
 Zonal myopathy, in childhood dermatomyositis, 126
 Zymosan, in Yersinia arthritis, 655

WE HAVE MOVED!

The business offices of *Arthritis and Rheumatism*, along with the Arthritis Foundation, have a new address and phone number:

Arthritis and Rheumatism
1314 Spring Street, NW
Atlanta, Georgia 30309
Telephone: 404-872-7100

All correspondence concerning subscriptions, address changes, reprints, and articles that have been accepted for publication should be directed to our new address.

